0001683168-23-008144.txt : 20231114 0001683168-23-008144.hdr.sgml : 20231114 20231114171932 ACCESSION NUMBER: 0001683168-23-008144 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 39 CONFORMED PERIOD OF REPORT: 20230930 FILED AS OF DATE: 20231114 DATE AS OF CHANGE: 20231114 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CNS Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001729427 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 822318545 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-39126 FILM NUMBER: 231408006 BUSINESS ADDRESS: STREET 1: 2100 WEST LOOP SOUTH STREET 2: SUITE 900 CITY: HOUSTON STATE: TX ZIP: 77027 BUSINESS PHONE: 1-800-946-9185 MAIL ADDRESS: STREET 1: 2100 WEST LOOP SOUTH STREET 2: SUITE 900 CITY: HOUSTON STATE: TX ZIP: 77027 10-Q 1 cns_i10q-093023.htm QUARTERLY REPORT

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 10-Q

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2023

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ____________ to ______________

Commission file number: 001-39126

CNS Pharmaceuticals, Inc.

(Name of registrant as specified in its charter)

Nevada	82-2318545
(State or other jurisdiction of Incorporation or Organization)	(I.R.S. Employer identification No.)

2100 West Loop South, Suite 900

Houston, Texas

77027

(Address of principal executive offices

(Zip Code)

800-946-9185

(Registrant’s telephone number, including area code)

N/A

(Former name or former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class	Trading Symbol	Name of Each Exchange on Which Registered
Common Stock	CNSP	The NASDAQ Stock Market LLC

Indicate by check mark whether the registrant (1) filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act:

Large accelerated Filer ☐	Accelerated Filer ☐
Non-accelerated Filer ☒	Smaller reporting company ☒
Emerging Growth Company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

The number of shares outstanding of the registrant’s common stock, par value $0.001 per share, as of November 14, 2023, was 5,248,598.

TABLE OF CONTENTS

		Page
PART I FINANCIAL INFORMATION

Item 1.	Financial Statements	3
	Balance Sheets as of September 30, 2023 and December 31, 2022 (unaudited)	3
	Statements of Operations for the three and nine months ended September 30, 2023 and 2022 (unaudited)	4
	Statements of Stockholders’ Equity (Deficit) for the nine months ended September 30, 2023 and 2022 (unaudited)	5
	Statements of Cash Flows for the nine months ended September 30, 2023 and 2022 (unaudited)	6
	Notes to the Financial Statements (unaudited)	7
Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	14
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	19
Item 4.	Controls and Procedures	19

PART II OTHER INFORMATION

Item 1.	Legal Proceedings	21
Item 1A.	Risk Factors	21
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	21
Item 3.	Defaults Upon Senior Securities	21
Item 4.	Mine Safety Disclosures	21
Item 5.	Other Information	21
Item 6.	Exhibits	22
Signatures		23

PART I - FINANCIAL INFORMATION

ITEM 1.

FINANCIAL STATEMENTS

CNS Pharmaceuticals, Inc.

Balance Sheets

(Unaudited)


	September 30, 2023			December 31, 2022

Assets
Current Assets:
Cash and cash equivalents	$	909,547		$	10,055,407
Prepaid expenses and other current assets		1,152,298			2,509,238
Total current assets		2,061,845			12,564,645

Noncurrent Assets:
Prepaid expenses, net of current portion		262,731			482,806
Property and equipment, net		3,470			5,664
Total noncurrent assets		266,201			488,470

Total Assets	$	2,328,046		$	13,053,115

Liabilities and Stockholders' Equity (Deficit)

Current Liabilities:
Accounts payable and accrued expenses	$	4,026,894		$	4,510,291
Notes payable		41,904			409,968
Total current liabilities		4,068,798			4,920,259

Total Liabilities		4,068,798			4,920,259

Commitments and contingencies		–			–

Stockholders' Equity (Deficit):
Preferred stock, $0.001 par value, 5,000,000 shares authorized and 0 shares issued and outstanding		–			–
Common stock, $0.001 par value, 75,000,000 shares authorized and 4,207,068 and 1,617,325 shares issued and outstanding, respectively		4,207			1,617
Additional paid-in capital		62,446,694			58,846,916
Accumulated deficit		(64,191,653	)		(50,715,677	)
Total Stockholders' Equity (Deficit)		(1,740,752	)		8,132,856

Total Liabilities and Stockholders' Equity (Deficit)	$	2,328,046		$	13,053,115

See accompanying notes to the unaudited financial statements.

CNS Pharmaceuticals, Inc.

Statements of Operations

(Unaudited)


	Three months ended			Three months ended			Nine months ended			Nine months ended
	September 30, 2023			September 30, 2022			September 30, 2023			September 30, 2022

Operating expenses:
General and administrative	$	1,123,268		$	1,211,102		$	3,661,853		$	3,814,513
Research and development		3,410,572			2,207,913			9,823,884			6,318,055

Total operating expenses		4,533,840			3,419,015			13,485,737			10,132,568

Loss from operations		(4,533,840	)		(3,419,015	)		(13,485,737	)		(10,132,568	)

Other income (expenses):
Interest income		12,883			–			20,685			–
Interest expense		(1,838	)		(538	)		(10,924	)		(4,715	)

Total other income (expense)		11,045			(538	)		9,761			(4,715	)

Net loss	$	(4,522,795	)	$	(3,419,553	)	$	(13,475,976	)	$	(10,137,283	)

Loss per share - basic	$	(1.08	)	$	(2.56	)	$	(4.05	)	$	(7.67	)
Loss per share - diluted	$	(1.08	)	$	(2.56	)	$	(4.05	)	$	(7.67	)

Weighted average shares outstanding - basic		4,177,069			1,334,417			3,327,636			1,321,065
Weighted average shares outstanding - diluted		4,177,069			1,334,417			3,327,636			1,321,065

See accompanying notes to the unaudited financial statements.

CNS Pharmaceuticals, Inc.

Statements of Stockholders' Equity (Deficit)

For the nine months ended September 30, 2023 and 2022

(Unaudited)


					Additional					Total
	Common Stock				Paid-in		Accumulated			Stockholders'
	Shares		Amount		Capital		Deficit			Equity (Deficit)

Balance December 31, 2022		1,617,325	$	1,617	$	58,846,916	$	(50,715,677	)	$	8,132,856

Exercise of warrants		609,000		609		–		–			609

Stock-based compensation		–		–		290,313		–			290,313

Net loss		–		–		–		(4,931,947	)		(4,931,947	)

Balance March 31, 2023		2,226,325		2,226		59,137,229		(55,647,624	)		3,491,831

Common stock issued for cash, net		659,677		660		1,968,447		–			1,969,107

Exercise of warrants		1,254,958		1,255		723,804		–			725,059

Stock-based compensation		–		–		289,670		–			289,670

Net loss		–		–		–		(4,021,234	)		(4,021,234	)

Balance June 30, 2023		4,140,960		4,141		62,119,150		(59,668,858	)		2,454,433

Common stock issued for cash, net		63,729		64		132,787		–			132,851

Stock-based compensation		2,379		2		194,757		–			194,759

Net loss		–		–		–		(4,522,795	)		(4,522,795	)

Balance September 30, 2023		4,207,068	$	4,207	$	62,446,694	$	(64,191,653	)	$	(1,740,752	)



Balance December 31, 2021		949,052	$	949	$	41,603,791	$	(35,441,543	)	$	6,163,197

Common stock issued for cash, net		316,316		316		10,625,470		–			10,625,786

Exercise of warrants		87,193		87		2,529		–			2,616

Stock-based compensation		–		–		336,685		–			336,685

Net loss		–		–		–		(3,151,778	)		(3,151,778	)

Balance March 31, 2022		1,352,561		1,352		52,568,475		(38,593,321	)		13,976,506

Stock-based compensation		–		–		286,841		–			286,841

Net loss		–		–		–		(3,565,952	)		(3,565,952	)

Balance June 30, 2022		1,352,561		1,352		52,855,316		(42,159,273	)		10,697,395

Stock-based compensation		–		–		289,721		–			289,721

Net loss		–		–		–		(3,419,553	)		(3,419,553	)

Balance September 30, 2022		1,352,561	$	1,352	$	53,145,037	$	(45,578,826	)	$	7,567,563

See accompanying notes to the unaudited financial statements.

CNS Pharmaceuticals, Inc.

Statements of Cash Flows

(Unaudited)


	Nine Months Ended			Nine Months Ended
	September 30, 2023			September 30, 2022

Cash Flows from Operating Activities:
Net loss	$	(13,475,976	)	$	(10,137,283	)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation		774,742			913,247
Depreciation		3,181			9,375
Loss of disposal of fixed assets		757			2,635
Changes in operating assets and liabilities:
Prepaid expenses and other current assets		1,577,015			1,134,824
Accounts payable and accrued expenses		(483,397	)		(175,290	)
Net cash used in operating activities		(11,603,678	)		(8,252,492	)

Cash Flows from Investing Activities:
Purchase of property and equipment		(1,744	)		(4,423	)
Net cash used in investing activities		(1,744	)		(4,423	)

Cash Flows from Financing Activities:
Payments on notes payable		(368,064	)		(348,534	)
Proceeds from exercise of warrants		725,668			2,616
Proceeds from sale of common stock		2,101,958			10,625,786
Net cash provided by financing activities		2,459,562			10,279,868

Net change in cash and cash equivalents		(9,145,860	)		2,022,953

Cash and cash equivalents, at beginning of period		10,055,407			5,004,517

Cash and cash equivalents, at end of period	$	909,547		$	7,027,470

Supplemental disclosures of cash flow information:
Cash paid for interest	$	10,924		$	5,782
Cash paid for income taxes	$	–		$	–

See accompanying notes to the unaudited financial statements.

CNS Pharmaceuticals, Inc.

Notes to the Financial Statements

(Unaudited)

Note 1 – Nature of Business

CNS Pharmaceuticals, Inc. (“we”, “our”, the “Company”) is a clinical pharmaceutical company organized as a Nevada corporation on July 27, 2017 to focus on the development of anti-cancer drug candidates.

Note 2 – Summary of Significant Accounting Policies

Basis of Presentation - The accompanying unaudited financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United Stated of America (“U.S. GAAP”) for interim unaudited financial information. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. The unaudited financial statements include all adjustments (consisting of normal recurring adjustments) which are, in the opinion of management, necessary in order to make the condensed financial statements not misleading. Operating results for the three and nine months ended September 30, 2023 are not necessarily indicative of the final results that may be expected for the year ending December 31, 2023. For more complete financial information, these unaudited financial statements should be read in conjunction with the audited financial statements for the period ended December 31, 2022 included in our Form 10-K filed with the SEC on March 31, 2023 (“Form 10-K”). Notes to the financial statements which would substantially duplicate the disclosures contained in the audited financial statements for the most recent fiscal period, as reported in the Form 10-K, have been omitted.

Liquidity and Going Concern - These financial statements have been prepared on a going concern basis, which assumes the Company will continue to realize its assets and discharge its liabilities in the normal course of business. The continuation of the Company as a going concern is dependent upon the ability of the Company to obtain equity financings to continue operations. The Company has a history of and expects to continue to report negative cash flows from operations and a net loss. Management believes that the cash on hand is sufficient to fund its planned operations into but not beyond the near term. These factors raise substantial doubt regarding the Company’s ability to continue as a going concern. These financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. The Company may seek additional funding through a combination of equity offerings, debt financings, government or other third-party funding, commercialization, marketing and distribution arrangements, other collaborations, strategic alliances and licensing arrangements and delay planned cash outlays or a combination thereof. Management cannot be certain that such events or a combination thereof can be achieved.

Cash and Cash Equivalents - The Company considers all highly liquid accounts with original maturities of three months or less at the date of acquisition to be cash equivalents. Periodically, the Company may carry cash balances at financial institutions in excess of the federally insured limit of $250,000. The amount in excess of the FDIC insurance as of September 30, 2023 was $659,547. The Company has not experienced losses on these accounts and management believes, based upon the quality of the financial institutions, that the credit risk with regard to these deposits is not significant.

Stock-based Compensation - Employee and non-employee share-based compensation is measured at the grant date, based on the fair value of the award, and is recognized as an expense over the requisite service period for stock options and restricted stock units.

Restricted Stock Units (“RSUs”) - Our RSUs vest over four years from the date of grant. The fair value of RSUs is the market price of our common stock at the date of grant.

Performance Units (“PUs”) - The PUs vest based on our performance against predefined share price targets and the achievement of Positive Interim, Clinical Data as defined by the Board.

Loss Per Common Share - Basic loss per common share is computed by dividing net loss available to common shareholders by the weighted-average number of common shares outstanding during the period. Diluted loss per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents. In periods when losses are reported, the weighted-average number of common shares outstanding excludes common stock equivalents, because their inclusion would be anti-dilutive. As of September 30, 2023, the Company’s potentially dilutive shares and options, which were not included in the calculation of net loss per share, included warrants to purchase 2,268,827 common shares unvested restricted stock units of 7,144 common shares, unvested performance units of 28,563 and options for 328,770 common shares, respectively. For the nine months ended September 30, 2022, the Company’s potentially dilutive shares and options, which were not included in the calculation of net loss per share, included warrants to purchase 524,000 common shares, unvested restricted stock units of 9,523 common shares, unvested performance units of 28,563 and options for 93,001 common shares, respectively.

Reclassification - Certain reclassifications may have been made to our prior year’s financial statements to conform to our current year presentation. These reclassifications had no effect on our previously reported results of operations or accumulated deficit.

Recent Accounting Pronouncements - In June 2016, the FASB issued Accounting Standards Update No. 2016-13, Financial Instruments-Credit Losses: Measurement of Credit Losses on Financial Instruments. ASU 2016-13 requires measurement and recognition of expected credit losses for financial assets. In April 2019, the FASB issued clarification to ASU 2016-13 within ASU 2019-04, Codification Improvements to Topic 326, Financial Instruments-Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments, or ASU 2016-13. The guidance is effective for fiscal years beginning after December 15, 2022. The Company adopted this standard on January 1, 2023, which had no material impact on the Company’s financial statements.

Note 3 – Note Payable

On November 14, 2022, the Company entered into a short-term note payable for an aggregate of $449,874, bearing interest at 5.88% per year to finance certain insurance policies. Principal and interest payments related to the note will be repaid over an 11-month period with the final payment due on October 31, 2023. As of September 30, 2023 and December 31, 2022, the Company’s note payable balance was $41,904 and $409,968, respectively.

Note 4 – Equity

The Company has authorized 75,000,000 shares of common stock having a par value of $0.001 per share. In addition, the Company authorized 5,000,000 shares of preferred stock to be issued having a par value of $0.001. The specific rights of the preferred stock shall be determined by the board of directors.

Pursuant to the terms of the Capital on Demand™ Sales Agreement with JonesTrading Institutional Services LLC and Brookline Capital Markets, a division of Arcadia Securities, LLC (collectively, the “Agent”), the Company may sell from time to time, through the Agent, shares of the Company’s common stock with an aggregate sales price of up to $20.0 million. During the nine months ended September 30, 2023, the Company sold 723,406 shares of common stock to the Agent for net proceeds of $2,101,958.

Stock Options

In 2017, the Board of Directors of the Company approved the CNS Pharmaceuticals, Inc. 2017 Stock Plan (the “2017 Plan”). The 2017 Plan allows for the Board of Directors to grant various forms of incentive awards for up to 66,667 shares of common stock.

In 2020, the Board of Directors of the Company approved the CNS Pharmaceuticals, Inc. 2020 Stock Plan (the “2020 Plan”). The 2020 Plan allows for the Board of Directors to grant various forms of incentive awards for up to 100,000 shares of common stock. The 2020 Plan was amended effective as of August 9, 2023, which was approved by the Company’s stockholders at the Company’s annual meeting on September 14, 2023. The amendment increased the 2020 Plan by 745,800 shares of common stock.

On December 30, 2022, the Board of Directors of the Company appointed Faith Charles as an independent member of the Company’s Board of Directors and as Chairperson of the Board of Directors. Ms. Charles will receive an annual retainer for her service as Chairperson of $30,000 and, on the date of her appointment, was granted a ten-year option to purchase 3,500 shares of Company common stock at an exercise price of $2.40 vesting in 36 equal monthly installments succeeding the issuance date. The total fair value of these option grants at issuance was $7,091.

On March 29, 2023, the Board of Directors approved, based upon the recommendation of the Compensation Committee, cash bonuses totaling $550,750 to the officers of the Company. In addition, the officers and an employee were awarded a total of 29,988 options at an exercise price of $0.996. Of the options issued, 50% vest over 2 years and 50% vest upon the Company’s common stock price exceeding various closing prices ranging from $6.00 - $24.00 per share. The total fair value of these option grants at issuance was $25,820.

On May 3, 2023, the Board of Directors of the Company appointed Bettina M. Cockroft, M.D., M.B.A as an independent member of the Company’s Board of Directors. Dr. Cockroft was granted a ten-year option to purchase 2,099 shares of Company common stock at an exercise price of $1.67 vesting in 36 equal monthly installments succeeding the issuance date. The total fair value of these option grants at issuance was $3,514.

On August 4, 2023, the Board of Directors approved the issuance of 6,500 options to Dr. Cockroft. The options have a ten-year term at an exercise price of $2.27 and vest in 36 equal monthly installments succeeding the issuance date. The total fair value of these option grants at issuance was $12,771.

On August 27, 2023, the Board of Directors approved the issuance of 193,690 options to the board of directors. The options have a ten-year term at an exercise price of $1.90 and vest on the first anniversary date of issuance. The total fair value of these option grants at issuance was $313,846.

During the nine months ended September 30, 2023 and 2022, the Company recognized $727,864 and $877,510 of stock-based compensation, respectively, related to outstanding stock options. At September 30, 2023, the Company had $940,197 of unrecognized expenses related to outstanding options.

The following table summarizes the stock option activity for the nine months ended September 30, 2023:

Schedule of stock option activity
	Options			Weighted-Average Exercise Price Per Share
Outstanding, December 31, 2022		93,001		$	67.42
Granted		235,777			1.78
Exercised		–			–
Forfeited		(8	)		120.00
Expired		–			–
Outstanding, September 30, 2023		328,770		$	20.35
Exercisable, September 30, 2023		82,261		$	60.99

As of September 30, 2023, the outstanding stock options have a weighted average remaining term of 8.79 years and aggregate intrinsic value of options vested and outstanding of $0 and $4,318, respectively. As of September 30, 2023, there were no awards remaining to be issued under the 2017 Plan and 545,610 awards remaining to be issued under the 2020 Plan.

Stock Warrants

During the nine months ended September 30, 2023, the Company received $725,668 in cash proceeds from the exercise of 238,958 warrants previously issued at an exercise price of $3.03 and 1,625,000 warrants previously issued at an exercise price of $0.001.

The following table summarizes the stock warrant activity for the nine months ended September 30, 2023:

Schedule of warrants activity
	Warrants			Weighted-Average Exercise Price Per Share
Outstanding, December 31, 2022		4,133,252		$	4.35
Granted		–			–
Exercised		(1,863,958	)		0.39
Forfeited		–			–
Expired		(467	)		45.00
Outstanding, September 30, 2023		2,268,827		$	7.59
Exercisable, September 30, 2023		2,268,827		$	7.59

As of September 30, 2023, the outstanding and exercisable warrants have a weighted average remaining term of 4.02 years and had no aggregate intrinsic value.

Restricted Stock Units

During the nine months ended September 30, 2023, the Company recognized $17,888 of stock-based compensation, related to outstanding RSUs. At September 30, 2023, the Company had $59,624 of unrecognized expenses related to outstanding RSUs.

The following table summarizes the RSUs activity for the nine months ended September 30, 2023:


	RSUs			Weighted-Average Grant Date Fair Value
Non-vested, December 31, 2022		9,523		$	10.02
Granted		–			–
Vested		(2,379	)		10.02
Forfeited		–			–
Non-vested, September 30, 2023		7,144		$	10.02

Performance Units

During the nine months ended September 30, 2023, the Company recognized $28,990 related to outstanding stock PUs. At September 30, 2023, the Company had $104,958 of unrecognized expenses related to PUs.

The following table summarizes the PUs activity for the nine months ended September 30, 2023:

Schedule of performance units activity
	PUs		Weighted-Average Grant Date Fair Value
Non-vested, December 31, 2022		28,563	$	5.94
Granted		–		–
Vested		–		–
Forfeited		–		–
Non-vested, September 30, 2023		28,563	$	5.94

Note 5 – Commitments and Contingencies

Executive Employment Agreements

On September 1, 2017, the Company entered into an employment agreement with Mr. John Climaco pursuant to which Mr. Climaco agreed to serve as Chief Executive Officer and Director of the Company commencing on such date for an initial term of three years. On September 1, 2020, the Company entered into an amendment to the employment agreement with Mr. Climaco. The amendment extends the term of employment under the Employment Agreement, which was originally for a three-year period, for additional twelve-month periods, unless and until either the Company or Mr. Climaco provides written notice to the other party not less than sixty days before such anniversary date that such party is electing not to extend the term. If the Company provides notice of its election not to extend the term, Mr. Climaco may terminate his employment at any time prior to the expiration of the term by giving written notice to the Company at least thirty days prior to the effective date of termination, and upon the earlier of such effective date of termination or the expiration of the term, Mr. Climaco shall be entitled to receive the same severance benefits as are provided upon a termination of employment by the Company without cause. Pursuant to the Amendment, the severance benefits shall be twelve months of Mr. Climaco’s base salary. Such severance payment shall be made in a single lump sum sixty days following the termination, provided that Mr. Climaco has executed and delivered to the Company and has not revoked a general release of the Company. Pursuant to the employment agreement, the compensation committee of the board of directors reviews the base salary payable to Mr. Climaco annually during the term of the agreement. On February 6, 2021, the compensation committee of the board of directors set Mr. Climaco’s 2021 annual base salary to $525,000.

On June 28, 2019, we entered into employment letters with Drs. Silberman and Picker. Dr. Silberman agreed to commit 50% of her time to our matters and Dr. Picker agreed to commit 25% of his time to our matters.

On March 29, 2023, the Board of Directors approved, based upon the recommendation of the Compensation Committee, cash bonuses totaling $550,750 to the officers of the Company.

Scientific Advisory Board

On July 15, 2021, our Board approved the following compensation policy for members of the Scientific Advisory Board. The Scientific Advisory board consists of Dr. Sigmond Hsu. The scientific advisory board member shall receive annual cash compensation of $68,600. During the nine months ended September 30, 2023 and 2022, the Company paid $0 and $76,087 related to the Scientific Advisory Board compensation. As of September 30, 2023, the Company has accrued $151,584 related to Dr. Hsu’s Scientific Advisory Board compensation.

WP744 Portfolio (Berubicin)

On November 21, 2017, the Company entered into a Collaboration and Asset Purchase Agreement with Reata Pharmaceuticals, Inc. (“Reata”). Through this agreement, the Company purchased all of Reata’s rights, title, interest and previously conducted research and development results in the chemical compound commonly known as Berubicin. In exchange for these rights, the Company agreed to pay Reata an amount equal to 2.25% of the net sales of Berubicin for a period of 10 years from the Company’s first commercial sale of Berubicin plus $10,000. Reata also agreed to collaborate with the Company on the development of Berubicin, from time to time.

On December 28, 2017, the Company entered into a Technology Rights and Development Agreement with Houston Pharmaceuticals, Inc. (“HPI”). HPI is affiliated with Dr. Waldemar Priebe, our founder. Pursuant to this agreement, the Company obtained a worldwide exclusive license to the chemical compound commonly known as WP744. In exchange for these rights, the Company agreed to pay consideration to HPI as follows: (i) a royalty of 2% of net sales of any product utilizing WP744 for a period of ten years after the first commercial sale of such; and (ii) $100,000 upon beginning Phase II clinical trials (paid in 2021); and (iii) $200,000 upon the approval by the FDA of a New Drug Application for any product utilizing WP744; and (iv) a series of quarterly development payments totaling $750,000 beginning immediately after the Company’s raise of $7,000,000 of investment capital. In addition, the Company issued 6,667 shares of the Company’s common stock valued at $1.35 per share to HPI upon execution of the agreement. On November 13, 2019, the Company closed its IPO, thereby fulfilling all conditions precedent and completing the acquisition of the intellectual property discussed in the HPI agreement. During the nine months ended September 30, 2023 and 2022, the Company recognized $37,500 and $262,500, respectively, related to this agreement. Unrelated to this agreement, from time to time, the Company purchases pharmaceutical products from HPI which are necessary for the manufacturing of Berubicin API and drug product in related party transactions which are reviewed and approved by the Company’s audit committee based upon the standards of providing superior pricing and time to delivery than that available from unrelated third parties. During the nine months ended September 30, 2023 and 2022, the Company expensed $0 and $41,075 respectively related to the purchase of pharmaceutical products from HPI.

On August 30, 2018, we entered into a sublicense agreement with WPD Pharmaceuticals, Inc. (“WPD”). Pursuant to the agreement, the Company granted WPD an exclusive sublicense, even as to us, for the patent rights we licensed pursuant to the HPI License within the following countries: Poland, Estonia, Latvia, Lithuania, Belarus, Ukraine, Moldova, Romania, Bulgaria, Serbia, Macedonia, Albania, Armenia, Azerbaijan, Georgia, Montenegro, Bosnia, Croatia, Slovenia, Slovakia, Czech Republic, Hungary, Chechnya, Uzbekistan, Kazakhstan, Kyrgyzstan, Tajikistan, Turkmenistan, Greece, Austria, and Russia. The sublicense agreement provides that WPD must use commercially reasonable development efforts to attempt to develop and commercialize licensed products in the above mentioned territories, which means the expenditure of at least $2.0 million on the development, testing, regulatory approval or commercialization of the licensed products during the three year period immediately following the date of the sublicense agreement. In the event that WPD fails to use commercially reasonable development efforts by the foregoing three-year deadline, we have the right to terminate this sublicense agreement. As of December 31, 2021, the Company has received reports of the WPD expenditures related to this agreement, has conducted due inquiry into validating those expenditures, and has determined that WPD has exercised commercially reasonable development efforts and has therefore fulfilled the terms of the agreement necessary to secure their rights under the sublicense in perpetuity subject to the ongoing obligations of the sublicense. In consideration for the rights granted under the sublicense agreement, to the extent we are required to make any payments to HPI pursuant to the HPI License as a result of this sublicense agreement, WPD agreed to advance us such payments, and to pay us a royalty equal to 1% of such payments. WPD is a Polish corporation that is majority-owned by an entity controlled by Dr. Priebe, our founder.

On November 21, 2022, CNS entered into an Investigational Medicinal Product Supply Agreement with Pomeranian Medical University (“PUM”) in Szczecin, Poland. CNS agreed to sell berubicin hydrochloride drug product (and related reference standards) to PUM at a discount to the historical cost of manufacturing so that PUM may conduct an investigator-initiated clinical trial of Berubicin in CNS lymphomas. PUM agreed to pay CNS the following payments: (i) PLN 5,870 upon delivery of 2 vials each of berubicin and berubicinol reference standards, (ii) PLN 873,201 upon delivery of a first batch of 150 berubicin drug product vials, and (iii) PLN 873,201 upon delivery of a second batch of 150 berubicin drug product vials. As of December 31, 2022, the reference standards were delivered, and the Company recognized $1,302 in accounts receivable and as a reduction to research and development expense. In April 2023, the first batch of berubicin drug product vials were delivered, and the Company recognized $196,303 in accounts receivable and as a reduction to research and development expense. As of September 30, 2023, the outstanding accounts receivable balance of $197,605 was collected in full.

On August 31, 2018, the Company entered into a sublicense agreement with Animal Life Sciences, LLC (“ALI”), pursuant to which we granted ALI an exclusive sublicense, even as to us, for the patent rights we licensed pursuant to the HPI License solely for the treatment of cancer in non-human animals through any type of administration. In consideration for the rights granted under the sublicense agreement, ALI agreed to issue us membership interests in ALI equal to 1.52% of the outstanding ALI membership interests. As additional consideration for the rights granted, to the extent we are required to make any payments to HPI pursuant to the HPI License as a result of this sublicense agreement, ALI agreed to advance us such payments, and to pay us a royalty equal to 1% of such payments. Dr. Waldemar Priebe, our founder, is also the founder and a shareholder of ALI, holds 38% of the membership interests of ALI.

On June 10, 2020, the FDA granted Orphan Drug Designation (“ODD”) for Berubicin for the treatment of malignant gliomas. ODD from the FDA is available for drugs targeting diseases with less than 200,000 cases per year. ODD may enable market exclusivity of 7 years from the date of approval of a NDA in the United States. During that period the FDA generally could not approve another product containing the same drug for the same designated indication. Orphan drug exclusivity will not bar approval of another product under certain circumstances, including if a subsequent product with the same active ingredient for the same indication is shown to be clinically superior to the approved product on the basis of greater efficacy or safety, or providing a major contribution to patient care, or if the company with orphan drug exclusivity is not able to meet market demand. The ODD now constitutes our primary intellectual property protections although the Company is exploring if there are other patents that could be filed related to Berubicin to extend additional protections.

On July 24, 2021, the Company received Fast Track Designation from the FDA for Berubicin. Fast Track Designation is designed to facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet medical need.

WP1244 Portfolio

On January 10, 2020, Company entered into a Patent and Technology License Agreement (“Agreement”) with The Board of Regents of The University of Texas System, an agency of the State of Texas, on behalf of The University of Texas M. D. Anderson Cancer Center (“UTMDACC”). Pursuant to the Agreement, the Company obtained a royalty-bearing, worldwide, exclusive license to certain intellectual property rights, including patent rights, related to the Company’s recently announced WP1244 drug technology. In consideration, the Company must make payments to UTMDACC including an up-front license fee, annual maintenance fee, milestone payments and royalty payments (including minimum annual royalties) on sales of licensed products developed under the Agreement. The term of the Agreement expires on the last to occur of: (a) the expiration of all patents subject to the Agreement, or (b) fifteen years after execution; provided that UTMDACC has the right to terminate this Agreement in the event that the Company fails to meet certain commercial diligence milestones. The commercial diligence milestones are as follows (i) initiated PC toxicology to support filing of Investigational New Drug Application (“IND”) or New Drug Application (“NDA”) for the Licensed Product within the eighteen (18) month period following the Effective Date (ii) file and IND for the Licensed Product within three (3) year period following the Effective Date and (iii) Commencement of Phase I Study within the five (5) year period following the Effective Date. The Company has not met the commercial diligence milestones required as of the date hereof. As such, UTMDACC has the right to terminate the Agreement upon notice to the Company. As of the date of this report, UTMDACC has not notified the Company of its intention to terminate the Agreement. During the nine months ended September 30, 2023 and 2022, the Company paid $45,092 and $49,607, respectively.

On May 7, 2020, pursuant to the WP1244 Portfolio license agreement described above, the Company entered into a Sponsored Research Agreement with UTMDACC to perform research relating to novel anticancer agents targeting CNS malignancies. The Company agreed to fund approximately $1,134,000 over a two-year period, which has been fully paid by the Company in 2021. This agreement was extended and expired on March 31, 2023. The principal investigator for this agreement is Dr. Waldemar Priebe, our founder.

Note 6 – Subsequent Events

On October 16, 2023, the Company entered into a warrant exercise inducement offer letter (the “Inducement Letter”) with a holder of certain existing warrants (“Holder”) to receive new warrants to purchase up to a number of shares of common stock equal to 200% (the “Inducement Warrants”) of the number of warrant shares issued pursuant to the exercise of such certain existing warrants to purchase shares of common stock (the “Existing Warrants”) pursuant to which the Holder agreed to exercise for cash their Existing Warrants to purchase up to 1,878,000 shares of the Company’s common stock, at a Reduced Exercise Price (as defined below), in exchange for the Company’s agreement to issue the Inducement Warrants to purchase up to 3,756,000 shares of the Company’s common stock (the “Inducement Warrant Shares”). The Existing Warrants consist of: (i) warrants, originally issued on December 22, 2020 and amended on December 5, 2022; (ii) warrants, originally issued on January 10, 2022 and amended on December 5, 2022; and (iii) warrants issued on December 5, 2022. Pursuant to the Inducement Letter, the exercise price for such Existing Warrants was reduced to $1.28 per share (the “Reduced Exercise Price”). The Company received aggregate gross proceeds of $2,403,840 from the exercise of the Existing Warrants before deducting financial advisory fees and other expenses payable by it. Pursuant to the Inducement Letter, although the exercise of the warrants has occurred and full payment of the exercise price has been made, the Holder has directed that a number of shares be held in abeyance and not yet issued until they direct us to do so. As such, the shares have not been issued and do not appear in our count of common shares outstanding.

Pursuant to the terms of the Capital on Demand™ Sales Agreement with JonesTrading Institutional Services LLC and Brookline Capital Markets, a division of Arcadia Securities, LLC (collectively, the “Agent”), the Company may sell from time to time, through the Agent, shares of the Company’s common stock with an aggregate sales price of up to $20.0 million. Subsequent to the quarter ended on September 30, 2023, the Company sold 129,530 shares of common stock to the Agent for net proceeds of $215,641.

ITEM 2.

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

You should read the following discussion and analysis of our financial condition and results of operations in conjunction with the financial statements and the related notes appearing elsewhere in this Form 10-Q. This discussion contains forward-looking statements reflecting our current expectations that involve risks and uncertainties. See Item 1A. “Risk Factors” of our Form 10-K for the year ended December 31, 2022, available on the Security and Exchange Commission's (“SEC”) EDGAR website at www.sec.gov, for a discussion of the uncertainties, risks and assumptions associated with these statements. Actual results and the timing of events could differ materially from those discussed in our forward-looking statements as a result of many factors, including those set forth under “Risk Factors” and elsewhere in this Form 10-Q.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

We make forward-looking statements under the “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and in other sections of this Form 10-Q. In some cases, you can identify these statements by forward-looking words such as “may,” “might,” “should,” “would,” “could,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “potential” or “continue,” and the negative of these terms and other comparable terminology. These forward-looking statements, which are subject to known and unknown risks, uncertainties and assumptions about us, may include projections of our future financial performance based on our growth strategies and anticipated trends in our business. These statements are only predictions based on our current expectations and projections about future events. There are important factors that could cause our actual results, level of activity, performance or achievements to differ materially from the results, level of activity, performance or achievements expressed or implied by the forward-looking statements. In particular, you should consider the numerous risks and uncertainties described under Item 1A. “Risk Factors” of our Form 10-K for the year ended December 31, 2022 and in other filings made by us from time to time with the SEC.

While we believe we have identified material risks, these risks and uncertainties are not exhaustive. Other sections of this Form 10-Q may describe additional factors that could adversely impact our business and financial performance. Moreover, we operate in a very competitive and rapidly changing environment. New risks and uncertainties emerge from time to time, and it is not possible to predict all risks and uncertainties, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.

Although we believe the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance or achievements. Moreover, neither we nor any other person assumes responsibility for the accuracy or completeness of any of these forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. We are under no duty to update any of these forward-looking statements after the date of this Form 10-Q to conform our prior statements to actual results or revised expectations, and we do not intend to do so.

Forward-looking statements include, but are not limited to, statements about:

	·	our ability to obtain additional funding to develop our product candidates;

	·	the need to obtain regulatory approval of our product candidates;

	·	the success of our clinical trials through all phases of clinical development;

	·	compliance with obligations under intellectual property licenses with third parties;

	·	any delays in regulatory review and approval of product candidates in clinical development;

	·	our ability to commercialize our product candidates;

	·	market acceptance of our product candidates;

	·	competition from existing products or new products that may emerge;


	·	potential product liability claims;

	·	our dependency on third-party manufacturers to supply or manufacture our products;

	·	our ability to establish or maintain collaborations, licensing or other arrangements;

	·	our ability and third parties’ abilities to protect intellectual property rights;

	·	our ability to adequately support future growth; and

	·	our ability to attract and retain key personnel to manage our business effectively.

We caution you not to place undue reliance on the forward-looking statements, which speak only as of the date of this Form 10-Q in the case of forward-looking statements contained in this Form 10-Q.

You should not rely upon forward-looking statements as predictions of future events. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. We qualify all of our forward-looking statements by these cautionary statements. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Therefore, you should not rely on any of the forward-looking statements. In addition, with respect to all of our forward-looking statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.

Overview

We are a clinical pharmaceutical company organized as a Nevada corporation in July 2017 to focus on the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors, based on intellectual property that we license under license agreements with Houston Pharmaceuticals, Inc. (“HPI”) and The University of Texas M.D. Anderson Cancer Center (“UTMDACC”) and own pursuant to a collaboration and asset purchase agreement with Reata Pharmaceuticals, Inc. (“Reata”).

We believe our lead drug candidate, Berubicin, may be a significant development in the treatment of Glioblastoma and other CNS malignancies, and if approved by the U.S. Food and Drug Administration (“FDA”), could give Glioblastoma patients an important new therapeutic alternative to the current standard of care. Glioblastomas are tumors that arise from astrocytes, which are star-shaped cells making up the supportive tissue of the brain. These tumors are usually highly malignant (cancerous) because the cells reproduce quickly, and they are supported by a large network of blood vessels. Berubicin is an anthracycline, which is a class of drugs that are among the most powerful and extensively used chemotherapy drugs known. Based on limited clinical data, we believe Berubicin is the first anthracycline that appears to cross the blood brain barrier in significant concentrations targeting brain cancer cells. While our focus is currently on the development of Berubicin, we are also in the process of attempting to secure intellectual property rights to additional compounds that we plan to develop into drugs to treat CNS and other cancers.

Berubicin was discovered at UTMDACC by Dr. Waldemar Priebe, the founder of the Company. Through a series of transactions, Berubicin was initially licensed to Reata. Reata initiated several Phase I clinical trials with Berubicin for CNS malignancies, one of which was for malignant gliomas, but subsequently allowed their IND with the FDA to lapse for strategic reasons. This required us to obtain a new IND for Berubicin before beginning further clinical trials. On December 17, 2020, we announced that our IND application with the FDA for Berubicin for the treatment of Glioblastoma Multiforme was in effect. We initiated this trial for patient enrollment during the second quarter of 2021 with the first patient dosed during the third quarter of 2021 to investigate the efficacy of Berubicin in adults with Glioblastoma Multiforme who have failed first-line therapy. The first patient on the trial was treated during the third quarter of 2021. Correspondence between the Company and the FDA resulted in modifications to our initial trial design, including designating overall survival (OS) as the primary endpoint of the study. OS is a rigorous endpoint that the FDA has recognized as a basis for approval of oncology drugs when a statistically significant improvement can be shown relative to a randomized control arm.

The current trial being conducted will evaluate the efficacy of Berubicin in patients with Glioblastoma Multiforme who have failed primary treatment for their disease, and results will be compared to the efficacy of Lomustine, a current standard of care in this setting, with a 2 to 1 randomization of the estimated 243 patients to Berubicin or Lomustine. Patients receiving Berubicin will be administered a 2-hour IV infusion of 7.5 mg/m2 berubicin hydrochloride daily for three consecutive days followed by 18 days off (a 21-day cycle). Lomustine is administered orally once every six weeks. The trial will include a pre-planned, non-binding interim futility analysis which will be conducted by an independent Data Safety Monitoring Board (DSMB) to recommend whether this study should continue as planned based on Berubicin showing statistically significant value as a second-line treatment for patients with glioblastoma compared with Lomustine. We will conduct this analysis after at least 50% of the patients in the interim analysis population (30-50% of total expected patients for the trial) can be evaluated as having failed the primary efficacy endpoint (death). This recommendation will review the number of deaths on each arm to ensure that the overall survival of patients receiving Berubicin shows a statistically significant comparability to or is even higher than those receiving Lomustine. The median survival of patients receiving second-line treatment for glioblastoma has historically been shown to be approximately 6 months. We have historically used 6 months as an estimate for the median time to a 50% mortality rate. Taking into account the recent rate of enrollment and the number of patients that can be adequately assessed for their follow-up outcomes, we are anticipating that the DSMB will be able to perform this interim analysis and we can release the data during the fourth quarter of 2023. Additional analyses that will be provided based on this data will be comparisons of secondary endpoints, including progression-free survival (PFS), response rates, and safety assessments. Even if Berubicin is approved, there is no assurance that patients will choose an infusion treatment, as compared to the current standard of care, which requires oral administration.

We do not have manufacturing facilities and all manufacturing activities are contracted out to third parties. Additionally, we do not have a sales organization.

On November 21, 2017, we entered into a Collaboration and Asset Purchase Agreement with Reata (the “Reata Agreement”). Pursuant to the Reata Agreement we purchased all of Reata’s intellectual property and development data regarding Berubicin, including all trade secrets, knowhow, confidential information and other intellectual property rights.

On December 28, 2017, we obtained the rights to a worldwide, exclusive royalty-bearing, license to the chemical compound commonly known as Berubicin from HPI in an agreement we refer to as the HPI License. HPI is affiliated with Dr. Priebe, our founder. Under the HPI License we obtained the exclusive right to develop certain chemical compounds for use in the treatment of cancer anywhere in the world. In the HPI License we agreed to pay HPI: (i) development fees of $750,000 over a three-year period beginning November 2019; (ii) a 2% royalty on net sales; (iii) a $50,000 per year license fee; (iv) milestone payments of $100,000 upon the commencement of a Phase II trial and $1.0 million upon the approval of a New Drug Application (“NDA”) for Berubicin; and (v) 6,667 shares of our common stock. The patents we licensed from HPI expired in March 2020.

With the Reata Agreement and the HPI License, we believe we have obtained all rights and intellectual property necessary to develop Berubicin. As stated earlier, it is our plan to obtain additional intellectual property covering other compounds which, subject to the receipt of additional financing, may be developed into drugs for brain and other cancers.

On January 10, 2020, we entered into a Patent and Technology License Agreement (the “WP1244 Agreement”) with The Board of Regents of The University of Texas System, an agency of the State of Texas, on behalf of the UTMDACC. Pursuant to the WP1244 Agreement, we obtained a royalty-bearing, worldwide, exclusive license to certain intellectual property rights, including patent rights, related to our portfolio of WP1244 drug technology. In consideration, we must make payments to UTMDACC including an up-front license fee, annual maintenance fee, milestone payments and royalty payments (including minimum annual royalties) for sales of licensed products developed under the WP1244 Agreement. The term of the WP1244 Agreement expires on the last to occur of: (a) the expiration of all patents subject to the WP1244 Agreement, or (b) fifteen years after execution; provided that UTMDACC has the right to terminate the WP1244 Agreement in the event that we fail to meet certain commercial diligence milestones. We have not met the commercial diligence milestones required as of the date hereof. As such, UTMDACC has the right to terminate the WP1244 Agreement upon notice to us. As of the date of this report, UTMDACC has not notified us of its intention to terminate the WP1244 Agreement.

On May 7, 2020, pursuant to the WP1244 portfolio license agreement described above, the Company entered into a Sponsored Research Agreement with UTMDACC to perform research relating to novel anticancer agents targeting CNS malignancies. The Company agreed to fund approximately $1,134,000 over a two-year period. The Company paid and recorded $334,000 in 2020 related to this agreement in research and development expenses in the Company’s Statements of Operations. The remaining $800,000 was paid in 2021. The principal investigator for this agreement is Dr. Priebe. The work conducted under this Sponsored Research Agreement has produced a new mesylate salt of WP1244 termed WP1874. We believe the enhanced solubility of this salt may increase its ability to be formulated for use in an IV infusion, while maintaining similar potency and toxicity characteristics. As such, WP1874 will be the primary focus in our development efforts of the WP1244 portfolio. This agreement was extended and expired on March 31, 2023.

Results of Operations for the Three Months Ended September 30, 2023 Compared to the Three Months Ended September 30, 2022

General and Administrative Expense

General and administrative expense was approximately $1,123,000 for the three months ended September 30, 2023 compared to approximately $1,211,000 for the comparable period in 2022. The decrease in general and administrative expense was mainly attributable to decreases of approximately $73,000 in legal and professional expenses, $29,000 in insurance expenses and $68,000 in stock compensation and $6,000 in other general and administrative expenses, which were offset by increases of approximately $15,000 in marketing and advertising, $28,000 in board compensation and $45,000 in travel expenses.

Research and Development Expense

Research and development expense was approximately $3,411,000 for the three months ended September 30, 2023 compared to approximately $2,208,000 for the comparable period in 2022. The increase in research and development expenses during the period was mainly attributed to the timing of research organization (CRO) expenses and patient treatment costs related to continued progress with our clinical trial for Berubicin. Our CRO expenditures are primarily for labor related to activating selected trial sites, managing patient enrollment processes, collecting and managing data from patient treatments throughout the trial, processing reimbursement to the sites for patient treatment, and assisting with necessary submissions to amend the IND. CRO expenditures are expected to remain relatively consistent with the current quarter throughout the remainder of the trial as site activation efforts and the associated costs thereof transition into reimbursing clinical trial sites for patient treatment costs as site and patient enrollment increases. We expect to incur increased research and development costs in the future as we continue our clinical trial for Berubicin primarily due to higher patient enrollment and the associated cost of treating these patients.

Net Loss

The net loss for the three months ended September 30, 2023 was approximately $4,523,000 compared to approximately $3,420,000 for the comparable period in 2022. The change in net loss is attributable to an increase in CRO expenses and patient treatment costs related to continued progress with our clinical trial for Berubicin, a credit to research and development expense in the prior year period for the funds collected from WPD Pharmaceuticals related to their purchase of Berubicin drug product for their clinical trials, as well as increases in legal and professional fees and other expenses.

Results of Operations for the Nine Months Ended September 30, 2023 Compared to the Nine Months Ended September 30, 2022

General and Administrative Expense

General and administrative expense was approximately $3,662,000 for the nine months ended September 30, 2023 compared to approximately $3,815,000 for the comparable period in 2022. The decrease in general and administrative expense was mainly attributable to decreases of approximately $175,000 for employee compensation and taxes, $111,000 in stock-based compensation, $117,000 in legal and professional expenses, and $69,000 in insurance expenses, which were offset by increases of approximately $112,000 in marketing and advertising, $70,000 in board compensation and $118,000 in travel expenses, and $19,000 in other expenses.

Research and Development Expense

Research and development expense was approximately $9,824,000 for the nine months ended September 30, 2023 compared to approximately $6,318,000 for the comparable period in 2022. The increase in research and development expenses during the period was mainly attributed to the timing of research organization (CRO) expenses and patient treatment costs related to continued progress with our clinical trial for Berubicin. Our CRO expenditures are primarily for labor related to activating selected trial sites, managing patient enrollment processes, collecting and managing data from patient treatments throughout the trial, processing reimbursement to the sites for patient treatment, and assisting with necessary submissions to amend the IND. CRO expenditures are expected to remain relatively consistent with the current quarter throughout the remainder of the trial as site activation efforts and the associated costs thereof transition into reimbursing clinical trial sites for patient treatment costs as site and patient enrollment increases. We expect to incur increased research and development costs in the future as we continue our clinical trial for Berubicin primarily due to higher patient enrollment and the associated cost of treating these patients.

Net Loss

The net loss for the nine months ended September 30, 2023 was approximately $13,476,000 compared to approximately $10,137,000 for the comparable period in 2022. The change in net loss is attributable to an increase in CRO expenses related to continued progress with our clinical trial for Berubicin, a credit to research and development expense in the prior year period for the funds collected from WPD Pharmaceuticals related to their purchase of Berubicin drug product for their clinical trials.

Liquidity and Capital Resources

On September 30, 2023, we had cash of approximately $910,000 and we had a working capital deficit of approximately $2,007,000. We fund our operations from proceeds from equity sales.

We believe that our cash on hand is sufficient to fund our planned operations into, but not beyond, the fourth quarter of 2023, and with the cash received subsequent to September 30, 2023 for the Inducement Warrant Shares, is sufficient to fund our planned operations through the end of the fourth quarter of 2023.

Our plan of operations is primarily focused on completing a clinical trial for Berubicin. We estimate that we will require additional financing of approximately $9.4 to $13.4 million to complete the clinical trial for Berubicin (taking into account our cash on hand as of September 30, 2023 of approximately $0.9 million), approximately $5.0 million to support near-term WP1244/WP1874 preclinical work, plus such additional working capital to fund our operations during the pendency of the trial. The timing and costs of clinical trials are difficult to predict and trial plans may change in response to evolving circumstances and as such the foregoing estimates may prove to be inaccurate.

We will need to raise additional capital in order to meet our obligations and execute our business plan. If we are unable to raise sufficient funds, we will be required to develop and implement an alternative plan to further extend payables, reduce overhead or scale back our business plan until sufficient additional capital is raised to support further operations. There can be no assurance that such a plan will be successful.

Summary of Cash Flows

Cash used in operating activities

Net cash used in operating activities was approximately $11,604,000 and $8,252,000 for the nine months ended September 30, 2023 and 2022, respectively, and mainly included payments made for clinical trial preparation, officer compensation, insurance, marketing and professional fees to our consultants, attorneys and accountants.

Cash provided by financing activities

Net cash provided by financing activities was approximately $2,460,000 for the nine months ended September 30, 2023, related to the sale of common stock and exercise of warrants, which were offset by the repayment of notes payable. Net cash provided by financing activities was approximately $10,280,000 for the nine months ended September 30, 2022, related to the sale of common stock and exercise of warrants, which were offset by the repayment of notes payable.

Off-balance Sheet Arrangements

As of September 30, 2023, we did not have any relationships with unconsolidated entities or financial partnerships, such as entities often referred to as structured finance or special purpose entities, established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes.

Purchase Commitments

We do not have any material commitments for capital expenditures, although we are required to pay certain milestones fees to HPI as described in the section “Overview” above.

JOBS Act Accounting Election

The Jumpstart Our Business Startups Act of 2012, or the JOBS Act, exempts an “emerging growth company” such as us from being required to comply with new or revised financial accounting standards until private companies are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. We elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, we, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of our financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.

Critical Accounting Policies and Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates, assumptions and judgments that affect the amounts reported in the financial statements, including the notes thereto. As a result, management is required to routinely make judgments and estimates about the effects of matters that are inherently uncertain. Actual results may differ from these estimates under different conditions or assumptions. Management determined there were no critical accounting estimates.

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information required under this item.

Item 4.

Controls and Procedures

Evaluation of Disclosure Controls and Procedures and Changes in Internal Control over Financial Reporting

We maintain a set of disclosure controls and procedures designed to ensure that material information required to be disclosed in our filings under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and that material information is accumulated and communicated to our management, including our chief executive officer, who serves as our principal executive officer, and our chief financial officer, who serves as our principal financial officer, as appropriate, to allow timely decisions regarding required disclosures.

Under the supervision, and with the participation of our management, including our chief executive officer and our chief financial officer, we conducted an evaluation of the effectiveness, as of September 30, 2023, of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by an issuer in the reports that it files or submits under the Exchange Act is accumulated and communicated to the issuer’s management, including its principal executive officer and principal financial officer, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

Based upon such evaluation, our chief executive officer and our chief financial officer have concluded that, as of September 30, 2023, our disclosure controls and procedures were, and continue to be, ineffective because of the material weaknesses in our internal control over financial reporting due to lack of segregation of duties (resulting from the limited number of personnel available), limited access to timely and complete information regarding the status of costs incurred in the activation of investigational sites and costs from treating patients in our study which is a result of the use of a third-party Contract Research Organization (“CRO”) to manage the study, and the lack of formal documentation of our control environment. Management is commencing actions to address the lack of formal documentation of our control environment, although this will not address the lack of segregation of duties. Management is also working with the CRO to improve the timeliness and completeness of the data reported to the Company to address this material weakness, as well as conducting increased analytical analysis of such data to be performed by the Company.

In light of the material weakness described above, we continue to perform additional analysis and other post-closing procedures to ensure our financial statements are prepared in accordance with GAAP. Accordingly, we believe that the financial statements included in this report fairly present, in all material respects, our financial condition, results of operations and cash flows for the periods presented. Additional experienced personnel will be hired in the accounting and finance department, appropriate consultants will be retained, and our accounting system will be upgraded as soon as it becomes economically feasible and sustainable.

Other than as described above, there has been no change in our internal control over financial reporting during our most recent calendar quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II - OTHER INFORMATION

Item 1.

Legal Proceedings

From time to time in the ordinary course of our business, we may be involved in legal proceedings, the outcomes of which may not be determinable. The results of litigation are inherently unpredictable. Any claims against us, whether meritorious or not, could be time consuming, result in costly litigation, require significant amounts of management time and result in diversion of significant resources. We are not able to estimate an aggregate amount or range of reasonably possible losses for those legal matters for which losses are not probable and estimable. We have insurance policies covering potential losses where such coverage is cost effective.

We are not at this time involved in any legal proceedings.

Item 1A.

Risk Factors

In addition to the other information set forth in this report, you should carefully consider the factors discussed in the section entitled “Risk Factors” in our 2022 Annual Report on Form 10-K, filed with the SEC, which are incorporated herein by reference. The risks described in such reports are not the only risks facing our Company. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition and/or operating results.

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

None.

Item 3.

Defaults Upon Senior Securities

None.

Item 4.

Mine Safety Disclosures

Not applicable.

Item 5.

Other Information

During the period covered by this Quarterly Report, none of the Company’s directors or executive officers has adopted or terminated a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement (each as defined in Item 408 of Regulation S-K under the Securities Exchange Act of 1934, as amended).

Item 6.

Exhibits

INDEX TO EXHIBITS

Exhibit Number		Description


31.1*		Certification of the Principal Executive Officer pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934.
31.2*		Certification of the Principal Financial Officer pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934.
32.1*(1)		Certification of the Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2*(1)		Certification of the Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.INS*		Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document)
101.SCH*		Inline XBRL Taxonomy Extension Schema Document
101.CAL*		Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF*		Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB*		Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE*		Inline XBRL Taxonomy Extension Presentation Linkbase Document
104*		Cover Page Interactive Data File (formatted in iXBRL, and included in exhibit 101).

______________

*	Filed herewith.

(1)	The certifications on Exhibit 32 hereto are deemed not “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liability of that Section. Such certifications will not be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

CNS PHARMACEUTICALS, INC.

SIGNATURE	TITLE	DATE

/s/ John Climaco	Chief Executive Officer and Director	November 14 2023
John Climaco	(principal executive officer)

/s/ Christopher Downs	Chief Financial Officer	November 14 2023
Christopher Downs	(principal financial and accounting officer)

EX-31.1 2 cns_ex3101.htm CERTIFICATION

Exhibit 31.1

CERTIFICATION BY CHIEF EXECUTIVE OFFICER

I, John Climaco, certify that:

1. I have reviewed this quarterly report on Form 10-Q of CNS Pharmaceuticals, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and we have:

a. designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b. designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c. evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d. disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting.

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a. all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b. any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

November 14, 2023

By: /s/ John Climaco

John Climaco

Chief Executive Officer

(Principal executive officer)

EX-31.2 3 cns_ex3102.htm CERTIFICATION

Exhibit 31.2

CERTIFICATION BY CHIEF FINANCIAL OFFICER

I, Christopher Downs, certify that:

1. I have reviewed this quarterly report on Form 10-Q of CNS Pharmaceuticals, Inc.;

b. any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

November 14, 2023

By: /s/ Christopher Downs

Christopher Downs

Chief Financial Officer

(Principal financial and accounting officer)

EX-32.1 4 cns_ex3201.htm CERTIFICATION

Exhibit 32.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

(Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code)

Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), the undersigned officer of CNS Pharmaceuticals, Inc., a Nevada corporation (the "Company"), does hereby certify, to such officer’s knowledge, that:

The quarterly report on Form 10-Q for the quarter ended September 30, 2023 (the "Form 10-Q") of the Company fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended and information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.

November 14, 2023

By: /s/ John Climaco

John Climaco

Chief Executive Officer

(Principal Executive Officer)

EX-32.2 5 cns_ex3202.htm CERTIFICATION

Exhibit 32.2

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

(Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code)

November 14, 2023

By: /s/ Christopher Downs

Christopher Downs

Chief Financial Officer

(Principal financial and accounting officer)

EX-101.SCH 6 cnsp-20230930.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Balance Sheets (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Statements of Stockholders' Equity (Deficit) (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - Nature of Business link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Note Payable link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Equity link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Summary of Significant Accounting Policies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Note Payable (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Equity (Details - Option Activity) link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Equity (Details - Warrant Activity) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Equity (Details - Restricted Stock Units Activity) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Equity (Details - Performance Units Activity) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Equity (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Commitments and Contingencies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 cnsp-20230930_cal.xml XBRL CALCULATION FILE EX-101.DEF 8 cnsp-20230930_def.xml XBRL DEFINITION FILE EX-101.LAB 9 cnsp-20230930_lab.xml XBRL LABEL FILE Equity Components [Axis] Common Stock [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] Antidilutive Securities [Axis] Warrants [Member] Award Type [Axis] Restricted Stock Units (RSUs) [Member] Performance Units [Member] Stock Options [Member] Counterparty Name [Axis] Agent [Member] Plan Name [Axis] Plan 2017 [Member] Plan 2020 [Member] Title of Individual [Axis] Faith Charles [Member] Officer [Member] Vesting [Axis] Share-Based Payment Arrangement, Tranche One [Member] Share-Based Payment Arrangement, Tranche Two [Member] Statistical Measurement [Axis] Minimum [Member] Maximum [Member] Related Party, Type [Axis] Dr Cockroft [Member] Board of Directors Chairman [Member] Equity Option [Member] Class of Warrant or Right [Axis] Warrant Price 3.03 [Member] Warrant Price 0.001 [Member] Related Party Transaction [Axis] Mr Climaco [Member] Officers [Member] Scientific Advisory Board [Member] Mr Hsu Scientific Advisory Board [Member] Transaction Type [Axis] Technology Rights Agr [Member] Houston Pharm [Member] Product and Service [Axis] Houston Pharmaceuticals [Member] Pum [Member] Patent And Technology License Agr [Member] U T M D A C C [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Statement of Financial Position [Abstract] Assets Current Assets: Cash and cash equivalents Prepaid expenses and other current assets Total current assets Noncurrent Assets: Prepaid expenses, net of current portion Property and equipment, net Total noncurrent assets Total Assets Liabilities and Stockholders' Equity (Deficit) Current Liabilities: Accounts payable and accrued expenses Notes payable Total current liabilities Total Liabilities Commitments and contingencies Stockholders' Equity (Deficit): Preferred stock, $0.001 par value, 5,000,000 shares authorized and 0 shares issued and outstanding Common stock, $0.001 par value, 75,000,000 shares authorized and 4,207,068 and 1,617,325 shares issued and outstanding, respectively Additional paid-in capital Accumulated deficit Total Stockholders' Equity (Deficit) Total Liabilities and Stockholders' Equity (Deficit) Preferred stock, par value Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] Operating expenses: General and administrative Research and development Total operating expenses Loss from operations Other income (expenses): Interest income Interest expense Total other income (expense) Net loss Loss per share - basic Loss per share - diluted Weighted average shares outstanding - basic Weighted average shares outstanding - diluted Statement [Table] Statement [Line Items] Beginning balance, value Beginning balance, shares Common stock issued for cash, net Common stock issued for cash net, shares Exercise of warrants Exercise of warrants, shares Stock-based compensation Net loss Stock-based compensation, shares Ending balance, value Ending balance, shares Statement of Cash Flows [Abstract] Cash Flows from Operating Activities: Adjustments to reconcile net loss to net cash used in operating activities: Stock-based compensation Depreciation Loss of disposal of fixed assets Changes in operating assets and liabilities: Prepaid expenses and other current assets Accounts payable and accrued expenses Net cash used in operating activities Cash Flows from Investing Activities: Purchase of property and equipment Net cash used in investing activities Cash Flows from Financing Activities: Payments on notes payable Proceeds from exercise of warrants Proceeds from sale of common stock Net cash provided by financing activities Net change in cash and cash equivalents Cash and cash equivalents, at beginning of period Cash and cash equivalents, at end of period Supplemental disclosures of cash flow information: Cash paid for interest Cash paid for income taxes Organization, Consolidation and Presentation of Financial Statements [Abstract] Nature of Business Accounting Policies [Abstract] Summary of Significant Accounting Policies Debt Disclosure [Abstract] EX-101.PRE 10 cnsp-20230930_pre.xml XBRL PRESENTATION FILE XML 11 R1.htm IDEA: XBRL DOCUMENT

Cover - shares	9 Months Ended
Cover - shares	Sep. 30, 2023	Nov. 14, 2023
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Sep. 30, 2023
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2023
Current Fiscal Year End Date	--12-31
Entity File Number	001-39126
Entity Registrant Name	CNS Pharmaceuticals, Inc.
Entity Central Index Key	0001729427
Entity Tax Identification Number	82-2318545
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	2100 West Loop South
Entity Address, Address Line Two	Suite 900
Entity Address, City or Town	Houston
Entity Address, State or Province	TX
Entity Address, Postal Zip Code	77027
City Area Code	800
Local Phone Number	946-9185
Title of 12(b) Security	Common Stock
Trading Symbol	CNSP
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		5,248,598

XML 12 R2.htm IDEA: XBRL DOCUMENT

Balance Sheets (Unaudited) - USD ($)	Sep. 30, 2023	Dec. 31, 2022
Current Assets:
Cash and cash equivalents	$ 909,547	$ 10,055,407
Prepaid expenses and other current assets	1,152,298	2,509,238
Total current assets	2,061,845	12,564,645
Noncurrent Assets:
Prepaid expenses, net of current portion	262,731	482,806
Property and equipment, net	3,470	5,664
Total noncurrent assets	266,201	488,470
Total Assets	2,328,046	13,053,115
Current Liabilities:
Accounts payable and accrued expenses	4,026,894	4,510,291
Notes payable	41,904	409,968
Total current liabilities	4,068,798	4,920,259
Total Liabilities	4,068,798	4,920,259
Commitments and contingencies
Stockholders' Equity (Deficit):
Preferred stock, $0.001 par value, 5,000,000 shares authorized and 0 shares issued and outstanding	0	0
Common stock, $0.001 par value, 75,000,000 shares authorized and 4,207,068 and 1,617,325 shares issued and outstanding, respectively	4,207	1,617
Additional paid-in capital	62,446,694	58,846,916
Accumulated deficit	(64,191,653)	(50,715,677)
Total Stockholders' Equity (Deficit)	(1,740,752)	8,132,856
Total Liabilities and Stockholders' Equity (Deficit)	$ 2,328,046	$ 13,053,115

XML 13 R3.htm IDEA: XBRL DOCUMENT

Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Sep. 30, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	75,000,000	75,000,000
Common stock, shares issued	4,207,068	1,617,325
Common stock, shares outstanding	4,207,068	1,617,325

XML 14 R4.htm IDEA: XBRL DOCUMENT

Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
Statements of Operations (Unaudited) - USD ($)	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Operating expenses:
General and administrative	$ 1,123,268	$ 1,211,102	$ 3,661,853	$ 3,814,513
Research and development	3,410,572	2,207,913	9,823,884	6,318,055
Total operating expenses	4,533,840	3,419,015	13,485,737	10,132,568
Loss from operations	(4,533,840)	(3,419,015)	(13,485,737)	(10,132,568)
Other income (expenses):
Interest income	12,883	0	20,685	0
Interest expense	(1,838)	(538)	(10,924)	(4,715)
Total other income (expense)	11,045	(538)	9,761	(4,715)
Net loss	$ (4,522,795)	$ (3,419,553)	$ (13,475,976)	$ (10,137,283)
Loss per share - basic	$ (1.08)	$ (2.56)	$ (4.05)	$ (7.67)
Loss per share - diluted	$ (1.08)	$ (2.56)	$ (4.05)	$ (7.67)
Weighted average shares outstanding - basic	4,177,069	1,334,417	3,327,636	1,321,065
Weighted average shares outstanding - diluted	4,177,069	1,334,417	3,327,636	1,321,065

XML 15 R5.htm IDEA: XBRL DOCUMENT

Statements of Stockholders' Equity (Deficit) (Unaudited) - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Beginning balance, value at Dec. 31, 2021	$ 949	$ 41,603,791	$ (35,441,543)	$ 6,163,197
Beginning balance, shares at Dec. 31, 2021	949,052
Common stock issued for cash, net	$ 316	10,625,470		10,625,786
Common stock issued for cash net, shares	316,316
Exercise of warrants	$ 87	2,529		2,616
Exercise of warrants, shares	87,193
Stock-based compensation		336,685		336,685
Net loss			(3,151,778)	(3,151,778)
Ending balance, value at Mar. 31, 2022	$ 1,352	52,568,475	(38,593,321)	13,976,506
Ending balance, shares at Mar. 31, 2022	1,352,561
Beginning balance, value at Dec. 31, 2021	$ 949	41,603,791	(35,441,543)	6,163,197
Beginning balance, shares at Dec. 31, 2021	949,052
Net loss				(10,137,283)
Ending balance, value at Sep. 30, 2022	$ 1,352	53,145,037	(45,578,826)	7,567,563
Ending balance, shares at Sep. 30, 2022	1,352,561
Beginning balance, value at Mar. 31, 2022	$ 1,352	52,568,475	(38,593,321)	13,976,506
Beginning balance, shares at Mar. 31, 2022	1,352,561
Stock-based compensation		286,841		286,841
Net loss			(3,565,952)	(3,565,952)
Ending balance, value at Jun. 30, 2022	$ 1,352	52,855,316	(42,159,273)	10,697,395
Ending balance, shares at Jun. 30, 2022	1,352,561
Stock-based compensation		289,721		289,721
Net loss			(3,419,553)	(3,419,553)
Ending balance, value at Sep. 30, 2022	$ 1,352	53,145,037	(45,578,826)	7,567,563
Ending balance, shares at Sep. 30, 2022	1,352,561
Beginning balance, value at Dec. 31, 2022	$ 1,617	58,846,916	(50,715,677)	8,132,856
Beginning balance, shares at Dec. 31, 2022	1,617,325
Exercise of warrants	$ 609			609
Exercise of warrants, shares	609,000
Stock-based compensation		290,313		290,313
Net loss			(4,931,947)	(4,931,947)
Ending balance, value at Mar. 31, 2023	$ 2,226	59,137,229	(55,647,624)	3,491,831
Ending balance, shares at Mar. 31, 2023	2,226,325
Beginning balance, value at Dec. 31, 2022	$ 1,617	58,846,916	(50,715,677)	8,132,856
Beginning balance, shares at Dec. 31, 2022	1,617,325
Net loss				(13,475,976)
Ending balance, value at Sep. 30, 2023	$ 4,207	62,446,694	(64,191,653)	(1,740,752)
Ending balance, shares at Sep. 30, 2023	4,207,068
Beginning balance, value at Mar. 31, 2023	$ 2,226	59,137,229	(55,647,624)	3,491,831
Beginning balance, shares at Mar. 31, 2023	2,226,325
Common stock issued for cash, net	$ 660	1,968,447		1,969,107
Common stock issued for cash net, shares	659,677
Exercise of warrants	$ 1,255	723,804		725,059
Exercise of warrants, shares	1,254,958
Stock-based compensation		289,670		289,670
Net loss			(4,021,234)	(4,021,234)
Ending balance, value at Jun. 30, 2023	$ 4,141	62,119,150	(59,668,858)	2,454,433
Ending balance, shares at Jun. 30, 2023	4,140,960
Common stock issued for cash, net	$ 64	132,787		132,851
Common stock issued for cash net, shares	63,729
Stock-based compensation	$ 2	194,757		194,759
Net loss			(4,522,795)	(4,522,795)
Stock-based compensation, shares	2,379
Ending balance, value at Sep. 30, 2023	$ 4,207	$ 62,446,694	$ (64,191,653)	$ (1,740,752)
Ending balance, shares at Sep. 30, 2023	4,207,068

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481687/323-10-50-3

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482907/825-10-50-28

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482765/220-10-50-6

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-3

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-8

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-9

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-4

Reference 13: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480167/946-830-55-10

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483581/946-220-45-7

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(9))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(1)(d))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-30

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B

Reference 32: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-31

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483499/205-20-50-7

Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482740/230-10-45-28

Reference 36: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A

Reference 37: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B

Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2

Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1

+ Details

- Definition

Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.

+ References + Details

- Definition

Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481372/852-10-55-10

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480167/946-830-55-12

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(19))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.6-05(4))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(4)(b))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(6))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(7))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481687/323-10-50-3

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482907/825-10-50-28

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 310
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2

+ Details

XML 16 R6.htm IDEA: XBRL DOCUMENT

Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
Statements of Cash Flows (Unaudited) - USD ($)	Sep. 30, 2023	Sep. 30, 2022
Cash Flows from Operating Activities:
Net loss	$ (13,475,976)	$ (10,137,283)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation	774,742	913,247
Depreciation	3,181	9,375
Loss of disposal of fixed assets	757	2,635
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	1,577,015	1,134,824
Accounts payable and accrued expenses	(483,397)	(175,290)
Net cash used in operating activities	(11,603,678)	(8,252,492)
Cash Flows from Investing Activities:
Purchase of property and equipment	(1,744)	(4,423)
Net cash used in investing activities	(1,744)	(4,423)
Cash Flows from Financing Activities:
Payments on notes payable	(368,064)	(348,534)
Proceeds from exercise of warrants	725,668	2,616
Proceeds from sale of common stock	2,101,958	10,625,786
Net cash provided by financing activities	2,459,562	10,279,868
Net change in cash and cash equivalents	(9,145,860)	2,022,953
Cash and cash equivalents, at beginning of period	10,055,407	5,004,517
Cash and cash equivalents, at end of period	909,547	7,027,470
Supplemental disclosures of cash flow information:
Cash paid for interest	10,924	5,782
Cash paid for income taxes	$ 0	$ 0

XML 17 R7.htm IDEA: XBRL DOCUMENT

Nature of Business

9 Months Ended

Sep. 30, 2023

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Nature of Business

Note 1 – Nature of Business

XML 18 R8.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies

9 Months Ended

Sep. 30, 2023

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

Note 2 – Summary of Significant Accounting Policies

Restricted Stock Units (“RSUs”) - Our RSUs vest over four years from the date of grant. The fair value of RSUs is the market price of our common stock at the date of grant.

Performance Units (“PUs”) - The PUs vest based on our performance against predefined share price targets and the achievement of Positive Interim, Clinical Data as defined by the Board.

XML 19 R9.htm IDEA: XBRL DOCUMENT

Note Payable

9 Months Ended

Sep. 30, 2023

Debt Disclosure [Abstract]

Note Payable

Note 3 – Note Payable

XML 20 R10.htm IDEA: XBRL DOCUMENT

Equity

9 Months Ended

Sep. 30, 2023

Equity [Abstract]

Equity

Note 4 – Equity

Stock Options

The following table summarizes the stock option activity for the nine months ended September 30, 2023:

Schedule of stock option activity
	Options			Weighted-Average Exercise Price Per Share
Outstanding, December 31, 2022		93,001		$	67.42
Granted		235,777			1.78
Exercised		–			–
Forfeited		(8	)		120.00
Expired		–			–
Outstanding, September 30, 2023		328,770		$	20.35
Exercisable, September 30, 2023		82,261		$	60.99

Stock Warrants

The following table summarizes the stock warrant activity for the nine months ended September 30, 2023:

Schedule of warrants activity
	Warrants			Weighted-Average Exercise Price Per Share
Outstanding, December 31, 2022		4,133,252		$	4.35
Granted		–			–
Exercised		(1,863,958	)		0.39
Forfeited		–			–
Expired		(467	)		45.00
Outstanding, September 30, 2023		2,268,827		$	7.59
Exercisable, September 30, 2023		2,268,827		$	7.59

As of September 30, 2023, the outstanding and exercisable warrants have a weighted average remaining term of 4.02 years and had no aggregate intrinsic value.

Restricted Stock Units

The following table summarizes the RSUs activity for the nine months ended September 30, 2023:


	RSUs			Weighted-Average Grant Date Fair Value
Non-vested, December 31, 2022		9,523		$	10.02
Granted		–			–
Vested		(2,379	)		10.02
Forfeited		–			–
Non-vested, September 30, 2023		7,144		$	10.02

Performance Units

The following table summarizes the PUs activity for the nine months ended September 30, 2023:

Schedule of performance units activity
	PUs		Weighted-Average Grant Date Fair Value
Non-vested, December 31, 2022		28,563	$	5.94
Granted		–		–
Vested		–		–
Forfeited		–		–
Non-vested, September 30, 2023		28,563	$	5.94

- Definition

The entire disclosure for equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-14

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481062/946-235-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481062/946-235-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 505
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481004/946-505-50-6

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480237/815-40-50-6

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//505/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-14

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-14

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 16
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-16

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-18

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-18

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-18

+ Details

XML 21 R11.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies

9 Months Ended

Sep. 30, 2023

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

Note 5 – Commitments and Contingencies

Executive Employment Agreements

On March 29, 2023, the Board of Directors approved, based upon the recommendation of the Compensation Committee, cash bonuses totaling $550,750 to the officers of the Company.

Scientific Advisory Board

WP744 Portfolio (Berubicin)

WP1244 Portfolio

XML 22 R12.htm IDEA: XBRL DOCUMENT

Subsequent Events

9 Months Ended

Sep. 30, 2023

Subsequent Events [Abstract]

Subsequent Events

Note 6 – Subsequent Events

Pursuant to the terms of the Capital on Demand™ Sales Agreement with JonesTrading Institutional Services LLC and Brookline Capital Markets, a division of Arcadia Securities, LLC (collectively, the “Agent”), the Company may sell from time to time, through the Agent, shares of the Company’s common stock with an aggregate sales price of up to $20.0 million. Subsequent to the quarter ended on September 30, 2023, the Company sold 129,530 shares of common stock to the Agent for net proceeds of $215,641.

XML 23 R13.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Policies)	9 Months Ended
Summary of Significant Accounting Policies (Policies)	Sep. 30, 2023
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation - The accompanying unaudited financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United Stated of America (“U.S. GAAP”) for interim unaudited financial information. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. The unaudited financial statements include all adjustments (consisting of normal recurring adjustments) which are, in the opinion of management, necessary in order to make the condensed financial statements not misleading. Operating results for the three and nine months ended September 30, 2023 are not necessarily indicative of the final results that may be expected for the year ending December 31, 2023. For more complete financial information, these unaudited financial statements should be read in conjunction with the audited financial statements for the period ended December 31, 2022 included in our Form 10-K filed with the SEC on March 31, 2023 (“Form 10-K”). Notes to the financial statements which would substantially duplicate the disclosures contained in the audited financial statements for the most recent fiscal period, as reported in the Form 10-K, have been omitted.
Liquidity and Going Concern	Liquidity and Going Concern - These financial statements have been prepared on a going concern basis, which assumes the Company will continue to realize its assets and discharge its liabilities in the normal course of business. The continuation of the Company as a going concern is dependent upon the ability of the Company to obtain equity financings to continue operations. The Company has a history of and expects to continue to report negative cash flows from operations and a net loss. Management believes that the cash on hand is sufficient to fund its planned operations into but not beyond the near term. These factors raise substantial doubt regarding the Company’s ability to continue as a going concern. These financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. The Company may seek additional funding through a combination of equity offerings, debt financings, government or other third-party funding, commercialization, marketing and distribution arrangements, other collaborations, strategic alliances and licensing arrangements and delay planned cash outlays or a combination thereof. Management cannot be certain that such events or a combination thereof can be achieved.
Cash and Cash Equivalents	Cash and Cash Equivalents - The Company considers all highly liquid accounts with original maturities of three months or less at the date of acquisition to be cash equivalents. Periodically, the Company may carry cash balances at financial institutions in excess of the federally insured limit of $250,000. The amount in excess of the FDIC insurance as of September 30, 2023 was $659,547. The Company has not experienced losses on these accounts and management believes, based upon the quality of the financial institutions, that the credit risk with regard to these deposits is not significant.
Stock-based Compensation	Stock-based Compensation - Employee and non-employee share-based compensation is measured at the grant date, based on the fair value of the award, and is recognized as an expense over the requisite service period for stock options and restricted stock units.
Restricted Stock Units (“RSUs”)	Restricted Stock Units (“RSUs”) - Our RSUs vest over four years from the date of grant. The fair value of RSUs is the market price of our common stock at the date of grant.
Performance Units (“PUs”)	Performance Units (“PUs”) - The PUs vest based on our performance against predefined share price targets and the achievement of Positive Interim, Clinical Data as defined by the Board.
Loss Per Common Share	Loss Per Common Share - Basic loss per common share is computed by dividing net loss available to common shareholders by the weighted-average number of common shares outstanding during the period. Diluted loss per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents. In periods when losses are reported, the weighted-average number of common shares outstanding excludes common stock equivalents, because their inclusion would be anti-dilutive. As of September 30, 2023, the Company’s potentially dilutive shares and options, which were not included in the calculation of net loss per share, included warrants to purchase 2,268,827 common shares unvested restricted stock units of 7,144 common shares, unvested performance units of 28,563 and options for 328,770 common shares, respectively. For the nine months ended September 30, 2022, the Company’s potentially dilutive shares and options, which were not included in the calculation of net loss per share, included warrants to purchase 524,000 common shares, unvested restricted stock units of 9,523 common shares, unvested performance units of 28,563 and options for 93,001 common shares, respectively.
Reclassification - Certain reclassifications may have been made to our prior year’s financial statements to conform to our current year presentation. These reclassifications had no effect on our previously reported results of operations or accumulated deficit.	Reclassification - Certain reclassifications may have been made to our prior year’s financial statements to conform to our current year presentation. These reclassifications had no effect on our previously reported results of operations or accumulated deficit.
Recent Accounting Pronouncements	Recent Accounting Pronouncements - In June 2016, the FASB issued Accounting Standards Update No. 2016-13, Financial Instruments-Credit Losses: Measurement of Credit Losses on Financial Instruments. ASU 2016-13 requires measurement and recognition of expected credit losses for financial assets. In April 2019, the FASB issued clarification to ASU 2016-13 within ASU 2019-04, Codification Improvements to Topic 326, Financial Instruments-Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments, or ASU 2016-13. The guidance is effective for fiscal years beginning after December 15, 2022. The Company adopted this standard on January 1, 2023, which had no material impact on the Company’s financial statements.

XML 24 R14.htm IDEA: XBRL DOCUMENT

Equity (Tables)

9 Months Ended

Sep. 30, 2023

Equity [Abstract]

Schedule of stock option activity

Schedule of stock option activity
	Options			Weighted-Average Exercise Price Per Share
Outstanding, December 31, 2022		93,001		$	67.42
Granted		235,777			1.78
Exercised		–			–
Forfeited		(8	)		120.00
Expired		–			–
Outstanding, September 30, 2023		328,770		$	20.35
Exercisable, September 30, 2023		82,261		$	60.99

Schedule of warrants activity

Schedule of warrants activity
	Warrants			Weighted-Average Exercise Price Per Share
Outstanding, December 31, 2022		4,133,252		$	4.35
Granted		–			–
Exercised		(1,863,958	)		0.39
Forfeited		–			–
Expired		(467	)		45.00
Outstanding, September 30, 2023		2,268,827		$	7.59
Exercisable, September 30, 2023		2,268,827		$	7.59

Schedule of restricted stock units activity


	RSUs			Weighted-Average Grant Date Fair Value
Non-vested, December 31, 2022		9,523		$	10.02
Granted		–			–
Vested		(2,379	)		10.02
Forfeited		–			–
Non-vested, September 30, 2023		7,144		$	10.02

Schedule of performance units activity

Schedule of performance units activity
	PUs		Weighted-Average Grant Date Fair Value
Non-vested, December 31, 2022		28,563	$	5.94
Granted		–		–
Vested		–		–
Forfeited		–		–
Non-vested, September 30, 2023		28,563	$	5.94

XML 25 R15.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Cash in excess of FDIC	$ 659,547
Restricted Stock Units (RSUs) [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Unvested performance units	7,144	9,523	9,523
Performance Units [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Unvested performance units	28,563	28,563	28,563
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Options outstanding	328,770	93,001
Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive shares	2,268,827	524,000

XML 26 R16.htm IDEA: XBRL DOCUMENT

Note Payable (Details Narrative) - USD ($)	Nov. 14, 2022	Sep. 30, 2023	Dec. 31, 2022
Debt Disclosure [Abstract]
Short-term note payable	$ 449,874
Interest rate	5.88%
Maturity period	Oct. 31, 2023
Notes payable		$ 41,904	$ 409,968

XML 27 R17.htm IDEA: XBRL DOCUMENT

Equity (Details - Option Activity) - Stock Options [Member]	9 Months Ended
	Sep. 30, 2023 $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of options outstanding, Beginning \| shares	93,001
Weighted average exercise price per share, Beginning \| $ / shares	$ 67.42
Number of options, Granted \| shares	235,777
Weighted average exercise price per share, Granted \| $ / shares	$ 1.78
Number of options, Exercised \| shares	0
Weighted average exercise price per share, Exercised \| $ / shares	$ 0
Number of options, Forfeited \| shares	(8)
Weighted average exercise price per share, Forfeited \| $ / shares	$ 120.00
Number of options, Expired \| shares	0
Weighted average exercise price per share, Expired \| $ / shares	$ 0
Number of options outstanding, Ending \| shares	328,770
Weighted average exercise price per share, Ending \| $ / shares	$ 20.35
Number of options outstanding, Exercisable \| shares	82,261
Weighted average exercise price per share, Exercisable \| $ / shares	$ 60.99

XML 28 R18.htm IDEA: XBRL DOCUMENT

Equity (Details - Warrant Activity) - Warrants [Member]	9 Months Ended
Equity (Details - Warrant Activity) - Warrants [Member]	Sep. 30, 2023 $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of warrants outstanding, Beginning \| shares	4,133,252
Weighted average exercise price per share, Beginning \| $ / shares	$ 4.35
Number of warrants, Granted \| shares	0
Weighted average exercise price per share, Granted \| $ / shares	$ 0
Number of warrants, Exercised \| shares	(1,863,958)
Weighted average exercise price per share, Exercised \| $ / shares	$ 0.39
Number of warrants, Forfeited \| shares	0
Weighted average exercise price per share, Forfeited \| $ / shares	$ 0
Number of warrants, Expired \| shares	(467)
Weighted average exercise price per share, Expired \| $ / shares	$ 45.00
Number of warrants outstanding, Ending \| shares	2,268,827
Weighted average exercise price per share, Ending \| $ / shares	$ 7.59
Number of warrants outstanding, Exercisable \| shares	2,268,827
Weighted average exercise price per share, Exercisable \| $ / shares	$ 7.59

XML 29 R19.htm IDEA: XBRL DOCUMENT

Equity (Details - Restricted Stock Units Activity) - Restricted Stock Units (RSUs) [Member]	9 Months Ended
	Sep. 30, 2023 $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of nonvested outstanding, Beginning \| shares	9,523
Weighted average grant date fair value, Beginning \| $ / shares	$ 10.02
Granted \| shares	0
Weighted average grant date fair value, Granted \| $ / shares	$ 0
Vested \| shares	(2,379)
Weighted average grant date fair value, Vested \| $ / shares	$ 10.02
Forfeited \| shares	0
Weighted average grant date fair value, Forfeited \| $ / shares	$ 0
Number of nonvested outstanding, Ending \| shares	7,144
Weighted average grant date fair value, Ending \| $ / shares	$ 10.02

XML 30 R20.htm IDEA: XBRL DOCUMENT

Equity (Details - Performance Units Activity) - Performance Units [Member]	9 Months Ended
	Sep. 30, 2023 $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of nonvested outstanding, Beginning \| shares	28,563
Weighted average grant date fair value, Beginning \| $ / shares	$ 5.94
Granted \| shares	0
Weighted average grant date fair value, Granted \| $ / shares	$ 0
Vested \| shares	0
Weighted average grant date fair value, Vested \| $ / shares	$ 0
Forfeited \| shares	0
Weighted average grant date fair value, Forfeited \| $ / shares	$ 0
Number of nonvested outstanding, Ending \| shares	28,563
Weighted average grant date fair value, Ending \| $ / shares	$ 5.94

XML 31 R21.htm IDEA: XBRL DOCUMENT

Equity (Details Narrative) - USD ($)						9 Months Ended
Equity (Details Narrative) - USD ($)	Aug. 27, 2023	Aug. 04, 2023	May 03, 2023	Mar. 29, 2023	Dec. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Aug. 09, 2023	Dec. 31, 2022
Class of Warrant or Right [Line Items]
Common stock, shares authorized						75,000,000			75,000,000
Common stock, par value						$ 0.001			$ 0.001
Preferred stock shares authorized						5,000,000			5,000,000
Preferred stock, par value						$ 0.001			$ 0.001
Proceeds from common stock						$ 2,101,958	$ 10,625,786
Options outstanding						4,318
Employees were awarded shares				29,988
Share based compensartion expense						$ 774,742	913,247
Weighted average remaining term						8 years 9 months 14 days
Options vested						$ 0
Cash proceeds						$ 725,668	2,616
Warrant Price 3.03 [Member]
Class of Warrant or Right [Line Items]
Issuance of warrants						238,958
Warrant Price 0.001 [Member]
Class of Warrant or Right [Line Items]
Issuance of warrants						1,625,000
Dr Cockroft [Member]
Class of Warrant or Right [Line Items]
Options outstanding		$ 12,771	$ 3,514
Issuance of common stock		6,500	2,099
Common stock exercise price		$ 2.27	$ 1.67
Stock Options [Member]
Class of Warrant or Right [Line Items]
Stock to be issued						235,777
Exercise price						$ 20.35			$ 67.42
Options outstanding				$ 25,820
Employees were awarded shares						328,770			93,001
Unrecognized compensation expense						$ 940,197
Equity Option [Member]
Class of Warrant or Right [Line Items]
Share based compensartion expense						$ 727,864	$ 877,510
Warrants [Member]
Class of Warrant or Right [Line Items]
Weighted average remaining term						4 years 7 days
Aggregate intrinsic value of warrants outstanding						$ 0
Restricted Stock Units (RSUs) [Member]
Class of Warrant or Right [Line Items]
Share based compensartion expense						17,888
Unrecognized compensation expense						59,624
Performance Units [Member]
Class of Warrant or Right [Line Items]
Share based compensartion expense						28,990
Unrecognized compensation expense						$ 104,958
Share-Based Payment Arrangement, Tranche One [Member]
Class of Warrant or Right [Line Items]
Vested percentage				50.00%
Vested term				2 years
Share-Based Payment Arrangement, Tranche Two [Member]
Class of Warrant or Right [Line Items]
Vested percentage				50.00%
Share-Based Payment Arrangement, Tranche Two [Member] \| Minimum [Member]
Class of Warrant or Right [Line Items]
Stock price				$ 6.00
Share-Based Payment Arrangement, Tranche Two [Member] \| Maximum [Member]
Class of Warrant or Right [Line Items]
Stock price				24.00
Faith Charles [Member]
Class of Warrant or Right [Line Items]
Annual retainer					$ 30,000
Stock to be issued					3,500
Exercise price					$ 2.40
Options outstanding					$ 7,091
Officer [Member]
Class of Warrant or Right [Line Items]
Exercise price				$ 0.996
Cash bonuses				$ 550,750
Board of Directors Chairman [Member]
Class of Warrant or Right [Line Items]
Options outstanding	$ 313,846
Issuance of common stock	193,690
Common stock exercise price	$ 1.90
Plan 2017 [Member]
Class of Warrant or Right [Line Items]
Shares authorized under plan						66,667
Stock to be issued						0
Plan 2020 [Member]
Class of Warrant or Right [Line Items]
Shares authorized under plan						100,000		745,800
Stock to be issued						545,610
Agent [Member]
Class of Warrant or Right [Line Items]
Issuance of common stock shares						723,406
Proceeds from common stock						$ 2,101,958

XML 32 R22.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies (Details Narrative) - USD ($)		9 Months Ended
	Feb. 06, 2021	Sep. 30, 2023	Sep. 30, 2022	Apr. 30, 2023	Mar. 29, 2023	Dec. 31, 2022
Houston Pharmaceuticals [Member]
Product Liability Contingency [Line Items]
Cost of goods and services sold		$ 0	$ 41,075
Officers [Member]
Product Liability Contingency [Line Items]
Cash bonuses approved					$ 550,750
Scientific Advisory Board [Member]
Product Liability Contingency [Line Items]
Labour and related expense		0	76,087
Mr Hsu Scientific Advisory Board [Member]
Product Liability Contingency [Line Items]
Accrued related to compensation		151,584
Houston Pharm [Member] \| Technology Rights Agr [Member]
Product Liability Contingency [Line Items]
Royalty income, nonoperating		37,500	262,500
Pum [Member]
Product Liability Contingency [Line Items]
Accounts receivable		197,605		$ 196,303		$ 1,302
U T M D A C C [Member] \| Patent And Technology License Agr [Member]
Product Liability Contingency [Line Items]
License fee		$ 45,092	$ 49,607
Mr Climaco [Member]
Product Liability Contingency [Line Items]
Annual base salary	$ 525,000

XML 33 cns_i10q-093023_htm.xml IDEA: XBRL DOCUMENT 0001729427 2023-01-01 2023-09-30 0001729427 2023-11-14 0001729427 2023-09-30 0001729427 2022-12-31 0001729427 2023-07-01 2023-09-30 0001729427 2022-07-01 2022-09-30 0001729427 2022-01-01 2022-09-30 0001729427 us-gaap:CommonStockMember 2022-12-31 0001729427 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001729427 us-gaap:RetainedEarningsMember 2022-12-31 0001729427 us-gaap:CommonStockMember 2023-03-31 0001729427 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001729427 us-gaap:RetainedEarningsMember 2023-03-31 0001729427 2023-03-31 0001729427 us-gaap:CommonStockMember 2023-06-30 0001729427 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001729427 us-gaap:RetainedEarningsMember 2023-06-30 0001729427 2023-06-30 0001729427 us-gaap:CommonStockMember 2021-12-31 0001729427 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001729427 us-gaap:RetainedEarningsMember 2021-12-31 0001729427 2021-12-31 0001729427 us-gaap:CommonStockMember 2022-03-31 0001729427 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001729427 us-gaap:RetainedEarningsMember 2022-03-31 0001729427 2022-03-31 0001729427 us-gaap:CommonStockMember 2022-06-30 0001729427 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001729427 us-gaap:RetainedEarningsMember 2022-06-30 0001729427 2022-06-30 0001729427 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001729427 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001729427 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001729427 2023-01-01 2023-03-31 0001729427 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001729427 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001729427 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001729427 2023-04-01 2023-06-30 0001729427 us-gaap:CommonStockMember 2023-07-01 2023-09-30 0001729427 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2023-09-30 0001729427 us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0001729427 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001729427 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001729427 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001729427 2022-01-01 2022-03-31 0001729427 us-gaap:CommonStockMember 2022-04-01 2022-06-30 0001729427 us-gaap:AdditionalPaidInCapitalMember 2022-04-01 2022-06-30 0001729427 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0001729427 2022-04-01 2022-06-30 0001729427 us-gaap:CommonStockMember 2022-07-01 2022-09-30 0001729427 us-gaap:AdditionalPaidInCapitalMember 2022-07-01 2022-09-30 0001729427 us-gaap:RetainedEarningsMember 2022-07-01 2022-09-30 0001729427 us-gaap:CommonStockMember 2023-09-30 0001729427 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001729427 us-gaap:RetainedEarningsMember 2023-09-30 0001729427 us-gaap:CommonStockMember 2022-09-30 0001729427 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0001729427 us-gaap:RetainedEarningsMember 2022-09-30 0001729427 2022-09-30 0001729427 CNSP:WarrantsMember 2023-01-01 2023-09-30 0001729427 us-gaap:RestrictedStockUnitsRSUMember 2023-09-30 0001729427 CNSP:PerformanceUnitsMember 2023-09-30 0001729427 CNSP:StockOptionsMember 2023-09-30 0001729427 CNSP:WarrantsMember 2022-01-01 2022-09-30 0001729427 us-gaap:RestrictedStockUnitsRSUMember 2022-09-30 0001729427 CNSP:PerformanceUnitsMember 2022-09-30 0001729427 CNSP:StockOptionsMember 2022-09-30 0001729427 2022-11-14 0001729427 2022-11-13 2022-11-14 0001729427 CNSP:AgentMember 2023-01-01 2023-09-30 0001729427 CNSP:Plan2017Member 2023-09-30 0001729427 CNSP:Plan2020Member 2023-09-30 0001729427 CNSP:Plan2020Member 2023-08-09 0001729427 CNSP:FaithCharlesMember 2022-12-29 2022-12-30 0001729427 CNSP:FaithCharlesMember 2022-12-30 0001729427 srt:OfficerMember 2023-03-29 0001729427 2023-03-29 0001729427 us-gaap:ShareBasedCompensationAwardTrancheOneMember 2023-03-28 2023-03-29 0001729427 us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2023-03-28 2023-03-29 0001729427 srt:MinimumMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2023-03-28 2023-03-29 0001729427 srt:MaximumMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2023-03-28 2023-03-29 0001729427 CNSP:StockOptionsMember 2023-03-29 0001729427 CNSP:DrCockroftMember 2023-05-02 2023-05-03 0001729427 CNSP:DrCockroftMember 2023-05-03 0001729427 CNSP:DrCockroftMember 2023-08-03 2023-08-04 0001729427 CNSP:DrCockroftMember 2023-08-04 0001729427 srt:BoardOfDirectorsChairmanMember 2023-08-26 2023-08-27 0001729427 srt:BoardOfDirectorsChairmanMember 2023-08-27 0001729427 us-gaap:StockOptionMember 2023-01-01 2023-09-30 0001729427 us-gaap:StockOptionMember 2022-01-01 2022-09-30 0001729427 CNSP:Plan2017Member 2023-01-01 2023-09-30 0001729427 CNSP:Plan2020Member 2023-01-01 2023-09-30 0001729427 CNSP:WarrantPrice303Member 2023-01-01 2023-09-30 0001729427 CNSP:WarrantPrice0001Member 2023-01-01 2023-09-30 0001729427 CNSP:WarrantsMember 2023-01-01 2023-09-30 0001729427 CNSP:WarrantsMember 2023-09-30 0001729427 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-09-30 0001729427 CNSP:PerformanceUnitsMember 2023-01-01 2023-09-30 0001729427 CNSP:StockOptionsMember 2022-12-31 0001729427 CNSP:StockOptionsMember 2023-01-01 2023-09-30 0001729427 CNSP:WarrantsMember 2022-12-31 0001729427 us-gaap:RestrictedStockUnitsRSUMember 2022-12-31 0001729427 CNSP:PerformanceUnitsMember 2022-12-31 0001729427 CNSP:MrClimacoMember 2021-02-05 2021-02-06 0001729427 CNSP:OfficersMember 2023-03-29 0001729427 CNSP:ScientificAdvisoryBoardMember 2023-01-01 2023-09-30 0001729427 CNSP:ScientificAdvisoryBoardMember 2022-01-01 2022-09-30 0001729427 CNSP:MrHsuScientificAdvisoryBoardMember 2023-09-30 0001729427 CNSP:HoustonPharmMember CNSP:TechnologyRightsAgrMember 2023-01-01 2023-09-30 0001729427 CNSP:HoustonPharmMember CNSP:TechnologyRightsAgrMember 2022-01-01 2022-09-30 0001729427 CNSP:HoustonPharmaceuticalsMember 2023-01-01 2023-09-30 0001729427 CNSP:HoustonPharmaceuticalsMember 2022-01-01 2022-09-30 0001729427 CNSP:PumMember 2022-12-31 0001729427 CNSP:PumMember 2023-04-30 0001729427 CNSP:PumMember 2023-09-30 0001729427 CNSP:UTMDACCMember CNSP:PatentAndTechnologyLicenseAgrMember 2023-01-01 2023-09-30 0001729427 CNSP:UTMDACCMember CNSP:PatentAndTechnologyLicenseAgrMember 2022-01-01 2022-09-30 iso4217:USD shares iso4217:USD shares pure 0001729427 false --12-31 2023 Q3

10-Q true 2023-09-30 false 001-39126 CNS Pharmaceuticals, Inc. NV 82-2318545 2100 West Loop South Suite 900 Houston TX 77027 800 946-9185 Common Stock CNSP NASDAQ Yes Yes Non-accelerated Filer true true false false 5248598

909547

10055407

1152298

2509238

2061845

12564645

262731

482806

3470

5664

266201

488470

2328046

13053115

4026894

4510291

41904

409968

4068798

4920259

4068798

4920259

0.001

5000000

0.001

75000000

4207068

1617325

4207

1617

62446694

58846916

-64191653

-50715677

-1740752

8132856

2328046

13053115

1123268

1211102

3661853

3814513

3410572

2207913

9823884

6318055

4533840

3419015

13485737

10132568

-4533840

-3419015

-13485737

-10132568

12883

20685

1838

538

10924

4715

11045

-538

9761

-4715

-4522795

-3419553

-13475976

-10137283

-1.08

-2.56

-4.05

-7.67

-1.08

-2.56

-4.05

-7.67

4177069

1334417

3327636

1321065

4177069

1334417

3327636

1321065

1617325

1617

58846916

-50715677

8132856

609000 609 609

290313

-4931947

2226325

2226

59137229

-55647624

3491831

659677

660

1968447

1969107

1254958 1255 723804 725059

289670

-4021234

4140960

4141

62119150

-59668858

2454433

63729

132787

132851

2379

194757

194759

-4522795

4207068

4207

62446694

-64191653

-1740752

949052

949

41603791

-35441543

6163197

316316

316

10625470

10625786

87193 87 2529 2616

336685

-3151778

1352561

1352

52568475

-38593321

13976506

286841

-3565952

1352561

1352

52855316

-42159273

10697395

289721

-3419553

1352561

1352

53145037

-45578826

7567563

-13475976

-10137283

774742

913247

3181

9375

-757

-2635

-1577015

-1134824

-483397

-175290

-11603678

-8252492

1744

4423

-1744

-4423

368064

348534

725668

2616

2101958

10625786

2459562

10279868

-9145860

2022953

10055407

5004517

909547

7027470

10924

5782

Note 1 – Nature of Business CNS Pharmaceuticals, Inc. (“we”, “our”, the “Company”) is a clinical pharmaceutical company organized as a Nevada corporation on July 27, 2017 to focus on the development of anti-cancer drug candidates.

Note 2 – Summary of Significant Accounting Policies Basis of Presentation - The accompanying unaudited financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United Stated of America (“U.S. GAAP”) for interim unaudited financial information. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. The unaudited financial statements include all adjustments (consisting of normal recurring adjustments) which are, in the opinion of management, necessary in order to make the condensed financial statements not misleading. Operating results for the three and nine months ended September 30, 2023 are not necessarily indicative of the final results that may be expected for the year ending December 31, 2023. For more complete financial information, these unaudited financial statements should be read in conjunction with the audited financial statements for the period ended December 31, 2022 included in our Form 10-K filed with the SEC on March 31, 2023 (“Form 10-K”). Notes to the financial statements which would substantially duplicate the disclosures contained in the audited financial statements for the most recent fiscal period, as reported in the Form 10-K, have been omitted. Liquidity and Going Concern - These financial statements have been prepared on a going concern basis, which assumes the Company will continue to realize its assets and discharge its liabilities in the normal course of business. The continuation of the Company as a going concern is dependent upon the ability of the Company to obtain equity financings to continue operations. The Company has a history of and expects to continue to report negative cash flows from operations and a net loss. Management believes that the cash on hand is sufficient to fund its planned operations into but not beyond the near term. These factors raise substantial doubt regarding the Company’s ability to continue as a going concern. These financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. The Company may seek additional funding through a combination of equity offerings, debt financings, government or other third-party funding, commercialization, marketing and distribution arrangements, other collaborations, strategic alliances and licensing arrangements and delay planned cash outlays or a combination thereof. Management cannot be certain that such events or a combination thereof can be achieved. Cash and Cash Equivalents - The Company considers all highly liquid accounts with original maturities of three months or less at the date of acquisition to be cash equivalents. Periodically, the Company may carry cash balances at financial institutions in excess of the federally insured limit of $250,000. The amount in excess of the FDIC insurance as of September 30, 2023 was $659,547. The Company has not experienced losses on these accounts and management believes, based upon the quality of the financial institutions, that the credit risk with regard to these deposits is not significant. Stock-based Compensation - Employee and non-employee share-based compensation is measured at the grant date, based on the fair value of the award, and is recognized as an expense over the requisite service period for stock options and restricted stock units. Restricted Stock Units (“RSUs”) - Our RSUs vest over four years from the date of grant. The fair value of RSUs is the market price of our common stock at the date of grant. Performance Units (“PUs”) - The PUs vest based on our performance against predefined share price targets and the achievement of Positive Interim, Clinical Data as defined by the Board. Loss Per Common Share - Basic loss per common share is computed by dividing net loss available to common shareholders by the weighted-average number of common shares outstanding during the period. Diluted loss per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents. In periods when losses are reported, the weighted-average number of common shares outstanding excludes common stock equivalents, because their inclusion would be anti-dilutive. As of September 30, 2023, the Company’s potentially dilutive shares and options, which were not included in the calculation of net loss per share, included warrants to purchase <span id="xdx_904_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsMember_zgwjM82y8HF6" title="Antidilutive shares">2,268,827 common shares unvested restricted stock units of <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_c20230930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zF0if0HhKbb4" title="Unvested restricted stock units">7,144 common shares, unvested performance units of <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_c20230930__us-gaap--AwardTypeAxis__custom--PerformanceUnitsMember_zKhV55QGkxXk" title="Unvested performance units">28,563 and options for 328,770 common shares, respectively. For the nine months ended September 30, 2022, the Company’s potentially dilutive shares and options, which were not included in the calculation of net loss per share, included warrants to purchase<span id="xdx_901_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsMember_zANKKWT9obeb" title="Antidilutive shares"> 524,000 common shares, unvested restricted stock units of <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_c20220930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zofAbVLZYc47" title="Unvested restricted stock units">9,523 common shares, unvested performance units of <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_c20220930__us-gaap--AwardTypeAxis__custom--PerformanceUnitsMember_zEkMGDp8ZAje" title="Unvested performance units">28,563 and options for 93,001 common shares, respectively. Reclassification - Certain reclassifications may have been made to our prior year’s financial statements to conform to our current year presentation. These reclassifications had no effect on our previously reported results of operations or accumulated deficit. Recent Accounting Pronouncements - In June 2016, the FASB issued Accounting Standards Update No. 2016-13, Financial Instruments-Credit Losses: Measurement of Credit Losses on Financial Instruments. ASU 2016-13 requires measurement and recognition of expected credit losses for financial assets. In April 2019, the FASB issued clarification to ASU 2016-13 within ASU 2019-04, Codification Improvements to Topic 326, Financial Instruments-Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments, or ASU 2016-13. The guidance is effective for fiscal years beginning after December 15, 2022. The Company adopted this standard on January 1, 2023, which had no material impact on the Company’s financial statements.

Basis of Presentation - The accompanying unaudited financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United Stated of America (“U.S. GAAP”) for interim unaudited financial information. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. The unaudited financial statements include all adjustments (consisting of normal recurring adjustments) which are, in the opinion of management, necessary in order to make the condensed financial statements not misleading. Operating results for the three and nine months ended September 30, 2023 are not necessarily indicative of the final results that may be expected for the year ending December 31, 2023. For more complete financial information, these unaudited financial statements should be read in conjunction with the audited financial statements for the period ended December 31, 2022 included in our Form 10-K filed with the SEC on March 31, 2023 (“Form 10-K”). Notes to the financial statements which would substantially duplicate the disclosures contained in the audited financial statements for the most recent fiscal period, as reported in the Form 10-K, have been omitted.

Liquidity and Going Concern - These financial statements have been prepared on a going concern basis, which assumes the Company will continue to realize its assets and discharge its liabilities in the normal course of business. The continuation of the Company as a going concern is dependent upon the ability of the Company to obtain equity financings to continue operations. The Company has a history of and expects to continue to report negative cash flows from operations and a net loss. Management believes that the cash on hand is sufficient to fund its planned operations into but not beyond the near term. These factors raise substantial doubt regarding the Company’s ability to continue as a going concern. These financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. The Company may seek additional funding through a combination of equity offerings, debt financings, government or other third-party funding, commercialization, marketing and distribution arrangements, other collaborations, strategic alliances and licensing arrangements and delay planned cash outlays or a combination thereof. Management cannot be certain that such events or a combination thereof can be achieved.

Cash and Cash Equivalents - The Company considers all highly liquid accounts with original maturities of three months or less at the date of acquisition to be cash equivalents. Periodically, the Company may carry cash balances at financial institutions in excess of the federally insured limit of $250,000. The amount in excess of the FDIC insurance as of September 30, 2023 was $659,547. The Company has not experienced losses on these accounts and management believes, based upon the quality of the financial institutions, that the credit risk with regard to these deposits is not significant.

659547

Stock-based Compensation - Employee and non-employee share-based compensation is measured at the grant date, based on the fair value of the award, and is recognized as an expense over the requisite service period for stock options and restricted stock units.

Restricted Stock Units (“RSUs”) - Our RSUs vest over four years from the date of grant. The fair value of RSUs is the market price of our common stock at the date of grant. Performance Units (“PUs”) - The PUs vest based on our performance against predefined share price targets and the achievement of Positive Interim, Clinical Data as defined by the Board.

Loss Per Common Share - Basic loss per common share is computed by dividing net loss available to common shareholders by the weighted-average number of common shares outstanding during the period. Diluted loss per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents. In periods when losses are reported, the weighted-average number of common shares outstanding excludes common stock equivalents, because their inclusion would be anti-dilutive. As of September 30, 2023, the Company’s potentially dilutive shares and options, which were not included in the calculation of net loss per share, included warrants to purchase <span id="xdx_904_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsMember_zgwjM82y8HF6" title="Antidilutive shares">2,268,827 common shares unvested restricted stock units of <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_c20230930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zF0if0HhKbb4" title="Unvested restricted stock units">7,144 common shares, unvested performance units of <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_c20230930__us-gaap--AwardTypeAxis__custom--PerformanceUnitsMember_zKhV55QGkxXk" title="Unvested performance units">28,563 and options for 328,770 common shares, respectively. For the nine months ended September 30, 2022, the Company’s potentially dilutive shares and options, which were not included in the calculation of net loss per share, included warrants to purchase<span id="xdx_901_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsMember_zANKKWT9obeb" title="Antidilutive shares"> 524,000 common shares, unvested restricted stock units of <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_c20220930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zofAbVLZYc47" title="Unvested restricted stock units">9,523 common shares, unvested performance units of <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_c20220930__us-gaap--AwardTypeAxis__custom--PerformanceUnitsMember_zEkMGDp8ZAje" title="Unvested performance units">28,563 and options for 93,001 common shares, respectively.

2268827

7144

28563

328770

524000

9523

28563

93001

Reclassification - Certain reclassifications may have been made to our prior year’s financial statements to conform to our current year presentation. These reclassifications had no effect on our previously reported results of operations or accumulated deficit.

Recent Accounting Pronouncements - In June 2016, the FASB issued Accounting Standards Update No. 2016-13, Financial Instruments-Credit Losses: Measurement of Credit Losses on Financial Instruments. ASU 2016-13 requires measurement and recognition of expected credit losses for financial assets. In April 2019, the FASB issued clarification to ASU 2016-13 within ASU 2019-04, Codification Improvements to Topic 326, Financial Instruments-Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments, or ASU 2016-13. The guidance is effective for fiscal years beginning after December 15, 2022. The Company adopted this standard on January 1, 2023, which had no material impact on the Company’s financial statements.

Note 3 – Note Payable On November 14, 2022, the Company entered into a short-term note payable for an aggregate of $449,874, bearing interest at 5.88% per year to finance certain insurance policies. Principal and interest payments related to the note will be repaid over an 11-month period with the final payment due on October 31, 2023. As of September 30, 2023 and December 31, 2022, the Company’s note payable balance was $41,904 and $409,968, respectively.

449874

0.0588

2023-10-31

41904

409968

Note 4 – Equity The Company has authorized 75,000,000 shares of common stock having a par value of $0.001 per share. In addition, the Company authorized 5,000,000 shares of preferred stock to be issued having a par value of $0.001. The specific rights of the preferred stock shall be determined by the board of directors. Pursuant to the terms of the Capital on Demand™ Sales Agreement with JonesTrading Institutional Services LLC and Brookline Capital Markets, a division of Arcadia Securities, LLC (collectively, the “Agent”), the Company may sell from time to time, through the Agent, shares of the Company’s common stock with an aggregate sales price of up to $20.0 million. During the nine months ended September 30, 2023, the Company sold 723,406 shares of common stock to the Agent for net proceeds of $2,101,958. Stock Options In 2017, the Board of Directors of the Company approved the CNS Pharmaceuticals, Inc. 2017 Stock Plan (the “2017 Plan”). The 2017 Plan allows for the Board of Directors to grant various forms of incentive awards for up to <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_c20230930__us-gaap--PlanNameAxis__custom--Plan2017Member_zivMbS7xD6E2" title="Shares authorized under plan">66,667 shares of common stock. In 2020, the Board of Directors of the Company approved the CNS Pharmaceuticals, Inc. 2020 Stock Plan (the “2020 Plan”). The 2020 Plan allows for the Board of Directors to grant various forms of incentive awards for up to <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_c20230930__us-gaap--PlanNameAxis__custom--Plan2020Member_zSzslZ84HDG5" title="Shares authorized under plan">100,000 shares of common stock. The 2020 Plan was amended effective as of August 9, 2023, which was approved by the Company’s stockholders at the Company’s annual meeting on September 14, 2023. The amendment increased the 2020 Plan by <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20230809__us-gaap--PlanNameAxis__custom--Plan2020Member_z0iZsF4fN849" title="Shares authorized under plan">745,800 shares of common stock. On December 30, 2022, the Board of Directors of the Company appointed Faith Charles as an independent member of the Company’s Board of Directors and as Chairperson of the Board of Directors. Ms. Charles will receive an annual retainer for her service as Chairperson of $30,000 and, on the date of her appointment, was granted a ten-year option to purchase <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20221229__20221230__srt--TitleOfIndividualAxis__custom--FaithCharlesMember_pdd" title="Option purchase shares">3,500 shares of Company common stock at an exercise price of $<span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20221230__srt--TitleOfIndividualAxis__custom--FaithCharlesMember_pdd" title="Exercise price">2.40 vesting in 36 equal monthly installments succeeding the issuance date. The total fair value of these option grants at issuance was $<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_c20221230__srt--TitleOfIndividualAxis__custom--FaithCharlesMember_pp0p0" title="Option issuance">7,091. On March 29, 2023, the Board of Directors approved, based upon the recommendation of the Compensation Committee, cash bonuses totaling $550,750 to the officers of the Company. In addition, the officers and an employee were awarded a total of 29,988 options at an exercise price of $<span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20230329__srt--TitleOfIndividualAxis__srt--OfficerMember_pdd" title="Exercise price">0.996. Of the options issued, <span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_dp_c20230328__20230329__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheOneMember_zgUzoFWHgr6c" title="Vested percentage">50% vest over <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dtY_c20230328__20230329__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheOneMember_zzO04q0fdEZ7" title="Vested term">2 years and <span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_dp_c20230328__20230329__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheTwoMember_z5aDJY8QOHP8" title="Vested percentage">50% vest upon the Company’s common stock price exceeding various closing prices ranging from $<span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_c20230328__20230329__srt--RangeAxis__srt--MinimumMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheTwoMember_pdd" title="Stock price">6.00 - $<span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_c20230328__20230329__srt--RangeAxis__srt--MaximumMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheTwoMember_pdd" title="Stock price">24.00 per share. The total fair value of these option grants at issuance was $<span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_c20230329__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pp0p0" title="Option issuance">25,820. On May 3, 2023, the Board of Directors of the Company appointed Bettina M. Cockroft, M.D., M.B.A as an independent member of the Company’s Board of Directors. Dr. Cockroft was granted a ten-year option to purchase <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_c20230502__20230503__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrCockroftMember_zggSfCP9av65" title="Issuance of common stock">2,099 shares of Company common stock at an exercise price of $<span id="xdx_900_eus-gaap--StockOptionExercisePriceDecrease_c20230502__20230503__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrCockroftMember_z8sfgphhfr76" title="Common stock exercise price">1.67 vesting in 36 equal monthly installments succeeding the issuance date. The total fair value of these option grants at issuance was $<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_c20230503__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrCockroftMember_zBDHDZbx09m4" title="Option issuance">3,514. On August 4, 2023, the Board of Directors approved the issuance of <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_c20230803__20230804__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrCockroftMember_zEHuduiEYu2f" title="Issuance of common stock">6,500 options to Dr. Cockroft. The options have a ten-year term at an exercise price of $<span id="xdx_90A_eus-gaap--StockOptionExercisePriceDecrease_c20230803__20230804__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrCockroftMember_zbLHo5lssL9k" title="Common stock exercise price">2.27 and vest in 36 equal monthly installments succeeding the issuance date. The total fair value of these option grants at issuance was $<span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_c20230804__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrCockroftMember_zaHG9lTlxd86" title="Option issuance">12,771. On August 27, 2023, the Board of Directors approved the issuance of <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_c20230826__20230827__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_zgwmUQJ4DcSb" title="Issuance of common stock">193,690 options to the board of directors. The options have a ten-year term at an exercise price of $1.90 and vest on the first anniversary date of issuance. The total fair value of these option grants at issuance was $<span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_c20230827__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_z9b3zYAwzQR1" title="Option issuance">313,846. During the nine months ended September 30, 2023 and 2022, the Company recognized $727,864 and $877,510 of stock-based compensation, respectively, related to outstanding stock options. At September 30, 2023, the Company had $<span id="xdx_902_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_pp0p0_c20230930__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zaGaErfYtUe1" title="Unrecognized compensation expense">940,197 of unrecognized expenses related to outstanding options. The following table summarizes the stock option activity for the nine months ended September 30, 2023: <table cellpadding="0" cellspacing="0" id="xdx_89E_eus-gaap--ScheduleOfShareBasedCompensationActivityTableTextBlock_zO13VsPsZE8h" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Equity (Details - Option Activity)"> <tr style="vertical-align: bottom"> <td>Schedule of stock option activity</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Options</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted-Average Exercise Price Per Share</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 66%">Outstanding, December 31, 2022</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20230101__20230930__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zNK27OYVTLpd" style="width: 14%; text-align: right" title="Number of options outstanding, Beginning">93,001</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20230101__20230930__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zoCQZLlgmpNj" style="width: 14%; text-align: right" title="Weighted average exercise price per share, Beginning">67.42</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230101__20230930__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zC13TM9kaQj" style="text-align: right" title="Number of options, Granted">235,777</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20230101__20230930__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zknBxMjyLqMc" style="text-align: right" title="Weighted average exercise price per share, Granted">1.78</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_d0_c20230101__20230930__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zg5COutyhTv7" style="text-align: right" title="Number of options, Exercised">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_d0_c20230101__20230930__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zo0EnfSoZZJ4" style="text-align: right" title="Weighted average exercise price per share, Exercised">–</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Forfeited</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20230101__20230930__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zb75B4U9Qfw9" style="text-align: right" title="Number of options, Forfeited">(8</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20230101__20230930__us-gaap--AwardTypeAxis__custom--StockOptionsMember_z9SpvqLF05qb" style="text-align: right" title="Weighted average exercise price per share, Forfeited">120.00</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 1pt">Expired</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_d0_c20230101__20230930__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zEU6tKRAMJK" style="border-bottom: Black 1pt solid; text-align: right" title="Number of options, Expired">–</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice_d0_c20230101__20230930__us-gaap--AwardTypeAxis__custom--StockOptionsMember_z3OI3rh9Zezk" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price per share, Expired">–</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Outstanding, September 30, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20230101__20230930__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zBvI1cJDFDe" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options outstanding, Ending">328,770</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20230101__20230930__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zlInWDXK1z1h" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price per share, Ending">20.35</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 2.5pt">Exercisable, September 30, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20230930__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zrNjtVRHc1Q8" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options outstanding, Exercisable">82,261</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20230930__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zXBiFzvoKLHk" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price per share, Exercisable">60.99</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> As of September 30, 2023, the outstanding stock options have a weighted average remaining term of <span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20230930_z61LipRHVee4" title="Weighted average remaining term">8.79 years and aggregate intrinsic value of options vested and outstanding of $0 and $4,318, respectively. As of September 30, 2023, there were <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_do_c20230101__20230930__us-gaap--PlanNameAxis__custom--Plan2017Member_z2iCGreMSot9" title="Stock to be issued">no awards remaining to be issued under the 2017 Plan and <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230101__20230930__us-gaap--PlanNameAxis__custom--Plan2020Member_z6B94ThJsyY3" title="Stock to be issued">545,610 awards remaining to be issued under the 2020 Plan. Stock Warrants During the nine months ended September 30, 2023, the Company received $725,668 in cash proceeds from the exercise of 238,958 warrants previously issued at an exercise price of $3.03 and 1,625,000 warrants previously issued at an exercise price of $0.001. The following table summarizes the stock warrant activity for the nine months ended September 30, 2023: <table cellpadding="0" cellspacing="0" id="xdx_897_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zmGCpBCa4rK8" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Equity (Details - Warrant Activity)"> <tr style="vertical-align: bottom"> <td>Schedule of warrants activity</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrants</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted-Average Exercise Price Per Share</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 66%">Outstanding, December 31, 2022</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_c20230101__20230930__us-gaap--AwardTypeAxis__custom--WarrantsMember_zAMtEOwZBCb9" style="width: 14%; text-align: right" title="Number of warrants outstanding, Beginning">4,133,252</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_c20230101__20230930__us-gaap--AwardTypeAxis__custom--WarrantsMember_zvxGqJwBybmk" style="width: 14%; text-align: right" title="Weighted average exercise price per share, Beginning">4.35</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_d0_c20230101__20230930__us-gaap--AwardTypeAxis__custom--WarrantsMember_zQoPjmaNat44" style="text-align: right" title="Number of warrants, Granted">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d0_c20230101__20230930__us-gaap--AwardTypeAxis__custom--WarrantsMember_ztcv0ZDZ3fwc" style="text-align: right" title="Weighted average exercise price per share, Granted">–</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20230101__20230930__us-gaap--AwardTypeAxis__custom--WarrantsMember_zPcTgT0SGyag" style="text-align: right" title="Number of warrants, Exercised">(1,863,958</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice_c20230101__20230930__us-gaap--AwardTypeAxis__custom--WarrantsMember_zckJdlsvS712" style="text-align: right" title="Weighted average exercise price per share, Exercised">0.39</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Forfeited</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_d0_c20230101__20230930__us-gaap--AwardTypeAxis__custom--WarrantsMember_zrNAbULNnMbg" style="text-align: right" title="Number of warrants, Forfeited">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice_d0_c20230101__20230930__us-gaap--AwardTypeAxis__custom--WarrantsMember_z9yMbKmTEKdb" style="text-align: right" title="Weighted average exercise price per share, Forfeited">–</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 1pt">Expired</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di0_c20230101__20230930__us-gaap--AwardTypeAxis__custom--WarrantsMember_zyk6knhiCf0i" style="border-bottom: Black 1pt solid; text-align: right" title="Number of warrants, Expired">(467</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOtherThanOptionsExpirationsInPeriodWeightedAverageExercisePrice_d0_c20230101__20230930__us-gaap--AwardTypeAxis__custom--WarrantsMember_z814vA40Ija9" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price per share, Expired">45.00</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Outstanding, September 30, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightOutstanding_iE_c20230101__20230930__us-gaap--AwardTypeAxis__custom--WarrantsMember_zXQXyit7GA8j" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of warrants outstanding, Ending">2,268,827</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iE_c20230101__20230930__us-gaap--AwardTypeAxis__custom--WarrantsMember_zAaSQD0E3Svf" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price per share, Ending">7.59</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 2.5pt">Exercisable, September 30, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20230930__us-gaap--AwardTypeAxis__custom--WarrantsMember_zVe9K2be89J7" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of warrants outstanding, Exercisable">2,268,827</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20230930__us-gaap--AwardTypeAxis__custom--WarrantsMember_zvdjMGqmeblc" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price per share, Exercisable">7.59</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> As of September 30, 2023, the outstanding and exercisable warrants have a weighted average remaining term of <span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20230930__us-gaap--AwardTypeAxis__custom--WarrantsMember_zUPyO9tkoOm2" title="Weighted average remaining term">4.02 years and had <span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iI_pp0p0_do_c20230930__us-gaap--AwardTypeAxis__custom--WarrantsMember_zs5MtL9A4Kc5" title="Aggregate intrinsic value of warrants outstanding">no aggregate intrinsic value. Restricted Stock Units During the nine months ended September 30, 2023, the Company recognized $17,888 of stock-based compensation, related to outstanding RSUs. At September 30, 2023, the Company had $<span id="xdx_90E_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_pp0p0_c20230930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zTkuTO6L6yI3" title="Unrecognized compensation expense">59,624 of unrecognized expenses related to outstanding RSUs. The following table summarizes the RSUs activity for the nine months ended September 30, 2023: <table cellpadding="0" cellspacing="0" id="xdx_89C_eus-gaap--ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_zGE76H82L1Nh" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Equity (Details - Restricted Stock Units Activity)"> <tr style="vertical-align: bottom"> <td>Schedule of restricted stock units activity</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">RSUs</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted-Average Grant Date Fair Value</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 66%">Non-vested, December 31, 2022</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20230101__20230930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zwcl37jR1IH9" style="width: 14%; text-align: right" title="Number of nonvested outstanding, Beginning">9,523</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20230101__20230930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zmVPGDAH3Nza" style="width: 14%; text-align: right" title="Weighted average grant date fair value, Beginning">10.02</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_d0_c20230101__20230930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zO84KkkjbAud" style="text-align: right" title="Granted">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_d0_c20230101__20230930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zxJFKpASPlW" style="text-align: right" title="Weighted average grant date fair value, Granted">–</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td>Vested</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20230101__20230930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zBbXlzqM8n91" style="text-align: right" title="Vested">(2,379</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice_c20230101__20230930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zbyTPhCL5kx6" style="text-align: right" title="Weighted average grant date fair value, Vested">10.02</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Forfeited</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_d0_c20230101__20230930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zk9vPEwyPohj" style="border-bottom: Black 1pt solid; text-align: right" title="Forfeited">–</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice_d0_c20230101__20230930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zSdltg0IZBng" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average grant date fair value, Forfeited">–</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 2.5pt">Non-vested, September 30, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20230101__20230930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zCMqcKgdKHk1" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of nonvested outstanding, Ending">7,144</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20230101__20230930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zSThhCYg2gkb" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average grant date fair value, Ending">10.02</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Performance Units During the nine months ended September 30, 2023, the Company recognized $28,990 related to outstanding stock PUs. At September 30, 2023, the Company had $<span id="xdx_908_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_pp0p0_c20230930__us-gaap--AwardTypeAxis__custom--PerformanceUnitsMember_zzG2Y2haxBJk" title="Unrecognized compensation expense">104,958 of unrecognized expenses related to PUs. The following table summarizes the PUs activity for the nine months ended September 30, 2023: <table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock_ztbReoCbZxzl" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Equity (Details - Performance Units Activity)"> <tr style="vertical-align: bottom"> <td> Schedule of performance units activity</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">PUs</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted-Average Grant Date Fair Value</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 66%">Non-vested, December 31, 2022</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20230101__20230930__us-gaap--AwardTypeAxis__custom--PerformanceUnitsMember_zkFFp9wcWn0j" style="width: 14%; text-align: right" title="Number of nonvested outstanding, Beginning">28,563</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20230101__20230930__us-gaap--AwardTypeAxis__custom--PerformanceUnitsMember_zRBMGm1fDax4" style="width: 14%; text-align: right" title="Weighted average grant date fair value, Beginning">5.94</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_d0_c20230101__20230930__us-gaap--AwardTypeAxis__custom--PerformanceUnitsMember_zYqUebnsQi9c" style="text-align: right" title="Granted">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_d0_c20230101__20230930__us-gaap--AwardTypeAxis__custom--PerformanceUnitsMember_zScjRDDDf5z4" style="text-align: right" title="Weighted average grant date fair value, Granted">–</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td>Vested</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_d0_c20230101__20230930__us-gaap--AwardTypeAxis__custom--PerformanceUnitsMember_zRcsEDfz4IBa" style="text-align: right" title="Vested">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice_d0_c20230101__20230930__us-gaap--AwardTypeAxis__custom--PerformanceUnitsMember_zYHjjhmzQv0l" style="text-align: right" title="Weighted average grant date fair value, Vested">–</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Forfeited</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_d0_c20230101__20230930__us-gaap--AwardTypeAxis__custom--PerformanceUnitsMember_zAF5FR1qugal" style="border-bottom: Black 1pt solid; text-align: right" title="Forfeited">–</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOtherThanOptionsExpirationsInPeriodWeightedAverageExercisePrice_d0_c20230101__20230930__us-gaap--AwardTypeAxis__custom--PerformanceUnitsMember_zlEgZiaaXgzi" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average grant date fair value, Forfeited">–</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 2.5pt">Non-vested, September 30, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20230101__20230930__us-gaap--AwardTypeAxis__custom--PerformanceUnitsMember_zNm3zYKwpV96" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of nonvested outstanding, Ending">28,563</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20230101__20230930__us-gaap--AwardTypeAxis__custom--PerformanceUnitsMember_zl0t63e0zd96" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average grant date fair value, Ending">5.94</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

75000000

0.001

5000000

0.001

723406

2101958

66667

100000

745800

30000

3500

2.40

7091

550750

29988

0.996

0.50

P2Y

0.50

6.00

24.00

25820

2099

1.67

3514

6500

2.27

12771

193690

1.90

313846

727864

877510

940197

<table cellpadding="0" cellspacing="0" id="xdx_89E_eus-gaap--ScheduleOfShareBasedCompensationActivityTableTextBlock_zO13VsPsZE8h" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Equity (Details - Option Activity)"> <tr style="vertical-align: bottom"> <td>Schedule of stock option activity</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Options</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted-Average Exercise Price Per Share</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 66%">Outstanding, December 31, 2022</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20230101__20230930__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zNK27OYVTLpd" style="width: 14%; text-align: right" title="Number of options outstanding, Beginning">93,001</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20230101__20230930__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zoCQZLlgmpNj" style="width: 14%; text-align: right" title="Weighted average exercise price per share, Beginning">67.42</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230101__20230930__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zC13TM9kaQj" style="text-align: right" title="Number of options, Granted">235,777</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20230101__20230930__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zknBxMjyLqMc" style="text-align: right" title="Weighted average exercise price per share, Granted">1.78</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_d0_c20230101__20230930__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zg5COutyhTv7" style="text-align: right" title="Number of options, Exercised">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_d0_c20230101__20230930__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zo0EnfSoZZJ4" style="text-align: right" title="Weighted average exercise price per share, Exercised">–</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Forfeited</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20230101__20230930__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zb75B4U9Qfw9" style="text-align: right" title="Number of options, Forfeited">(8</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20230101__20230930__us-gaap--AwardTypeAxis__custom--StockOptionsMember_z9SpvqLF05qb" style="text-align: right" title="Weighted average exercise price per share, Forfeited">120.00</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 1pt">Expired</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_d0_c20230101__20230930__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zEU6tKRAMJK" style="border-bottom: Black 1pt solid; text-align: right" title="Number of options, Expired">–</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice_d0_c20230101__20230930__us-gaap--AwardTypeAxis__custom--StockOptionsMember_z3OI3rh9Zezk" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price per share, Expired">–</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Outstanding, September 30, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20230101__20230930__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zBvI1cJDFDe" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options outstanding, Ending">328,770</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20230101__20230930__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zlInWDXK1z1h" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price per share, Ending">20.35</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 2.5pt">Exercisable, September 30, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20230930__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zrNjtVRHc1Q8" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options outstanding, Exercisable">82,261</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20230930__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zXBiFzvoKLHk" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price per share, Exercisable">60.99</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

93001

67.42

235777

1.78

120.00

328770

20.35

82261

60.99

P8Y9M14D

4318

545610

725668

238958

1625000

<table cellpadding="0" cellspacing="0" id="xdx_897_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zmGCpBCa4rK8" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Equity (Details - Warrant Activity)"> <tr style="vertical-align: bottom"> <td>Schedule of warrants activity</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrants</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted-Average Exercise Price Per Share</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 66%">Outstanding, December 31, 2022</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_c20230101__20230930__us-gaap--AwardTypeAxis__custom--WarrantsMember_zAMtEOwZBCb9" style="width: 14%; text-align: right" title="Number of warrants outstanding, Beginning">4,133,252</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_c20230101__20230930__us-gaap--AwardTypeAxis__custom--WarrantsMember_zvxGqJwBybmk" style="width: 14%; text-align: right" title="Weighted average exercise price per share, Beginning">4.35</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_d0_c20230101__20230930__us-gaap--AwardTypeAxis__custom--WarrantsMember_zQoPjmaNat44" style="text-align: right" title="Number of warrants, Granted">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d0_c20230101__20230930__us-gaap--AwardTypeAxis__custom--WarrantsMember_ztcv0ZDZ3fwc" style="text-align: right" title="Weighted average exercise price per share, Granted">–</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20230101__20230930__us-gaap--AwardTypeAxis__custom--WarrantsMember_zPcTgT0SGyag" style="text-align: right" title="Number of warrants, Exercised">(1,863,958</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice_c20230101__20230930__us-gaap--AwardTypeAxis__custom--WarrantsMember_zckJdlsvS712" style="text-align: right" title="Weighted average exercise price per share, Exercised">0.39</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Forfeited</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_d0_c20230101__20230930__us-gaap--AwardTypeAxis__custom--WarrantsMember_zrNAbULNnMbg" style="text-align: right" title="Number of warrants, Forfeited">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice_d0_c20230101__20230930__us-gaap--AwardTypeAxis__custom--WarrantsMember_z9yMbKmTEKdb" style="text-align: right" title="Weighted average exercise price per share, Forfeited">–</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 1pt">Expired</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di0_c20230101__20230930__us-gaap--AwardTypeAxis__custom--WarrantsMember_zyk6knhiCf0i" style="border-bottom: Black 1pt solid; text-align: right" title="Number of warrants, Expired">(467</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOtherThanOptionsExpirationsInPeriodWeightedAverageExercisePrice_d0_c20230101__20230930__us-gaap--AwardTypeAxis__custom--WarrantsMember_z814vA40Ija9" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price per share, Expired">45.00</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Outstanding, September 30, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightOutstanding_iE_c20230101__20230930__us-gaap--AwardTypeAxis__custom--WarrantsMember_zXQXyit7GA8j" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of warrants outstanding, Ending">2,268,827</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iE_c20230101__20230930__us-gaap--AwardTypeAxis__custom--WarrantsMember_zAaSQD0E3Svf" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price per share, Ending">7.59</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 2.5pt">Exercisable, September 30, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20230930__us-gaap--AwardTypeAxis__custom--WarrantsMember_zVe9K2be89J7" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of warrants outstanding, Exercisable">2,268,827</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20230930__us-gaap--AwardTypeAxis__custom--WarrantsMember_zvdjMGqmeblc" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price per share, Exercisable">7.59</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

4133252

4.35

1863958

0.39

467

45.00

2268827

7.59

2268827

7.59

P4Y7D

17888

59624

<table cellpadding="0" cellspacing="0" id="xdx_89C_eus-gaap--ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_zGE76H82L1Nh" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Equity (Details - Restricted Stock Units Activity)"> <tr style="vertical-align: bottom"> <td>Schedule of restricted stock units activity</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">RSUs</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted-Average Grant Date Fair Value</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 66%">Non-vested, December 31, 2022</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20230101__20230930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zwcl37jR1IH9" style="width: 14%; text-align: right" title="Number of nonvested outstanding, Beginning">9,523</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20230101__20230930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zmVPGDAH3Nza" style="width: 14%; text-align: right" title="Weighted average grant date fair value, Beginning">10.02</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_d0_c20230101__20230930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zO84KkkjbAud" style="text-align: right" title="Granted">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_d0_c20230101__20230930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zxJFKpASPlW" style="text-align: right" title="Weighted average grant date fair value, Granted">–</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td>Vested</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20230101__20230930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zBbXlzqM8n91" style="text-align: right" title="Vested">(2,379</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice_c20230101__20230930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zbyTPhCL5kx6" style="text-align: right" title="Weighted average grant date fair value, Vested">10.02</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Forfeited</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_d0_c20230101__20230930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zk9vPEwyPohj" style="border-bottom: Black 1pt solid; text-align: right" title="Forfeited">–</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice_d0_c20230101__20230930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zSdltg0IZBng" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average grant date fair value, Forfeited">–</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 2.5pt">Non-vested, September 30, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20230101__20230930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zCMqcKgdKHk1" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of nonvested outstanding, Ending">7,144</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20230101__20230930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zSThhCYg2gkb" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average grant date fair value, Ending">10.02</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

9523

10.02

2379

10.02

7144

10.02

28990

104958

<table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock_ztbReoCbZxzl" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Equity (Details - Performance Units Activity)"> <tr style="vertical-align: bottom"> <td> Schedule of performance units activity</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">PUs</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted-Average Grant Date Fair Value</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 66%">Non-vested, December 31, 2022</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20230101__20230930__us-gaap--AwardTypeAxis__custom--PerformanceUnitsMember_zkFFp9wcWn0j" style="width: 14%; text-align: right" title="Number of nonvested outstanding, Beginning">28,563</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20230101__20230930__us-gaap--AwardTypeAxis__custom--PerformanceUnitsMember_zRBMGm1fDax4" style="width: 14%; text-align: right" title="Weighted average grant date fair value, Beginning">5.94</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_d0_c20230101__20230930__us-gaap--AwardTypeAxis__custom--PerformanceUnitsMember_zYqUebnsQi9c" style="text-align: right" title="Granted">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_d0_c20230101__20230930__us-gaap--AwardTypeAxis__custom--PerformanceUnitsMember_zScjRDDDf5z4" style="text-align: right" title="Weighted average grant date fair value, Granted">–</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td>Vested</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_d0_c20230101__20230930__us-gaap--AwardTypeAxis__custom--PerformanceUnitsMember_zRcsEDfz4IBa" style="text-align: right" title="Vested">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice_d0_c20230101__20230930__us-gaap--AwardTypeAxis__custom--PerformanceUnitsMember_zYHjjhmzQv0l" style="text-align: right" title="Weighted average grant date fair value, Vested">–</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Forfeited</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_d0_c20230101__20230930__us-gaap--AwardTypeAxis__custom--PerformanceUnitsMember_zAF5FR1qugal" style="border-bottom: Black 1pt solid; text-align: right" title="Forfeited">–</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOtherThanOptionsExpirationsInPeriodWeightedAverageExercisePrice_d0_c20230101__20230930__us-gaap--AwardTypeAxis__custom--PerformanceUnitsMember_zlEgZiaaXgzi" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average grant date fair value, Forfeited">–</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 2.5pt">Non-vested, September 30, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20230101__20230930__us-gaap--AwardTypeAxis__custom--PerformanceUnitsMember_zNm3zYKwpV96" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of nonvested outstanding, Ending">28,563</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20230101__20230930__us-gaap--AwardTypeAxis__custom--PerformanceUnitsMember_zl0t63e0zd96" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average grant date fair value, Ending">5.94</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

28563

5.94

28563

5.94

Note 5 – Commitments and Contingencies Executive Employment Agreements On September 1, 2017, the Company entered into an employment agreement with Mr. John Climaco pursuant to which Mr. Climaco agreed to serve as Chief Executive Officer and Director of the Company commencing on such date for an initial term of three years. On September 1, 2020, the Company entered into an amendment to the employment agreement with Mr. Climaco. The amendment extends the term of employment under the Employment Agreement, which was originally for a three-year period, for additional twelve-month periods, unless and until either the Company or Mr. Climaco provides written notice to the other party not less than sixty days before such anniversary date that such party is electing not to extend the term. If the Company provides notice of its election not to extend the term, Mr. Climaco may terminate his employment at any time prior to the expiration of the term by giving written notice to the Company at least thirty days prior to the effective date of termination, and upon the earlier of such effective date of termination or the expiration of the term, Mr. Climaco shall be entitled to receive the same severance benefits as are provided upon a termination of employment by the Company without cause. Pursuant to the Amendment, the severance benefits shall be twelve months of Mr. Climaco’s base salary. Such severance payment shall be made in a single lump sum sixty days following the termination, provided that Mr. Climaco has executed and delivered to the Company and has not revoked a general release of the Company. Pursuant to the employment agreement, the compensation committee of the board of directors reviews the base salary payable to Mr. Climaco annually during the term of the agreement. On February 6, 2021, the compensation committee of the board of directors set Mr. Climaco’s 2021 annual base salary to $525,000. On June 28, 2019, we entered into employment letters with Drs. Silberman and Picker. Dr. Silberman agreed to commit 50% of her time to our matters and Dr. Picker agreed to commit 25% of his time to our matters. On March 29, 2023, the Board of Directors approved, based upon the recommendation of the Compensation Committee, cash bonuses totaling $550,750 to the officers of the Company. Scientific Advisory Board On July 15, 2021, our Board approved the following compensation policy for members of the Scientific Advisory Board. The Scientific Advisory board consists of Dr. Sigmond Hsu. The scientific advisory board member shall receive annual cash compensation of $68,600. During the nine months ended September 30, 2023 and 2022, the Company paid $0 and $76,087 related to the Scientific Advisory Board compensation. As of September 30, 2023, the Company has accrued $<span id="xdx_904_eus-gaap--DeferredCompensationLiabilityCurrent_iI_pp0p0_c20230930__srt--CounterpartyNameAxis__custom--MrHsuScientificAdvisoryBoardMember_zqTYn4kPhYVg" title="Accrued related to compensation">151,584 related to Dr. Hsu’s Scientific Advisory Board compensation. WP744 Portfolio (Berubicin) On November 21, 2017, the Company entered into a Collaboration and Asset Purchase Agreement with Reata Pharmaceuticals, Inc. (“Reata”). Through this agreement, the Company purchased all of Reata’s rights, title, interest and previously conducted research and development results in the chemical compound commonly known as Berubicin. In exchange for these rights, the Company agreed to pay Reata an amount equal to 2.25% of the net sales of Berubicin for a period of 10 years from the Company’s first commercial sale of Berubicin plus $10,000. Reata also agreed to collaborate with the Company on the development of Berubicin, from time to time. On December 28, 2017, the Company entered into a Technology Rights and Development Agreement with Houston Pharmaceuticals, Inc. (“HPI”). HPI is affiliated with Dr. Waldemar Priebe, our founder. Pursuant to this agreement, the Company obtained a worldwide exclusive license to the chemical compound commonly known as WP744. In exchange for these rights, the Company agreed to pay consideration to HPI as follows: (i) a royalty of 2% of net sales of any product utilizing WP744 for a period of ten years after the first commercial sale of such; and (ii) $100,000 upon beginning Phase II clinical trials (paid in 2021); and (iii) $200,000 upon the approval by the FDA of a New Drug Application for any product utilizing WP744; and (iv) a series of quarterly development payments totaling $750,000 beginning immediately after the Company’s raise of $7,000,000 of investment capital. In addition, the Company issued 6,667 shares of the Company’s common stock valued at $1.35 per share to HPI upon execution of the agreement. On November 13, 2019, the Company closed its IPO, thereby fulfilling all conditions precedent and completing the acquisition of the intellectual property discussed in the HPI agreement. During the nine months ended September 30, 2023 and 2022, the Company recognized $<span id="xdx_90C_eus-gaap--RoyaltyIncomeNonoperating_pp0p0_c20230101__20230930__us-gaap--TransactionTypeAxis__custom--TechnologyRightsAgrMember__srt--CounterpartyNameAxis__custom--HoustonPharmMember_zEy9Q2JNGmbk" title="Royalty income, nonoperating">37,500 and $<span id="xdx_906_eus-gaap--RoyaltyIncomeNonoperating_pp0p0_c20220101__20220930__us-gaap--TransactionTypeAxis__custom--TechnologyRightsAgrMember__srt--CounterpartyNameAxis__custom--HoustonPharmMember_zSsEMFstBTM" title="Royalty income, nonoperating">262,500, respectively, related to this agreement. Unrelated to this agreement, from time to time, the Company purchases pharmaceutical products from HPI which are necessary for the manufacturing of Berubicin API and drug product in related party transactions which are reviewed and approved by the Company’s audit committee based upon the standards of providing superior pricing and time to delivery than that available from unrelated third parties. During the nine months ended September 30, 2023 and 2022, the Company expensed $0 and $41,075 respectively related to the purchase of pharmaceutical products from HPI. On August 30, 2018, we entered into a sublicense agreement with WPD Pharmaceuticals, Inc. (“WPD”). Pursuant to the agreement, the Company granted WPD an exclusive sublicense, even as to us, for the patent rights we licensed pursuant to the HPI License within the following countries: Poland, Estonia, Latvia, Lithuania, Belarus, Ukraine, Moldova, Romania, Bulgaria, Serbia, Macedonia, Albania, Armenia, Azerbaijan, Georgia, Montenegro, Bosnia, Croatia, Slovenia, Slovakia, Czech Republic, Hungary, Chechnya, Uzbekistan, Kazakhstan, Kyrgyzstan, Tajikistan, Turkmenistan, Greece, Austria, and Russia. The sublicense agreement provides that WPD must use commercially reasonable development efforts to attempt to develop and commercialize licensed products in the above mentioned territories, which means the expenditure of at least $2.0 million on the development, testing, regulatory approval or commercialization of the licensed products during the three year period immediately following the date of the sublicense agreement. In the event that WPD fails to use commercially reasonable development efforts by the foregoing three-year deadline, we have the right to terminate this sublicense agreement. As of December 31, 2021, the Company has received reports of the WPD expenditures related to this agreement, has conducted due inquiry into validating those expenditures, and has determined that WPD has exercised commercially reasonable development efforts and has therefore fulfilled the terms of the agreement necessary to secure their rights under the sublicense in perpetuity subject to the ongoing obligations of the sublicense. In consideration for the rights granted under the sublicense agreement, to the extent we are required to make any payments to HPI pursuant to the HPI License as a result of this sublicense agreement, WPD agreed to advance us such payments, and to pay us a royalty equal to 1% of such payments. WPD is a Polish corporation that is majority-owned by an entity controlled by Dr. Priebe, our founder. On November 21, 2022, CNS entered into an Investigational Medicinal Product Supply Agreement with Pomeranian Medical University (“PUM”) in Szczecin, Poland. CNS agreed to sell berubicin hydrochloride drug product (and related reference standards) to PUM at a discount to the historical cost of manufacturing so that PUM may conduct an investigator-initiated clinical trial of Berubicin in CNS lymphomas. PUM agreed to pay CNS the following payments: (i) PLN 5,870 upon delivery of 2 vials each of berubicin and berubicinol reference standards, (ii) PLN 873,201 upon delivery of a first batch of 150 berubicin drug product vials, and (iii) PLN 873,201 upon delivery of a second batch of 150 berubicin drug product vials. As of December 31, 2022, the reference standards were delivered, and the Company recognized $1,302 in accounts receivable and as a reduction to research and development expense. In April 2023, the first batch of berubicin drug product vials were delivered, and the Company recognized $196,303 in accounts receivable and as a reduction to research and development expense. As of September 30, 2023, the outstanding accounts receivable balance of $197,605 was collected in full. On August 31, 2018, the Company entered into a sublicense agreement with Animal Life Sciences, LLC (“ALI”), pursuant to which we granted ALI an exclusive sublicense, even as to us, for the patent rights we licensed pursuant to the HPI License solely for the treatment of cancer in non-human animals through any type of administration. In consideration for the rights granted under the sublicense agreement, ALI agreed to issue us membership interests in ALI equal to 1.52% of the outstanding ALI membership interests. As additional consideration for the rights granted, to the extent we are required to make any payments to HPI pursuant to the HPI License as a result of this sublicense agreement, ALI agreed to advance us such payments, and to pay us a royalty equal to 1% of such payments. Dr. Waldemar Priebe, our founder, is also the founder and a shareholder of ALI, holds 38% of the membership interests of ALI. On June 10, 2020, the FDA granted Orphan Drug Designation (“ODD”) for Berubicin for the treatment of malignant gliomas. ODD from the FDA is available for drugs targeting diseases with less than 200,000 cases per year. ODD may enable market exclusivity of 7 years from the date of approval of a NDA in the United States. During that period the FDA generally could not approve another product containing the same drug for the same designated indication. Orphan drug exclusivity will not bar approval of another product under certain circumstances, including if a subsequent product with the same active ingredient for the same indication is shown to be clinically superior to the approved product on the basis of greater efficacy or safety, or providing a major contribution to patient care, or if the company with orphan drug exclusivity is not able to meet market demand. The ODD now constitutes our primary intellectual property protections although the Company is exploring if there are other patents that could be filed related to Berubicin to extend additional protections. On July 24, 2021, the Company received Fast Track Designation from the FDA for Berubicin. Fast Track Designation is designed to facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet medical need. WP1244 Portfolio On January 10, 2020, Company entered into a Patent and Technology License Agreement (“Agreement”) with The Board of Regents of The University of Texas System, an agency of the State of Texas, on behalf of The University of Texas M. D. Anderson Cancer Center (“UTMDACC”). Pursuant to the Agreement, the Company obtained a royalty-bearing, worldwide, exclusive license to certain intellectual property rights, including patent rights, related to the Company’s recently announced WP1244 drug technology. In consideration, the Company must make payments to UTMDACC including an up-front license fee, annual maintenance fee, milestone payments and royalty payments (including minimum annual royalties) on sales of licensed products developed under the Agreement. The term of the Agreement expires on the last to occur of: (a) the expiration of all patents subject to the Agreement, or (b) fifteen years after execution; provided that UTMDACC has the right to terminate this Agreement in the event that the Company fails to meet certain commercial diligence milestones. The commercial diligence milestones are as follows (i) initiated PC toxicology to support filing of Investigational New Drug Application (“IND”) or New Drug Application (“NDA”) for the Licensed Product within the eighteen (18) month period following the Effective Date (ii) file and IND for the Licensed Product within three (3) year period following the Effective Date and (iii) Commencement of Phase I Study within the five (5) year period following the Effective Date. The Company has not met the commercial diligence milestones required as of the date hereof. As such, UTMDACC has the right to terminate the Agreement upon notice to the Company. As of the date of this report, UTMDACC has not notified the Company of its intention to terminate the Agreement. During the nine months ended September 30, 2023 and 2022, the Company paid $<span id="xdx_902_eus-gaap--PaymentsToAcquireIntangibleAssets_pp0p0_c20230101__20230930__us-gaap--TransactionTypeAxis__custom--PatentAndTechnologyLicenseAgrMember__srt--CounterpartyNameAxis__custom--UTMDACCMember_zGnw3HSzFyH2" title="License fee">45,092 and $<span id="xdx_90C_eus-gaap--PaymentsToAcquireIntangibleAssets_pp0p0_c20220101__20220930__us-gaap--TransactionTypeAxis__custom--PatentAndTechnologyLicenseAgrMember__srt--CounterpartyNameAxis__custom--UTMDACCMember_zcvOsQVwsTOg" title="License fee">49,607, respectively. On May 7, 2020, pursuant to the WP1244 Portfolio license agreement described above, the Company entered into a Sponsored Research Agreement with UTMDACC to perform research relating to novel anticancer agents targeting CNS malignancies. The Company agreed to fund approximately $1,134,000 over a two-year period, which has been fully paid by the Company in 2021. This agreement was extended and expired on March 31, 2023. The principal investigator for this agreement is Dr. Waldemar Priebe, our founder.

525000

550750

76087

151584

37500

262500

41075

1302

196303

197605

45092

49607

Note 6 – Subsequent Events On October 16, 2023, the Company entered into a warrant exercise inducement offer letter (the “Inducement Letter”) with a holder of certain existing warrants (“Holder”) to receive new warrants to purchase up to a number of shares of common stock equal to 200% (the “Inducement Warrants”) of the number of warrant shares issued pursuant to the exercise of such certain existing warrants to purchase shares of common stock (the “Existing Warrants”) pursuant to which the Holder agreed to exercise for cash their Existing Warrants to purchase up to 1,878,000 shares of the Company’s common stock, at a Reduced Exercise Price (as defined below), in exchange for the Company’s agreement to issue the Inducement Warrants to purchase up to 3,756,000 shares of the Company’s common stock (the “Inducement Warrant Shares”). The Existing Warrants consist of: (i) warrants, originally issued on December 22, 2020 and amended on December 5, 2022; (ii) warrants, originally issued on January 10, 2022 and amended on December 5, 2022; and (iii) warrants issued on December 5, 2022. Pursuant to the Inducement Letter, the exercise price for such Existing Warrants was reduced to $1.28 per share (the “Reduced Exercise Price”). The Company received aggregate gross proceeds of $2,403,840 from the exercise of the Existing Warrants before deducting financial advisory fees and other expenses payable by it. Pursuant to the Inducement Letter, although the exercise of the warrants has occurred and full payment of the exercise price has been made, the Holder has directed that a number of shares be held in abeyance and not yet issued until they direct us to do so. As such, the shares have not been issued and do not appear in our count of common shares outstanding. Pursuant to the terms of the Capital on Demand™ Sales Agreement with JonesTrading Institutional Services LLC and Brookline Capital Markets, a division of Arcadia Securities, LLC (collectively, the “Agent”), the Company may sell from time to time, through the Agent, shares of the Company’s common stock with an aggregate sales price of up to $20.0 million. Subsequent to the quarter ended on September 30, 2023, the Company sold 129,530 shares of common stock to the Agent for net proceeds of $215,641.

EXCEL 34 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 36 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 37 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 117 165 1 false 32 0 false 4 false false R1.htm 00000001 - Document - Cover Sheet http://cnspharma.com/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - Balance Sheets (Unaudited) Sheet http://cnspharma.com/role/BalanceSheets Balance Sheets (Unaudited) Statements 2 false false R3.htm 00000003 - Statement - Balance Sheets (Unaudited) (Parenthetical) Sheet http://cnspharma.com/role/BalanceSheetsParenthetical Balance Sheets (Unaudited) (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Statements of Operations (Unaudited) Sheet http://cnspharma.com/role/StatementsOfOperations Statements of Operations (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Statements of Stockholders' Equity (Deficit) (Unaudited) Sheet http://cnspharma.com/role/StatementsOfStockholdersEquityDeficit Statements of Stockholders' Equity (Deficit) (Unaudited) Statements 5 false false R6.htm 00000006 - Statement - Statements of Cash Flows (Unaudited) Sheet http://cnspharma.com/role/StatementsOfCashFlows Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 00000007 - Disclosure - Nature of Business Sheet http://cnspharma.com/role/NatureOfBusiness Nature of Business Notes 7 false false R8.htm 00000008 - Disclosure - Summary of Significant Accounting Policies Sheet http://cnspharma.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 8 false false R9.htm 00000009 - Disclosure - Note Payable Sheet http://cnspharma.com/role/NotePayable Note Payable Notes 9 false false R10.htm 00000010 - Disclosure - Equity Sheet http://cnspharma.com/role/Equity Equity Notes 10 false false R11.htm 00000011 - Disclosure - Commitments and Contingencies Sheet http://cnspharma.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 11 false false R12.htm 00000012 - Disclosure - Subsequent Events Sheet http://cnspharma.com/role/SubsequentEvents Subsequent Events Notes 12 false false R13.htm 00000013 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://cnspharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://cnspharma.com/role/SummaryOfSignificantAccountingPolicies 13 false false R14.htm 00000014 - Disclosure - Equity (Tables) Sheet http://cnspharma.com/role/EquityTables Equity (Tables) Tables http://cnspharma.com/role/Equity 14 false false R15.htm 00000015 - Disclosure - Summary of Significant Accounting Policies (Details Narrative) Sheet http://cnspharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative Summary of Significant Accounting Policies (Details Narrative) Details http://cnspharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies 15 false false R16.htm 00000016 - Disclosure - Note Payable (Details Narrative) Sheet http://cnspharma.com/role/NotePayableDetailsNarrative Note Payable (Details Narrative) Details http://cnspharma.com/role/NotePayable 16 false false R17.htm 00000017 - Disclosure - Equity (Details - Option Activity) Sheet http://cnspharma.com/role/EquityDetails-OptionActivity Equity (Details - Option Activity) Details http://cnspharma.com/role/EquityTables 17 false false R18.htm 00000018 - Disclosure - Equity (Details - Warrant Activity) Sheet http://cnspharma.com/role/EquityDetails-WarrantActivity Equity (Details - Warrant Activity) Details http://cnspharma.com/role/EquityTables 18 false false R19.htm 00000019 - Disclosure - Equity (Details - Restricted Stock Units Activity) Sheet http://cnspharma.com/role/EquityDetails-RestrictedStockUnitsActivity Equity (Details - Restricted Stock Units Activity) Details http://cnspharma.com/role/EquityTables 19 false false R20.htm 00000020 - Disclosure - Equity (Details - Performance Units Activity) Sheet http://cnspharma.com/role/EquityDetails-PerformanceUnitsActivity Equity (Details - Performance Units Activity) Details http://cnspharma.com/role/EquityTables 20 false false R21.htm 00000021 - Disclosure - Equity (Details Narrative) Sheet http://cnspharma.com/role/EquityDetailsNarrative Equity (Details Narrative) Details http://cnspharma.com/role/EquityTables 21 false false R22.htm 00000022 - Disclosure - Commitments and Contingencies (Details Narrative) Sheet http://cnspharma.com/role/CommitmentsAndContingenciesDetailsNarrative Commitments and Contingencies (Details Narrative) Details http://cnspharma.com/role/CommitmentsAndContingencies 22 false false All Reports Book All Reports cns_i10q-093023.htm cnsp-20230930.xsd cnsp-20230930_cal.xml cnsp-20230930_def.xml cnsp-20230930_lab.xml cnsp-20230930_pre.xml http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 true true JSON 39 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "cns_i10q-093023.htm": { "nsprefix": "CNSP", "nsuri": "http://cnspharma.com/20230930", "dts": { "inline": { "local": [ "cns_i10q-093023.htm" ] }, "schema": { "local": [ "cnsp-20230930.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "calculationLink": { "local": [ "cnsp-20230930_cal.xml" ] }, "definitionLink": { "local": [ "cnsp-20230930_def.xml" ] }, "labelLink": { "local": [ "cnsp-20230930_lab.xml" ] }, "presentationLink": { "local": [ "cnsp-20230930_pre.xml" ] } }, "keyStandard": 154, "keyCustom": 11, "axisStandard": 13, "axisCustom": 0, "memberStandard": 11, "memberCustom": 20, "hidden": { "total": 37, "http://fasb.org/us-gaap/2023": 28, "http://xbrl.sec.gov/dei/2023": 5, "http://cnspharma.com/20230930": 4 }, "contextCount": 117, "entityCount": 1, "segmentCount": 32, "elementCount": 284, "unitCount": 4, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 371, "http://xbrl.sec.gov/dei/2023": 31 }, "report": { "R1": { "role": "http://cnspharma.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "cns_i10q-093023.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "cns_i10q-093023.htm", "first": true, "unique": true } }, "R2": { "role": "http://cnspharma.com/role/BalanceSheets", "longName": "00000002 - Statement - Balance Sheets (Unaudited)", "shortName": "Balance Sheets (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "cns_i10q-093023.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "cns_i10q-093023.htm", "first": true, "unique": true } }, "R3": { "role": "http://cnspharma.com/role/BalanceSheetsParenthetical", "longName": "00000003 - Statement - Balance Sheets (Unaudited) (Parenthetical)", "shortName": "Balance Sheets (Unaudited) (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "cns_i10q-093023.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:PreferredStockSharesIssued", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "span", "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "cns_i10q-093023.htm", "unique": true } }, "R4": { "role": "http://cnspharma.com/role/StatementsOfOperations", "longName": "00000004 - Statement - Statements of Operations (Unaudited)", "shortName": "Statements of Operations (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "From2023-07-012023-09-30", "name": "us-gaap:GeneralAndAdministrativeExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "cns_i10q-093023.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-07-012023-09-30", "name": "us-gaap:GeneralAndAdministrativeExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "cns_i10q-093023.htm", "first": true, "unique": true } }, "R5": { "role": "http://cnspharma.com/role/StatementsOfStockholdersEquityDeficit", "longName": "00000005 - Statement - Statements of Stockholders' Equity (Deficit) (Unaudited)", "shortName": "Statements of Stockholders' Equity (Deficit) (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "AsOf2021-12-31_us-gaap_CommonStockMember", "name": "us-gaap:StockholdersEquity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "cns_i10q-093023.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2022-01-012022-03-31_us-gaap_CommonStockMember", "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "cns_i10q-093023.htm", "unique": true } }, "R6": { "role": "http://cnspharma.com/role/StatementsOfCashFlows", "longName": "00000006 - Statement - Statements of Cash Flows (Unaudited)", "shortName": "Statements of Cash Flows (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "cns_i10q-093023.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:Depreciation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "cns_i10q-093023.htm", "unique": true } }, "R7": { "role": "http://cnspharma.com/role/NatureOfBusiness", "longName": "00000007 - Disclosure - Nature of Business", "shortName": "Nature of Business", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:NatureOfOperations", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "cns_i10q-093023.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:NatureOfOperations", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "cns_i10q-093023.htm", "first": true, "unique": true } }, "R8": { "role": "http://cnspharma.com/role/SummaryOfSignificantAccountingPolicies", "longName": "00000008 - Disclosure - Summary of Significant Accounting Policies", "shortName": "Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "cns_i10q-093023.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "cns_i10q-093023.htm", "first": true, "unique": true } }, "R9": { "role": "http://cnspharma.com/role/NotePayable", "longName": "00000009 - Disclosure - Note Payable", "shortName": "Note Payable", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:LongTermDebtTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "cns_i10q-093023.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:LongTermDebtTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "cns_i10q-093023.htm", "first": true, "unique": true } }, "R10": { "role": "http://cnspharma.com/role/Equity", "longName": "00000010 - Disclosure - Equity", "shortName": "Equity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "cns_i10q-093023.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "cns_i10q-093023.htm", "first": true, "unique": true } }, "R11": { "role": "http://cnspharma.com/role/CommitmentsAndContingencies", "longName": "00000011 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "cns_i10q-093023.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "cns_i10q-093023.htm", "first": true, "unique": true } }, "R12": { "role": "http://cnspharma.com/role/SubsequentEvents", "longName": "00000012 - Disclosure - Subsequent Events", "shortName": "Subsequent Events", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "cns_i10q-093023.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "cns_i10q-093023.htm", "first": true, "unique": true } }, "R13": { "role": "http://cnspharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies", "longName": "00000013 - Disclosure - Summary of Significant Accounting Policies (Policies)", "shortName": "Summary of Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "13", "firstAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "cns_i10q-093023.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "cns_i10q-093023.htm", "first": true, "unique": true } }, "R14": { "role": "http://cnspharma.com/role/EquityTables", "longName": "00000014 - Disclosure - Equity (Tables)", "shortName": "Equity (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "14", "firstAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "cns_i10q-093023.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "cns_i10q-093023.htm", "first": true, "unique": true } }, "R15": { "role": "http://cnspharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative", "longName": "00000015 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)", "shortName": "Summary of Significant Accounting Policies (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "15", "firstAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:CashUninsuredAmount", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "us-gaap:CashAndCashEquivalentsPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "cns_i10q-093023.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:CashUninsuredAmount", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "us-gaap:CashAndCashEquivalentsPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "cns_i10q-093023.htm", "first": true, "unique": true } }, "R16": { "role": "http://cnspharma.com/role/NotePayableDetailsNarrative", "longName": "00000016 - Disclosure - Note Payable (Details Narrative)", "shortName": "Note Payable (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "16", "firstAnchor": { "contextRef": "AsOf2022-11-14", "name": "us-gaap:ShortTermBorrowings", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "us-gaap:LongTermDebtTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "cns_i10q-093023.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2022-11-14", "name": "us-gaap:ShortTermBorrowings", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "us-gaap:LongTermDebtTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "cns_i10q-093023.htm", "first": true, "unique": true } }, "R17": { "role": "http://cnspharma.com/role/EquityDetails-OptionActivity", "longName": "00000017 - Disclosure - Equity (Details - Option Activity)", "shortName": "Equity (Details - Option Activity)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "17", "firstAnchor": { "contextRef": "AsOf2022-12-31_custom_StockOptionsMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "cns_i10q-093023.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-01-012023-09-30_custom_StockOptionsMember", "name": "us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "cns_i10q-093023.htm", "unique": true } }, "R18": { "role": "http://cnspharma.com/role/EquityDetails-WarrantActivity", "longName": "00000018 - Disclosure - Equity (Details - Warrant Activity)", "shortName": "Equity (Details - Warrant Activity)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "18", "firstAnchor": { "contextRef": "AsOf2022-12-31_custom_WarrantsMember", "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "cns_i10q-093023.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2022-12-31_custom_WarrantsMember", "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "cns_i10q-093023.htm", "first": true, "unique": true } }, "R19": { "role": "http://cnspharma.com/role/EquityDetails-RestrictedStockUnitsActivity", "longName": "00000019 - Disclosure - Equity (Details - Restricted Stock Units Activity)", "shortName": "Equity (Details - Restricted Stock Units Activity)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "19", "firstAnchor": { "contextRef": "AsOf2022-12-31_us-gaap_RestrictedStockUnitsRSUMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "cns_i10q-093023.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2022-12-31_us-gaap_RestrictedStockUnitsRSUMember", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "cns_i10q-093023.htm", "unique": true } }, "R20": { "role": "http://cnspharma.com/role/EquityDetails-PerformanceUnitsActivity", "longName": "00000020 - Disclosure - Equity (Details - Performance Units Activity)", "shortName": "Equity (Details - Performance Units Activity)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "20", "firstAnchor": { "contextRef": "AsOf2022-12-31_custom_PerformanceUnitsMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "cns_i10q-093023.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2022-12-31_custom_PerformanceUnitsMember", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "cns_i10q-093023.htm", "unique": true } }, "R21": { "role": "http://cnspharma.com/role/EquityDetailsNarrative", "longName": "00000021 - Disclosure - Equity (Details Narrative)", "shortName": "Equity (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "21", "firstAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:CommonStockSharesAuthorized", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "cns_i10q-093023.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "cns_i10q-093023.htm", "unique": true } }, "R22": { "role": "http://cnspharma.com/role/CommitmentsAndContingenciesDetailsNarrative", "longName": "00000022 - Disclosure - Commitments and Contingencies (Details Narrative)", "shortName": "Commitments and Contingencies (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "22", "firstAnchor": { "contextRef": "From2023-01-012023-09-30_custom_HoustonPharmaceuticalsMember", "name": "us-gaap:CostOfGoodsAndServicesSold", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "cns_i10q-093023.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-012023-09-30_custom_HoustonPharmaceuticalsMember", "name": "us-gaap:CostOfGoodsAndServicesSold", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "cns_i10q-093023.htm", "first": true, "unique": true } } }, "tag": { "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://cnspharma.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://cnspharma.com/role/BalanceSheets", "http://cnspharma.com/role/StatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "totalLabel": "Total Stockholders' Equity (Deficit)", "periodStartLabel": "Beginning balance, value", "periodEndLabel": "Ending balance, value", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r43", "r46", "r47", "r59", "r298", "r314", "r336", "r337", "r368", "r382", "r411", "r416", "r457", "r476" ] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "presentation": [ "http://cnspharma.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Accounts receivable", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r130", "r131" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://cnspharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities and Stockholders' Equity (Deficit)" } } }, "auth_ref": [] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesOutstanding", "presentation": [ "http://cnspharma.com/role/BalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Preferred stock, shares outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": [ "r42", "r296", "r314", "r476", "r477" ] }, "us-gaap_LaborAndRelatedExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LaborAndRelatedExpense", "crdr": "debit", "presentation": [ "http://cnspharma.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Labour and related expense", "documentation": "Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit." } } }, "auth_ref": [ "r407" ] }, "us-gaap_TransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TransactionDomain", "presentation": [ "http://cnspharma.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Agreement between buyer and seller for the exchange of financial instruments." } } }, "auth_ref": [ "r357" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://cnspharma.com/role/CommitmentsAndContingencies" ], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r60", "r135", "r136", "r350", "r420" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://cnspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r384" ] }, "CNSP_PumMember": { "xbrltype": "domainItemType", "nsuri": "http://cnspharma.com/20230930", "localname": "PumMember", "presentation": [ "http://cnspharma.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Pum [Member]" } } }, "auth_ref": [] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://cnspharma.com/role/StatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r205", "r206", "r207", "r284", "r412", "r413", "r414", "r455", "r476" ] }, "CNSP_PatentAndTechnologyLicenseAgrMember": { "xbrltype": "domainItemType", "nsuri": "http://cnspharma.com/20230930", "localname": "PatentAndTechnologyLicenseAgrMember", "presentation": [ "http://cnspharma.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Patent And Technology License Agr [Member]" } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://cnspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "CNSP_LiquidityAndGoingConcernPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://cnspharma.com/20230930", "localname": "LiquidityAndGoingConcernPolicyTextBlock", "presentation": [ "http://cnspharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Liquidity and Going Concern" } } }, "auth_ref": [] }, "us-gaap_ProductLiabilityContingencyLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProductLiabilityContingencyLineItems", "presentation": [ "http://cnspharma.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Product Liability Contingency [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r139", "r421", "r422", "r423" ] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [ "http://cnspharma.com/role/BalanceSheetsParenthetical", "http://cnspharma.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Preferred stock, par value", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r42", "r153" ] }, "CNSP_HoustonPharmaceuticalsMember": { "xbrltype": "domainItemType", "nsuri": "http://cnspharma.com/20230930", "localname": "HoustonPharmaceuticalsMember", "presentation": [ "http://cnspharma.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Houston Pharmaceuticals [Member]" } } }, "auth_ref": [] }, "CNSP_UTMDACCMember": { "xbrltype": "domainItemType", "nsuri": "http://cnspharma.com/20230930", "localname": "UTMDACCMember", "presentation": [ "http://cnspharma.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "U T M D A C C [Member]" } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://cnspharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "auth_ref": [] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://cnspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://cnspharma.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://cnspharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Cash and cash equivalents", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r21", "r78", "r354" ] }, "us-gaap_TransactionTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TransactionTypeAxis", "presentation": [ "http://cnspharma.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Transaction Type [Axis]", "documentation": "Information by type of agreement between buyer and seller for the exchange of financial instruments." } } }, "auth_ref": [ "r357" ] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://cnspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://cnspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "CNSP_StockIssuedForExerciseOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://cnspharma.com/20230930", "localname": "StockIssuedForExerciseOfWarrants", "crdr": "credit", "presentation": [ "http://cnspharma.com/role/StatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Exercise of warrants" } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://cnspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "CNSP_StockIssuedForExerciseOfWarrantsShares": { "xbrltype": "sharesItemType", "nsuri": "http://cnspharma.com/20230930", "localname": "StockIssuedForExerciseOfWarrantsShares", "presentation": [ "http://cnspharma.com/role/StatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Exercise of warrants, shares" } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsPolicyTextBlock", "presentation": [ "http://cnspharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents", "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value." } } }, "auth_ref": [ "r22" ] }, "CNSP_StockOptionsMember": { "xbrltype": "domainItemType", "nsuri": "http://cnspharma.com/20230930", "localname": "StockOptionsMember", "presentation": [ "http://cnspharma.com/role/EquityDetails-OptionActivity", "http://cnspharma.com/role/EquityDetailsNarrative", "http://cnspharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Stock Options [Member]" } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://cnspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "CNSP_RestrictedStockUnitsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://cnspharma.com/20230930", "localname": "RestrictedStockUnitsPolicyTextBlock", "presentation": [ "http://cnspharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Restricted Stock Units (\u201cRSUs\u201d)" } } }, "auth_ref": [] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedStockUnitsRSUMember", "presentation": [ "http://cnspharma.com/role/EquityDetails-RestrictedStockUnitsActivity", "http://cnspharma.com/role/EquityDetailsNarrative", "http://cnspharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Restricted Stock Units (RSUs) [Member]", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "CNSP_PerformanceUnitsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://cnspharma.com/20230930", "localname": "PerformanceUnitsPolicyTextBlock", "presentation": [ "http://cnspharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Performance Units (\u201cPUs\u201d)" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": [ "http://cnspharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities." } } }, "auth_ref": [ "r27" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://cnspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r387" ] }, "CNSP_Plan2017Member": { "xbrltype": "domainItemType", "nsuri": "http://cnspharma.com/20230930", "localname": "Plan2017Member", "presentation": [ "http://cnspharma.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Plan 2017 [Member]" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "CNSP_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOtherThanOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://cnspharma.com/20230930", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOtherThanOptionsExpirationsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://cnspharma.com/role/EquityDetails-PerformanceUnitsActivity", "http://cnspharma.com/role/EquityDetails-WarrantActivity" ], "lang": { "en-us": { "role": { "verboseLabel": "Weighted average exercise price per share, Expired", "terseLabel": "Weighted average grant date fair value, Forfeited", "label": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOtherThanOptionsExpirationsInPeriodWeightedAverageExercisePrice" } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding", "crdr": "debit", "presentation": [ "http://cnspharma.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Aggregate intrinsic value of warrants outstanding", "documentation": "Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [] }, "CNSP_AgentMember": { "xbrltype": "domainItemType", "nsuri": "http://cnspharma.com/20230930", "localname": "AgentMember", "presentation": [ "http://cnspharma.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Agent [Member]" } } }, "auth_ref": [] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://cnspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r388" ] }, "CNSP_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://cnspharma.com/20230930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice", "presentation": [ "http://cnspharma.com/role/EquityDetails-OptionActivity" ], "lang": { "en-us": { "role": { "label": "Weighted average exercise price per share, Expired" } } }, "auth_ref": [] }, "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerSharePolicyTextBlock", "presentation": [ "http://cnspharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Loss Per Common Share", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth_ref": [ "r27", "r28" ] }, "CNSP_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://cnspharma.com/20230930", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": [ "http://cnspharma.com/role/EquityDetails-WarrantActivity" ], "lang": { "en-us": { "role": { "verboseLabel": "Weighted average exercise price per share, Exercised", "label": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice" } } }, "auth_ref": [] }, "CNSP_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://cnspharma.com/20230930", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": [ "http://cnspharma.com/role/EquityDetails-RestrictedStockUnitsActivity", "http://cnspharma.com/role/EquityDetails-WarrantActivity" ], "lang": { "en-us": { "role": { "verboseLabel": "Weighted average exercise price per share, Forfeited", "label": "Weighted average grant date fair value, Forfeited" } } }, "auth_ref": [] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://cnspharma.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://cnspharma.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Total operating expenses", "label": "Operating Expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "CNSP_Plan2020Member": { "xbrltype": "domainItemType", "nsuri": "http://cnspharma.com/20230930", "localname": "Plan2020Member", "presentation": [ "http://cnspharma.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Plan 2020 [Member]" } } }, "auth_ref": [] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsAbstract", "presentation": [ "http://cnspharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets" } } }, "auth_ref": [] }, "CNSP_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://cnspharma.com/20230930", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice", "presentation": [ "http://cnspharma.com/role/EquityDetails-PerformanceUnitsActivity", "http://cnspharma.com/role/EquityDetails-RestrictedStockUnitsActivity" ], "lang": { "en-us": { "role": { "label": "Weighted average grant date fair value, Vested" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasic", "presentation": [ "http://cnspharma.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Loss per share - basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r87", "r103", "r104", "r105", "r106", "r107", "r111", "r113", "r115", "r116", "r117", "r119", "r227", "r228", "r258", "r268", "r358" ] }, "CNSP_AnnualBaseSalary": { "xbrltype": "monetaryItemType", "nsuri": "http://cnspharma.com/20230930", "localname": "AnnualBaseSalary", "crdr": "debit", "presentation": [ "http://cnspharma.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Annual base salary" } } }, "auth_ref": [] }, "CNSP_FaithCharlesMember": { "xbrltype": "domainItemType", "nsuri": "http://cnspharma.com/20230930", "localname": "FaithCharlesMember", "presentation": [ "http://cnspharma.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Faith Charles [Member]" } } }, "auth_ref": [] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://cnspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r392" ] }, "us-gaap_PaymentsToAcquireIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireIntangibleAssets", "crdr": "credit", "presentation": [ "http://cnspharma.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "License fee", "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill." } } }, "auth_ref": [ "r54" ] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": [ "http://cnspharma.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Related Party, Type [Axis]", "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "auth_ref": [ "r169", "r238", "r239", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r289", "r290", "r291", "r292", "r293", "r313", "r315", "r340", "r460" ] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://cnspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock", "presentation": [ "http://cnspharma.com/role/EquityTables" ], "lang": { "en-us": { "role": { "label": "Schedule of stock option activity", "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value." } } }, "auth_ref": [ "r9", "r10", "r34" ] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://cnspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://cnspharma.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://cnspharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accounts payable and accrued expenses", "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits." } } }, "auth_ref": [ "r12" ] }, "CNSP_DrCockroftMember": { "xbrltype": "domainItemType", "nsuri": "http://cnspharma.com/20230930", "localname": "DrCockroftMember", "presentation": [ "http://cnspharma.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Dr Cockroft [Member]" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpensesAbstract", "presentation": [ "http://cnspharma.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Operating expenses:" } } }, "auth_ref": [] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://cnspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://cnspharma.com/role/StatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r98", "r99", "r100", "r120", "r245", "r281", "r285", "r288", "r289", "r290", "r291", "r292", "r293", "r296", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r309", "r310", "r311", "r312", "r313", "r315", "r318", "r319", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r335", "r374" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesIssued", "presentation": [ "http://cnspharma.com/role/BalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common stock, shares issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r43" ] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://cnspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "CNSP_WarrantPrice303Member": { "xbrltype": "domainItemType", "nsuri": "http://cnspharma.com/20230930", "localname": "WarrantPrice303Member", "presentation": [ "http://cnspharma.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Warrant Price 3.03 [Member]" } } }, "auth_ref": [] }, "us-gaap_AccruedBonusesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedBonusesCurrent", "crdr": "credit", "presentation": [ "http://cnspharma.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://cnspharma.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Cash bonuses", "verboseLabel": "Cash bonuses approved", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r14" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://cnspharma.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://cnspharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r89" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareDiluted", "presentation": [ "http://cnspharma.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Loss per share - diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r87", "r103", "r104", "r105", "r106", "r107", "r113", "r115", "r116", "r117", "r119", "r227", "r228", "r258", "r268", "r358" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://cnspharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash Flows from Financing Activities:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://cnspharma.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://cnspharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r89" ] }, "us-gaap_NatureOfOperations": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NatureOfOperations", "presentation": [ "http://cnspharma.com/role/NatureOfBusiness" ], "lang": { "en-us": { "role": { "label": "Nature of Business", "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward." } } }, "auth_ref": [ "r71", "r73" ] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://cnspharma.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://cnspharma.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "General and administrative", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": [ "r52", "r319" ] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://cnspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "CNSP_WarrantPrice0001Member": { "xbrltype": "domainItemType", "nsuri": "http://cnspharma.com/20230930", "localname": "WarrantPrice0001Member", "presentation": [ "http://cnspharma.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Warrant Price 0.001 [Member]" } } }, "auth_ref": [] }, "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://cnspharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash Flows from Investing Activities:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://cnspharma.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://cnspharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r55", "r56", "r57" ] }, "srt_TitleOfIndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "TitleOfIndividualAxis", "presentation": [ "http://cnspharma.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "auth_ref": [ "r415", "r459" ] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://cnspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://cnspharma.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://cnspharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Common stock, $0.001 par value, 75,000,000 shares authorized and 4,207,068 and 1,617,325 shares issued and outstanding, respectively", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r43", "r263", "r368" ] }, "CNSP_OfficersMember": { "xbrltype": "domainItemType", "nsuri": "http://cnspharma.com/20230930", "localname": "OfficersMember", "presentation": [ "http://cnspharma.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Officers [Member]" } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightLineItems", "presentation": [ "http://cnspharma.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "CNSP_MrClimacoMember": { "xbrltype": "domainItemType", "nsuri": "http://cnspharma.com/20230930", "localname": "MrClimacoMember", "presentation": [ "http://cnspharma.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Mr Climaco [Member]" } } }, "auth_ref": [] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://cnspharma.com/role/BalanceSheetsParenthetical", "http://cnspharma.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common stock, shares authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r43", "r296" ] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://cnspharma.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://cnspharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Preferred stock, $0.001 par value, 5,000,000 shares authorized and 0 shares issued and outstanding", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r42", "r262", "r368" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": [ "http://cnspharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": [ "r27" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://cnspharma.com/role/BalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common stock, shares outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r5", "r43", "r296", "r314", "r476", "r477" ] }, "us-gaap_InterestIncomeOperating": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestIncomeOperating", "crdr": "credit", "calculation": { "http://cnspharma.com/role/StatementsOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://cnspharma.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Interest income", "documentation": "Amount of operating interest income, including, but not limited to, amortization and accretion of premiums and discounts on securities." } } }, "auth_ref": [ "r50", "r317", "r346", "r347", "r379", "r380", "r478" ] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://cnspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://cnspharma.com/role/StatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r5", "r18", "r74", "r83", "r84", "r85", "r98", "r99", "r100", "r102", "r108", "r110", "r120", "r133", "r134", "r167", "r205", "r206", "r207", "r213", "r214", "r219", "r220", "r221", "r222", "r223", "r224", "r226", "r230", "r231", "r232", "r233", "r234", "r235", "r237", "r276", "r277", "r278", "r284", "r335" ] }, "CNSP_ScientificAdvisoryBoardMember": { "xbrltype": "domainItemType", "nsuri": "http://cnspharma.com/20230930", "localname": "ScientificAdvisoryBoardMember", "presentation": [ "http://cnspharma.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Scientific Advisory Board [Member]" } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": [ "http://cnspharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://cnspharma.com/role/BalanceSheetsParenthetical", "http://cnspharma.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common stock, par value", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r43" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsMember", "presentation": [ "http://cnspharma.com/role/StatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r74", "r98", "r99", "r100", "r102", "r108", "r110", "r133", "r134", "r205", "r206", "r207", "r213", "r214", "r219", "r221", "r222", "r224", "r226", "r276", "r278", "r284", "r476" ] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharesOutstanding", "presentation": [ "http://cnspharma.com/role/StatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance, shares", "periodEndLabel": "Ending balance, shares", "label": "Shares, Outstanding", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://cnspharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Antidilutive shares", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r118" ] }, "CNSP_MrHsuScientificAdvisoryBoardMember": { "xbrltype": "domainItemType", "nsuri": "http://cnspharma.com/20230930", "localname": "MrHsuScientificAdvisoryBoardMember", "presentation": [ "http://cnspharma.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Mr Hsu Scientific Advisory Board [Member]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfStockholdersEquityAbstract", "auth_ref": [] }, "CNSP_TechnologyRightsAgrMember": { "xbrltype": "domainItemType", "nsuri": "http://cnspharma.com/20230930", "localname": "TechnologyRightsAgrMember", "presentation": [ "http://cnspharma.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Technology Rights Agr [Member]" } } }, "auth_ref": [] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "crdr": "debit", "calculation": { "http://cnspharma.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://cnspharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Accounts payable and accrued expenses", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid." } } }, "auth_ref": [ "r2" ] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesAuthorized", "presentation": [ "http://cnspharma.com/role/BalanceSheetsParenthetical", "http://cnspharma.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Preferred stock, shares authorized", "verboseLabel": "Preferred stock shares authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r42", "r296" ] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesIssued", "presentation": [ "http://cnspharma.com/role/BalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Preferred stock, shares issued", "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt." } } }, "auth_ref": [ "r42", "r153" ] }, "CNSP_HoustonPharmMember": { "xbrltype": "domainItemType", "nsuri": "http://cnspharma.com/20230930", "localname": "HoustonPharmMember", "presentation": [ "http://cnspharma.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Houston Pharm [Member]" } } }, "auth_ref": [] }, "us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalCashFlowElementsOperatingActivitiesAbstract", "presentation": [ "http://cnspharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash Flows from Operating Activities:" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://cnspharma.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://cnspharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Property and equipment, net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r4", "r259", "r266", "r368" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://cnspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r385" ] }, "us-gaap_StockOptionExercisePriceDecrease": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockOptionExercisePriceDecrease", "presentation": [ "http://cnspharma.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common stock exercise price", "documentation": "Per share decrease in exercise price of option. Excludes change due to standard antidilution provision and option granted under share-based payment arrangement." } } }, "auth_ref": [ "r166" ] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyDomain", "presentation": [ "http://cnspharma.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "auth_ref": [ "r169", "r238", "r239", "r289", "r290", "r291", "r292", "r293", "r313", "r315", "r340" ] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://cnspharma.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://cnspharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchase of property and equipment", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r54" ] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityComponentDomain", "presentation": [ "http://cnspharma.com/role/StatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r5", "r74", "r83", "r84", "r85", "r98", "r99", "r100", "r102", "r108", "r110", "r120", "r133", "r134", "r167", "r205", "r206", "r207", "r213", "r214", "r219", "r220", "r221", "r222", "r223", "r224", "r226", "r230", "r231", "r232", "r233", "r234", "r235", "r237", "r276", "r277", "r278", "r284", "r335" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://cnspharma.com/role/EquityDetails-OptionActivity" ], "lang": { "en-us": { "role": { "label": "Weighted average exercise price per share, Forfeited", "documentation": "Weighted average price of options that were either forfeited or expired." } } }, "auth_ref": [ "r435" ] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": [ "http://cnspharma.com/role/EquityDetails-WarrantActivity" ], "lang": { "en-us": { "role": { "periodStartLabel": "Weighted average exercise price per share, Beginning", "periodEndLabel": "Weighted average exercise price per share, Ending", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": [ "r166" ] }, "us-gaap_ClassOfWarrantOrRightAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightAxis", "presentation": [ "http://cnspharma.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Axis]", "documentation": "Information by type of warrant or right issued." } } }, "auth_ref": [ "r31" ] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://cnspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://cnspharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Recent Accounting Pronouncements", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "us-gaap_GainLossOnDispositionOfAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainLossOnDispositionOfAssets", "crdr": "credit", "calculation": { "http://cnspharma.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://cnspharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Loss of disposal of fixed assets", "label": "Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property", "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property." } } }, "auth_ref": [ "r410", "r417", "r418" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "crdr": "debit", "presentation": [ "http://cnspharma.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Unrecognized compensation expense", "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement." } } }, "auth_ref": [ "r204" ] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [ "http://cnspharma.com/role/SummaryOfSignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policies", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r58", "r93" ] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://cnspharma.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://cnspharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accumulated deficit", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r45", "r63", "r264", "r279", "r280", "r283", "r297", "r368" ] }, "us-gaap_PrepaidExpenseNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpenseNoncurrent", "crdr": "debit", "calculation": { "http://cnspharma.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://cnspharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Prepaid expenses, net of current portion", "documentation": "Sum of the carrying amounts as of the balance sheet date of amounts paid in advance for expenses which will be charged against earnings in periods after one year or beyond the operating cycle, if longer." } } }, "auth_ref": [ "r405" ] }, "us-gaap_PaymentForManagementFee": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentForManagementFee", "crdr": "credit", "presentation": [ "http://cnspharma.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Annual retainer", "documentation": "Amount paid to managing member or general partner for management of the day-to-day business functions of the limited liability company (LLC) or limited partnership (LP)." } } }, "auth_ref": [ "r409", "r458" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://cnspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [ "http://cnspharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Basis of Presentation", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "us-gaap_LongTermDebtTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtTextBlock", "presentation": [ "http://cnspharma.com/role/NotePayable" ], "lang": { "en-us": { "role": { "label": "Note Payable", "documentation": "The entire disclosure for long-term debt." } } }, "auth_ref": [ "r61" ] }, "us-gaap_ProceedsFromWarrantExercises": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromWarrantExercises", "crdr": "debit", "calculation": { "http://cnspharma.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://cnspharma.com/role/EquityDetailsNarrative", "http://cnspharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from exercise of warrants", "verboseLabel": "Cash proceeds", "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants." } } }, "auth_ref": [ "r408" ] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://cnspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r397" ] }, "srt_OfficerMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "OfficerMember", "presentation": [ "http://cnspharma.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Officer [Member]" } } }, "auth_ref": [ "r129", "r473" ] }, "us-gaap_PriorPeriodReclassificationAdjustmentDescription": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PriorPeriodReclassificationAdjustmentDescription", "presentation": [ "http://cnspharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Reclassification - Certain reclassifications may have been made to our prior year\u2019s financial statements to conform to our current year presentation. These reclassifications had no effect on our previously reported results of operations or accumulated deficit.", "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error." } } }, "auth_ref": [ "r404" ] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://cnspharma.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://cnspharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total Liabilities", "label": "Liabilities", "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future." } } }, "auth_ref": [ "r13", "r95", "r132", "r141", "r142", "r143", "r144", "r145", "r146", "r147", "r148", "r149", "r216", "r217", "r218", "r229", "r294", "r359", "r382", "r425", "r461", "r462" ] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://cnspharma.com/role/StatementsOfOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://cnspharma.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Loss from operations", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r121", "r123", "r125", "r127", "r360" ] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://cnspharma.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://cnspharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Additional paid-in capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": [ "r44", "r368", "r474" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": [ "http://cnspharma.com/role/EquityDetails-PerformanceUnitsActivity", "http://cnspharma.com/role/EquityDetails-RestrictedStockUnitsActivity", "http://cnspharma.com/role/EquityDetails-WarrantActivity" ], "lang": { "en-us": { "role": { "label": "Number of warrants, Forfeited", "verboseLabel": "Forfeited", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } } }, "auth_ref": [ "r192" ] }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "presentation": [ "http://cnspharma.com/role/EquityTables" ], "lang": { "en-us": { "role": { "label": "Schedule of warrants activity", "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable." } } }, "auth_ref": [ "r31" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": [ "http://cnspharma.com/role/EquityDetails-WarrantActivity" ], "lang": { "en-us": { "role": { "label": "Number of warrants, Granted", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r190" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://cnspharma.com/role/EquityDetails-WarrantActivity" ], "lang": { "en-us": { "role": { "verboseLabel": "Weighted average exercise price per share, Granted", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r190" ] }, "us-gaap_ClassOfWarrantOrRightTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightTable", "presentation": [ "http://cnspharma.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Table]", "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable." } } }, "auth_ref": [ "r31" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": [ "http://cnspharma.com/role/EquityDetails-PerformanceUnitsActivity", "http://cnspharma.com/role/EquityDetails-RestrictedStockUnitsActivity", "http://cnspharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Unvested performance units", "periodStartLabel": "Number of nonvested outstanding, Beginning", "periodEndLabel": "Number of nonvested outstanding, Ending", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": [ "r187", "r188" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://cnspharma.com/role/BalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://cnspharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total Liabilities and Stockholders' Equity (Deficit)", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r48", "r68", "r265", "r368", "r411", "r416", "r457" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": [ "http://cnspharma.com/role/EquityDetails-PerformanceUnitsActivity", "http://cnspharma.com/role/EquityDetails-RestrictedStockUnitsActivity" ], "lang": { "en-us": { "role": { "negatedLabel": "Vested", "label": "Vested", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": [ "r191" ] }, "us-gaap_ClassOfWarrantOrRightDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightDomain", "presentation": [ "http://cnspharma.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months." } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://cnspharma.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://cnspharma.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Research and development", "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use." } } }, "auth_ref": [ "r40", "r212", "r469" ] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://cnspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://cnspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r385" ] }, "us-gaap_CostOfGoodsAndServicesSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfGoodsAndServicesSold", "crdr": "debit", "presentation": [ "http://cnspharma.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Cost of goods and services sold", "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities." } } }, "auth_ref": [ "r51", "r245" ] }, "us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock", "presentation": [ "http://cnspharma.com/role/EquityTables" ], "lang": { "en-us": { "role": { "label": "Schedule of performance units activity", "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for outstanding performance shares." } } }, "auth_ref": [ "r11" ] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsTextBlock", "presentation": [ "http://cnspharma.com/role/SubsequentEvents" ], "lang": { "en-us": { "role": { "label": "Subsequent Events", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": [ "r241", "r242" ] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://cnspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://cnspharma.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://cnspharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Commitments and contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r17", "r39", "r261", "r295" ] }, "us-gaap_IncomeTaxesPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxesPaid", "crdr": "credit", "presentation": [ "http://cnspharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash paid for income taxes", "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income." } } }, "auth_ref": [ "r20", "r23" ] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://cnspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r385" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": [ "http://cnspharma.com/role/EquityDetails-PerformanceUnitsActivity", "http://cnspharma.com/role/EquityDetails-RestrictedStockUnitsActivity" ], "lang": { "en-us": { "role": { "periodStartLabel": "Weighted average grant date fair value, Beginning", "periodEndLabel": "Weighted average grant date fair value, Ending", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price", "documentation": "Weighted average grant-date fair value of non-vested options outstanding." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": [ "http://cnspharma.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Vested term", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": [ "r366" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue", "presentation": [ "http://cnspharma.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Stock price", "documentation": "Weighted average grant-date fair value of options vested." } } }, "auth_ref": [] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductOrServiceAxis", "presentation": [ "http://cnspharma.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "auth_ref": [ "r128", "r245", "r269", "r270", "r271", "r272", "r273", "r274", "r353", "r364", "r369", "r403", "r423", "r424", "r428", "r471" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://cnspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r385" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "presentation": [ "http://cnspharma.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Shares authorized under plan", "documentation": "Number of shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": [ "r367" ] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://cnspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r386" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "presentation": [ "http://cnspharma.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Vested percentage", "documentation": "Percentage of vesting of award under share-based payment arrangement." } } }, "auth_ref": [ "r429" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://cnspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r385" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "presentation": [ "http://cnspharma.com/role/EquityDetails-OptionActivity" ], "lang": { "en-us": { "role": { "label": "Number of options, Expired", "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements." } } }, "auth_ref": [ "r186" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://cnspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r385" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": [ "http://cnspharma.com/role/EquityDetails-OptionActivity" ], "lang": { "en-us": { "role": { "negatedLabel": "Number of options, Forfeited", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } }, "auth_ref": [ "r185" ] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [ "http://cnspharma.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Weighted average shares outstanding - diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r112", "r117" ] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductsAndServicesDomain", "presentation": [ "http://cnspharma.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "auth_ref": [ "r128", "r245", "r269", "r270", "r271", "r272", "r273", "r274", "r353", "r364", "r369", "r403", "r423", "r424", "r428", "r471" ] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [ "http://cnspharma.com/role/StatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Stock-based compensation", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [ "r35", "r36", "r173" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://cnspharma.com/role/EquityDetails-OptionActivity", "http://cnspharma.com/role/EquityDetails-PerformanceUnitsActivity", "http://cnspharma.com/role/EquityDetails-RestrictedStockUnitsActivity" ], "lang": { "en-us": { "role": { "label": "Weighted average exercise price per share, Granted", "verboseLabel": "Weighted average grant date fair value, Granted", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": [ "r183" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://cnspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r402" ] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://cnspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": [ "http://cnspharma.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "verboseLabel": "Options outstanding", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": [ "r32" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [ "http://cnspharma.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Weighted average shares outstanding - basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r111", "r117" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [ "http://cnspharma.com/role/EquityDetails-OptionActivity", "http://cnspharma.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "periodStartLabel": "Number of options outstanding, Beginning", "periodEndLabel": "Number of options outstanding, Ending", "label": "Employees were awarded shares", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r179", "r180" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": [ "http://cnspharma.com/role/EquityDetails-OptionActivity" ], "lang": { "en-us": { "role": { "label": "Weighted average exercise price per share, Exercised", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": [ "r184" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://cnspharma.com/role/EquityDetails-OptionActivity", "http://cnspharma.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "periodStartLabel": "Weighted average exercise price per share, Beginning", "periodEndLabel": "Weighted average exercise price per share, Ending", "label": "Exercise price", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": [ "r179", "r180" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": [ "http://cnspharma.com/role/EquityDetails-OptionActivity", "http://cnspharma.com/role/EquityDetails-WarrantActivity" ], "lang": { "en-us": { "role": { "label": "Number of options outstanding, Exercisable", "verboseLabel": "Number of warrants outstanding, Exercisable", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth_ref": [ "r181" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://cnspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "presentation": [ "http://cnspharma.com/role/EquityDetails-OptionActivity", "http://cnspharma.com/role/EquityDetails-WarrantActivity" ], "lang": { "en-us": { "role": { "label": "Weighted average exercise price per share, Exercisable", "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan." } } }, "auth_ref": [ "r181" ] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "CounterpartyNameAxis", "presentation": [ "http://cnspharma.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://cnspharma.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]" } } }, "auth_ref": [ "r96", "r97", "r150", "r155", "r240", "r355", "r357" ] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestPaidNet", "crdr": "credit", "presentation": [ "http://cnspharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash paid for interest", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": [ "r88", "r90", "r91" ] }, "us-gaap_ConversionOfStockSharesConverted1": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConversionOfStockSharesConverted1", "presentation": [ "http://cnspharma.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Issuance of warrants", "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": [ "r24", "r25", "r26" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://cnspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://cnspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": [ "http://cnspharma.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://cnspharma.com/role/EquityDetailsNarrative" ], "auth_ref": [ "r96", "r97", "r150", "r155", "r240", "r356", "r357" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://cnspharma.com/role/EquityDetails-OptionActivity", "http://cnspharma.com/role/EquityDetails-PerformanceUnitsActivity", "http://cnspharma.com/role/EquityDetails-RestrictedStockUnitsActivity", "http://cnspharma.com/role/EquityDetails-WarrantActivity", "http://cnspharma.com/role/EquityDetailsNarrative", "http://cnspharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r175", "r176", "r177", "r179", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r199", "r200", "r201", "r202", "r203" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Assets", "crdr": "debit", "calculation": { "http://cnspharma.com/role/BalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://cnspharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total Assets", "label": "Assets [Default Label]", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r66", "r79", "r95", "r121", "r124", "r126", "r132", "r141", "r142", "r143", "r144", "r145", "r146", "r147", "r148", "r149", "r215", "r217", "r229", "r260", "r308", "r368", "r382", "r425", "r426", "r461" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [ "http://cnspharma.com/role/EquityDetails-OptionActivity", "http://cnspharma.com/role/EquityDetails-PerformanceUnitsActivity", "http://cnspharma.com/role/EquityDetails-RestrictedStockUnitsActivity", "http://cnspharma.com/role/EquityDetails-WarrantActivity" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r172", "r174", "r175", "r176", "r177", "r179", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r199", "r200", "r201", "r202", "r203" ] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [ "http://cnspharma.com/role/EquityDetails-OptionActivity", "http://cnspharma.com/role/EquityDetails-PerformanceUnitsActivity", "http://cnspharma.com/role/EquityDetails-RestrictedStockUnitsActivity", "http://cnspharma.com/role/EquityDetails-WarrantActivity" ], "lang": { "en-us": { "role": { "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": [ "r172", "r174", "r175", "r176", "r177", "r179", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r199", "r200", "r201", "r202", "r203" ] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "calculation": { "http://cnspharma.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://cnspharma.com/role/EquityDetailsNarrative", "http://cnspharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from sale of common stock", "verboseLabel": "Proceeds from common stock", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": [ "r1" ] }, "srt_BoardOfDirectorsChairmanMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "BoardOfDirectorsChairmanMember", "presentation": [ "http://cnspharma.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Board of Directors Chairman [Member]" } } }, "auth_ref": [ "r415" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://cnspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://cnspharma.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://cnspharma.com/role/EquityDetailsNarrative", "http://cnspharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Stock-based compensation", "label": "Share based compensartion expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r2" ] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://cnspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r400" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://cnspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "us-gaap_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpense", "crdr": "debit", "calculation": { "http://cnspharma.com/role/StatementsOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://cnspharma.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "negatedLabel": "Interest expense", "label": "Interest Expense", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense." } } }, "auth_ref": [ "r38", "r70", "r86", "r122", "r236", "r320", "r380", "r475" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": [ "http://cnspharma.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "verboseLabel": "Weighted average remaining term", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r65" ] }, "us-gaap_RelatedPartyTransactionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionAxis", "presentation": [ "http://cnspharma.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Axis]", "documentation": "Information by type of related party transaction." } } }, "auth_ref": [ "r238", "r239", "r460" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionDomain", "presentation": [ "http://cnspharma.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Transaction between related party." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "presentation": [ "http://cnspharma.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Weighted average remaining term", "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r32" ] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://cnspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r399" ] }, "us-gaap_CashUninsuredAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashUninsuredAmount", "crdr": "debit", "presentation": [ "http://cnspharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Cash in excess of FDIC", "documentation": "The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation." } } }, "auth_ref": [] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://cnspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r396" ] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://cnspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r401" ] }, "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "presentation": [ "http://cnspharma.com/role/EquityTables" ], "lang": { "en-us": { "role": { "label": "Schedule of restricted stock units activity", "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year." } } }, "auth_ref": [ "r33" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://cnspharma.com/role/StatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r371", "r372", "r373", "r375", "r376", "r377", "r378", "r412", "r413", "r455", "r472", "r476" ] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": [ "http://cnspharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": [ "r27" ] }, "us-gaap_NotesPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NotesPayableCurrent", "crdr": "credit", "calculation": { "http://cnspharma.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://cnspharma.com/role/BalanceSheets", "http://cnspharma.com/role/NotePayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Notes payable", "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer." } } }, "auth_ref": [ "r12" ] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://cnspharma.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://cnspharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Prepaid expenses and other current assets", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r406" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://cnspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r383" ] }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonoperatingIncomeExpenseAbstract", "presentation": [ "http://cnspharma.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Other income (expenses):" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": [ "http://cnspharma.com/role/EquityDetails-OptionActivity", "http://cnspharma.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Number of options, Granted", "verboseLabel": "Stock to be issued", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r183" ] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PlanNameAxis", "presentation": [ "http://cnspharma.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": [ "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454" ] }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "presentation": [ "http://cnspharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Stock-based Compensation", "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost." } } }, "auth_ref": [ "r171", "r178", "r197", "r198", "r199", "r200", "r203", "r208", "r209", "r210", "r211" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://cnspharma.com/role/StatementsOfCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://cnspharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net change in cash and cash equivalents", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r0", "r55" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://cnspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r393" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeAxis", "presentation": [ "http://cnspharma.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r137", "r138", "r139", "r140", "r168", "r170", "r200", "r201", "r202", "r243", "r244", "r275", "r286", "r287", "r341", "r342", "r343", "r344", "r345", "r351", "r352", "r361", "r363", "r365", "r370", "r373", "r419", "r427", "r464", "r465", "r466", "r467", "r468" ] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://cnspharma.com/role/StatementsOfOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://cnspharma.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Total other income (expense)", "label": "Nonoperating Income (Expense)", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": [ "r53" ] }, "us-gaap_AssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsNoncurrent", "crdr": "debit", "calculation": { "http://cnspharma.com/role/BalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://cnspharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total noncurrent assets", "label": "Assets, Noncurrent", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r95", "r132", "r141", "r142", "r143", "r144", "r145", "r146", "r147", "r148", "r149", "r215", "r217", "r229", "r425", "r426", "r461" ] }, "us-gaap_StockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockOptionMember", "presentation": [ "http://cnspharma.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Equity Option [Member]", "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option)." } } }, "auth_ref": [ "r373" ] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MaximumMember", "presentation": [ "http://cnspharma.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "auth_ref": [ "r137", "r138", "r139", "r140", "r170", "r244", "r275", "r286", "r287", "r341", "r342", "r343", "r344", "r345", "r351", "r352", "r361", "r363", "r365", "r370", "r427", "r463", "r464", "r465", "r466", "r467", "r468" ] }, "us-gaap_IncreaseDecreaseInOperatingAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingAssetsAbstract", "presentation": [ "http://cnspharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities:" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": [ "http://cnspharma.com/role/StatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Common stock issued for cash, net", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": [ "r5", "r42", "r43", "r63", "r284", "r335", "r348", "r381" ] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://cnspharma.com/role/BalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://cnspharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r76", "r80", "r95", "r132", "r141", "r142", "r143", "r144", "r145", "r146", "r147", "r148", "r149", "r215", "r217", "r229", "r368", "r425", "r426", "r461" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeMember", "presentation": [ "http://cnspharma.com/role/EquityDetailsNarrative" ], "auth_ref": [ "r137", "r138", "r139", "r140", "r168", "r170", "r200", "r201", "r202", "r243", "r244", "r275", "r286", "r287", "r341", "r342", "r343", "r344", "r345", "r351", "r352", "r361", "r363", "r365", "r370", "r373", "r419", "r427", "r464", "r465", "r466", "r467", "r468" ] }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightOutstanding", "presentation": [ "http://cnspharma.com/role/EquityDetails-WarrantActivity", "http://cnspharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Options outstanding", "periodStartLabel": "Number of warrants outstanding, Beginning", "periodEndLabel": "Number of warrants outstanding, Ending", "documentation": "Number of warrants or rights outstanding." } } }, "auth_ref": [] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrentAbstract", "presentation": [ "http://cnspharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Current Assets:" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://cnspharma.com/role/BalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://cnspharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r15", "r77", "r95", "r132", "r141", "r142", "r143", "r144", "r145", "r146", "r147", "r148", "r149", "r216", "r217", "r218", "r229", "r368", "r425", "r461", "r462" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [ "http://cnspharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "periodStartLabel": "Cash and cash equivalents, at beginning of period", "periodEndLabel": "Cash and cash equivalents, at end of period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r21", "r55", "r92" ] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MinimumMember", "presentation": [ "http://cnspharma.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "auth_ref": [ "r137", "r138", "r139", "r140", "r170", "r244", "r275", "r286", "r287", "r341", "r342", "r343", "r344", "r345", "r351", "r352", "r361", "r363", "r365", "r370", "r427", "r463", "r464", "r465", "r466", "r467", "r468" ] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PlanNameDomain", "presentation": [ "http://cnspharma.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": [ "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://cnspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationAwardTrancheOneMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationAwardTrancheOneMember", "presentation": [ "http://cnspharma.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Tranche One [Member]", "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period." } } }, "auth_ref": [] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://cnspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r385" ] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://cnspharma.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 }, "http://cnspharma.com/role/StatementsOfOperations": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://cnspharma.com/role/StatementsOfCashFlows", "http://cnspharma.com/role/StatementsOfOperations", "http://cnspharma.com/role/StatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "totalLabel": "Net loss", "label": "Net loss", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r49", "r57", "r69", "r75", "r81", "r82", "r85", "r95", "r101", "r103", "r104", "r105", "r106", "r109", "r110", "r114", "r121", "r123", "r125", "r127", "r132", "r141", "r142", "r143", "r144", "r145", "r146", "r147", "r148", "r149", "r228", "r229", "r267", "r316", "r333", "r334", "r360", "r380", "r425" ] }, "us-gaap_DeferredCompensationLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredCompensationLiabilityCurrent", "crdr": "credit", "presentation": [ "http://cnspharma.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Accrued related to compensation", "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements payable within one year (or the operating cycle, if longer). Represents currently earned compensation under compensation arrangements that is not actually paid until a later date." } } }, "auth_ref": [ "r30", "r64" ] }, "us-gaap_DebtInstrumentInterestRateDuringPeriod": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentInterestRateDuringPeriod", "presentation": [ "http://cnspharma.com/role/NotePayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Interest rate", "documentation": "The average effective interest rate during the reporting period." } } }, "auth_ref": [ "r16", "r37", "r151" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AwardTypeAxis", "presentation": [ "http://cnspharma.com/role/EquityDetails-OptionActivity", "http://cnspharma.com/role/EquityDetails-PerformanceUnitsActivity", "http://cnspharma.com/role/EquityDetails-RestrictedStockUnitsActivity", "http://cnspharma.com/role/EquityDetails-WarrantActivity", "http://cnspharma.com/role/EquityDetailsNarrative", "http://cnspharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r175", "r176", "r177", "r179", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r199", "r200", "r201", "r202", "r203" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://cnspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r391" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://cnspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://cnspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r397" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityAbstract", "presentation": [ "http://cnspharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Stockholders' Equity (Deficit):" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": [ "http://cnspharma.com/role/EquityDetailsNarrative", "http://cnspharma.com/role/StatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Common stock issued for cash net, shares", "verboseLabel": "Issuance of common stock shares", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": [ "r5", "r42", "r43", "r63", "r282", "r335", "r348" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://cnspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r394", "r396", "r397" ] }, "us-gaap_ProductLiabilityContingencyTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProductLiabilityContingencyTable", "presentation": [ "http://cnspharma.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Product Liability Contingency [Table]", "documentation": "Information and financial data about the reasonably possible loss or the recognized and additional reasonably possible loss from product liability related to an individual product." } } }, "auth_ref": [ "r139", "r421", "r422", "r423" ] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://cnspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r395" ] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://cnspharma.com/role/StatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed." } } }, "auth_ref": [ "r98", "r99", "r100", "r120", "r245", "r281", "r285", "r288", "r289", "r290", "r291", "r292", "r293", "r296", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r309", "r310", "r311", "r312", "r313", "r315", "r318", "r319", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r335", "r374" ] }, "us-gaap_AssetsNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsNoncurrentAbstract", "presentation": [ "http://cnspharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Noncurrent Assets:" } } }, "auth_ref": [] }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "presentation": [ "http://cnspharma.com/role/EquityDetailsNarrative" ], "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://cnspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r397" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted", "presentation": [ "http://cnspharma.com/role/EquityDetails-PerformanceUnitsActivity", "http://cnspharma.com/role/EquityDetails-RestrictedStockUnitsActivity" ], "lang": { "en-us": { "role": { "label": "Granted", "documentation": "Net number of non-option equity instruments granted to participants." } } }, "auth_ref": [ "r6" ] }, "us-gaap_VestingAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VestingAxis", "presentation": [ "http://cnspharma.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Vesting [Axis]", "documentation": "Information by vesting schedule of award under share-based payment arrangement." } } }, "auth_ref": [ "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://cnspharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Current Liabilities:" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "presentation": [ "http://cnspharma.com/role/StatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Stock-based compensation, shares", "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)." } } }, "auth_ref": [ "r5", "r42", "r43", "r63" ] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://cnspharma.com/role/Equity" ], "lang": { "en-us": { "role": { "label": "Equity", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r62", "r94", "r152", "r154", "r156", "r157", "r158", "r159", "r160", "r161", "r162", "r163", "r164", "r165", "r167", "r225", "r338", "r339", "r349" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue", "crdr": "debit", "presentation": [ "http://cnspharma.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Options vested", "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r196" ] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "calculation": { "http://cnspharma.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://cnspharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Prepaid expenses and other current assets", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": [ "r2" ] }, "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationAwardTrancheTwoMember", "presentation": [ "http://cnspharma.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Tranche Two [Member]", "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://cnspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r396" ] }, "us-gaap_DebtInstrumentMaturityDate": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentMaturityDate", "presentation": [ "http://cnspharma.com/role/NotePayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Maturity period", "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format." } } }, "auth_ref": [ "r72", "r362", "r456" ] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Depreciation", "crdr": "debit", "calculation": { "http://cnspharma.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://cnspharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Depreciation", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": [ "r3", "r29" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised", "presentation": [ "http://cnspharma.com/role/EquityDetails-WarrantActivity" ], "lang": { "en-us": { "role": { "negatedLabel": "Number of warrants, Exercised", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised", "documentation": "Number of non-option equity instruments exercised by participants." } } }, "auth_ref": [ "r7" ] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://cnspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r396" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://cnspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r398" ] }, "us-gaap_VestingDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VestingDomain", "presentation": [ "http://cnspharma.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Vesting schedule of award under share-based payment arrangement." } } }, "auth_ref": [ "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations", "presentation": [ "http://cnspharma.com/role/EquityDetails-WarrantActivity" ], "lang": { "en-us": { "role": { "negatedLabel": "Number of warrants, Expired", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Expirations", "documentation": "Number of shares under non-option equity instrument agreements for which rights to exercise lapsed." } } }, "auth_ref": [ "r8" ] }, "us-gaap_RepaymentsOfNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RepaymentsOfNotesPayable", "crdr": "credit", "calculation": { "http://cnspharma.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://cnspharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Payments on notes payable", "label": "Repayments of Notes Payable", "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation." } } }, "auth_ref": [ "r19" ] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://cnspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r389" ] }, "us-gaap_RoyaltyIncomeNonoperating": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RoyaltyIncomeNonoperating", "crdr": "credit", "presentation": [ "http://cnspharma.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Royalty income, nonoperating", "documentation": "Ancillary revenue earned during the period from the consideration paid to the entity for the use of its rights and property by another party. Examples include licensing the use of copyrighted materials and leasing the extraction of natural resources." } } }, "auth_ref": [ "r53" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://cnspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://cnspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "us-gaap_ShortTermBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermBorrowings", "crdr": "credit", "presentation": [ "http://cnspharma.com/role/NotePayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Short-term note payable", "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r41", "r67", "r368", "r470" ] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [ "http://cnspharma.com/role/EquityDetails-OptionActivity" ], "lang": { "en-us": { "role": { "label": "Number of options, Exercised", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": [ "r5", "r42", "r43", "r63", "r184" ] }, "CNSP_WarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://cnspharma.com/20230930", "localname": "WarrantsMember", "presentation": [ "http://cnspharma.com/role/EquityDetails-WarrantActivity", "http://cnspharma.com/role/EquityDetailsNarrative", "http://cnspharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Warrants [Member]" } } }, "auth_ref": [] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://cnspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r396" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://cnspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r390" ] }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "presentation": [ "http://cnspharma.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Issuance of common stock", "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan." } } }, "auth_ref": [ "r5", "r42", "r43", "r63" ] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://cnspharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Supplemental disclosures of cash flow information:" } } }, "auth_ref": [] }, "CNSP_PerformanceUnitsMember": { "xbrltype": "domainItemType", "nsuri": "http://cnspharma.com/20230930", "localname": "PerformanceUnitsMember", "presentation": [ "http://cnspharma.com/role/EquityDetails-PerformanceUnitsActivity", "http://cnspharma.com/role/EquityDetailsNarrative", "http://cnspharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Performance Units [Member]" } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(1)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(2)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(4)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Subparagraph": "(c)", "Paragraph": "2", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19,20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19-26)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.21)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.25)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "25", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "710", "SubTopic": "10", "Section": "30", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483043/710-10-30-2" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.17)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "985", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.1(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//235/tableOfContent" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//440/tableOfContent" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//470/tableOfContent" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//505/tableOfContent" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "710", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483070/710-10-25-9" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r71": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r72": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22(a)(2))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r73": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//275/tableOfContent" }, "r74": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r75": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r76": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r77": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5" }, "r78": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r79": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r80": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r81": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r82": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r83": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r84": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r85": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r86": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(210.5-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r87": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r88": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17" }, "r89": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r90": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r91": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r92": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r93": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1" }, "r94": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r95": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r96": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r97": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r98": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r99": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r100": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r101": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r102": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r103": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r104": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r105": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r106": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//718/tableOfContent" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.C.Q3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.1.Q5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.3.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//855/tableOfContent" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "33", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "33", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "35A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "35A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column E)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1" }, "r353": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r354": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r355": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16" }, "r356": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21" }, "r357": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22" }, "r358": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52" }, "r359": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r360": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r361": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A" }, "r362": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r363": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r364": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r365": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8" }, "r366": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r367": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r368": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10" }, "r369": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2" }, "r370": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F" }, "r371": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r372": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r373": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1" }, "r374": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r375": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r376": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r377": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r378": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r379": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "39", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480228/946-830-45-39" }, "r380": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10" }, "r381": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11" }, "r382": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12" }, "r383": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r384": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r385": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r386": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r387": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r388": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r389": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r390": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r391": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r392": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r393": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r394": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r395": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r396": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r397": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r398": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r399": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r400": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r401": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r402": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" }, "r403": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4H", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H" }, "r404": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "205", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483504/205-10-50-1" }, "r405": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r406": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r407": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(b)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r408": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r409": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17" }, "r410": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r411": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r412": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r413": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r414": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r415": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13" }, "r416": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r417": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-5" }, "r418": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r419": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10" }, "r420": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//450/tableOfContent" }, "r421": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1" }, "r422": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r423": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r424": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r425": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r426": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r427": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r428": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r429": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r430": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r431": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r432": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r433": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r434": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r435": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r436": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r437": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r438": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r439": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r440": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r441": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r442": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r443": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r444": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r445": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r446": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r447": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r448": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r449": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r450": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r451": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r452": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r453": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r454": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r455": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r456": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r457": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r458": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r459": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2" }, "r460": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r461": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r462": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r463": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r464": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r465": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r466": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r467": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r468": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r469": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1" }, "r470": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r471": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B" }, "r472": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r473": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r474": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r475": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r476": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r477": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r478": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column E)(Footnote 6)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" } } } ZIP 40 0001683168-23-008144-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001683168-23-008144-xbrl.zip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�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end